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ABSTRACT 
Pervasive developmental disorders are a group of neurodevelopmental-
neuropsychiatrie disorders that are characterized by variable and severe 
pervasive impairments in several areas of child development, notably 
social interaction, communication and imagination. They ail share clinical 
features but differ in the seve rit y and age of onset of the impairments. 
Except for Rett Syndrome (RTT), the etiology of these disorders is 
unknown, but there is strong evidence that genetic factors contribute to 
their pathogenesis. While no major genes have been linked to theses 
disorders linkages, association and chromosomal studies suggest that 
many loci may be involved. 
One aim of the present study was to search for genetics variants 
associated with autism and other related disorders. This study represents 
the first family-based association study looking at the entire X 
chromosome using a French-Canadian autistic population, a genetically 
homogenous group. We found association between autism and markers at 
two loci. Our results support the existence of a putative gene located on 
the X chromosome and moreover the founder effect, in the French-
xv 
Canadian population, may provide greater power to fine map disease 
genes especially in complex traits. 
The second aim of the present thesis was to confirm the involvement of 
the MECP2 gene in our RTT group of patients. While we confirm the 
presence of mutations in this gene in our cohort of RTT patients we also 
demonstrated that clinical stringency greatly influences the mutation 
detection rate for this disorder. 
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ABRÉGÉ 
Les troubles envahissants du développement (TED) sont un groupe de 
désordres neurodéveloppementaux qui se caractérisent par des difficultés 
sévères dans différentes sphères du développement de l'enfant. Ces 
troubles partagent tous des traits cliniques mais diffèrent au niveau de la 
sévérité et de l'âge à lequel le trouble apparaît. L'origine de ces troubles 
n'est pas encore connue, à l'exception du syndrome de Rett, mais 
plusieurs évidences démontrent l'implication de facteurs génétiques. 
Jusqu'à présent aucun gène majeur n'a été lié aux TED. Cependant les 
études de liaison, d'associations ainsi que les études chromosomiques 
démontrent l'implication de plusieurs loci. 
Un des objectifs de la présente étude était de chercher pour des variants 
génétiques qui pourraient être associés aux TED. C'est la première étude 
d'association, basée sur des familles nucléaires, analysant le 
chromosome X et utilisant la population canadienne-française. Nous 
avons trouvez 2 régions chromosomiques potentiellement impliquées 
dans les TED. Ces résultats supportent l'existence d'un gène sur le 
chromosome X pour les TED et démontre que la population canadienne-
française, connue pour son effet fondateur, peu apporter une puissance 
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supérieure pour localiser un gène particulièrement pour les maladies dites 
«complexes» 
Le second objectif était de confirmer l'implication du gène MECP2 dans 
notre groupe de patients atteints du syndrome de Rett. Nous avons trouvé 
plusieurs mutations différentes dans notre cohorte confirmant le rôle de ce 
gène. De plus, nos résultats démontrent que la méthode d'évaluation 
clinique augmente considérablement la détection de mutation dans ce 
gène. 
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INTRODUCTION AND LITTERATURE REVIEW 
PERVASIVE OEVELOPMENTAL DISORDERS 
ln the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
published by the American Psychiatrie Association (DSM-IV 1994), autism 
is classified as belonging to the Pervasive Developmental Disorders 
(PDO) category. This group of disorders is characterized by variable and 
severe pervasive impairments in several areas of child development, 
notably social interaction, communication and imagination. Autism is part 
of this broad clinically heterogeneous class of PDD, together with 
Asperger syndrome (AS), and Pervasive Development Disorder Not 
Otherwise Specified (PDDNOS). These three entities share most of their 
symptoms and may have a common etiology (Rutter et al. 1999). These 
three disorders are also commonly referred to as to Autism Spectrum 
Oisorders. Aiso included within the PDD group are Childhood 
Disintegrative Disorder, an extremely rare childhood condition (Fombonne 
2002), and Rett syndrome (RS), a separate clinical entity with an 
identifiable genetic defect (Amir et al. 1999). 
Although the age of onset is variable, PDD symptoms usually appear 
during the first 3 years of life. Classification of POO into specifie disorders 
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is determined according to the following criteria: 1) the pervasiveness and 
severity of communication deficits (language deficit or general cognitive 
delay), 2) the seve rit y of social interaction deficits and 3) the age of onset. 
The diagnosis of each type of POO is based on clinical observations, 
information received from parental interview and questionnaires and, 
when possible, language and cognitive assessment. No biological 
markers such as blood, urine, and/or chromosomal or neurological tests 
exist to validate the clinical diagnosis. With the exception of RS, the POO 
are not clear-cut disorders but instead are clinically identified and 
differentiated according to the number and presence of problems in the 
spheres of social interaction, communication and, behaviour (Filipek et a!. 
1999). 
The overall prevalence of the POO (excluding RS) is 60 in 10 000 children 
(Fombonne 2003; Tidmarsh et a!. 2003). In 2003, Health Canada 
estimated that as many as 1 in 200 children were diagnosed with an 
Autism Spectrum Oisorder (Autism, Asperger, POONOS), (Canada Health 
web site; http://www.hc-sc.gc.ca/). 
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Autism Disorder 
Autism is the prototypical or classic form of the POO. It is a chronic and 
debilitating disorder characterized by complex behavioural and cognitive 
deficits. Symptoms typically become apparent in the 1-year period 
coincidental with the acquisition of speech. Occasionally, symptoms are 
not apparent until later but must appear before age 3 to meet diagnostic 
criteria for POO. 
ln order to be diagnosed with autism, individuals must present deficits in 
three areas of functioning (a Iso called triad of functioning) as defined by 
the OSM. These three areas are (1) social interaction and relationships 
(2) communication, and (3) imagination or restricted interests and 
stereotypie play. Oeficits in social interaction and relationships include, for 
example, the absence of emotional gestures, such as the lack of pointing 
to or showing objects to someone else. This kind of problem is a core 
feature of autism; they are manifest early in the child's development. 
Impairments in the area of communication are marked by the lack of 
verbal and non-verbal ski Ils. An example of this type of impairment is the 
absence of verbal communication skills. Finally, examples of deficits in the 
area of limited interests and activities or play are repetitive movements like 
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specifie hand and finger mannerisms (DSM-IV 1994; Cohen 1997; 
Tanguay 2000). Consequently, children with autism may have unusual 
focuses or fascinations. This trait persists throughout their lifetime, 
although the types of interests often change. Detailed in table 1 is a more 
extensive list of examples of behaviours that are representative of each 
group within the POO class. 
Table 1. Deficits specifie to each area of impairment in autism disorder 
Area of impairments Deficits 
Social interaction 
Communication 
Restricted interests 
and stereotypie play 
Lack of non-verbal behaviours (e.g. use of gesture 
in communicating) 
Failure to develop peer relationships 
Lack of spontaneous of social or emotional 
reciprocity 
Delay or lack in the development of spoken 
language 
Impairment in initiating or sustaining a conversation 
Stereotyped and repetitive use of language 
Lack of varied, spontaneous imitative play 
Restricted, repetitive and stereotyped pattern of 
behaviour 
Stereotyped or restricted patterns of interests 
Adherence to non-functional routines or rituals 
Stereotyped and repetitive motor mannerisms 
22 
ln order to be diagnosed with autism, an individual must present at least 
one of the impairments listed above, in each category. Clinical 
manifestations of autism vary widely according to subject's age at 
examination and the degree of mental deficiency observed. Nevertheless, 
children suffering from autism, with or without mental deficiency, share 
deficits in socio-emotional reciprocity that deeply affect familial and peer 
relations. Patterns of activities of these children are dominated by 
repetitive limb routines and sometimes involve other parts of the body 
(mannerisms). Furthermore, their areas of interest are usually restricted to 
simple sensory stimuli or to a very specifie domain of knowledge. 
The classification of autism has evolved and become more inclusive over 
time, which has, in turn, rendered exact prevalence rates difficult to 
estimate. Depending on the definition of autism, published reports relate 
prevalence rates ranging from 10/10000 to 70/10000 (0.1-0.7 %) 
(Fombonne 2002). This latter figure is based on a more inclusive 
definition, and includes three of the five Autism Spectrum Disorders 
autism, PDDNOS and AS. Another recurrent statistic is that autism occurs 
three to four times more often in boys than in girls. 
23 
Asperger Syndrome 
The main clinical features differentiating Asperger syndrome (AS) from 
autism are the absence of intellectual deficiency and no language delay 
before age 3. Similarly to autism, children with AS have qualitative 
abnormalities in reciprocal social interactions and show a restricted, 
stereotyped and repetitive pattern of interests and activities. AS seems to 
occur later than autism but this could result from the fact that symptoms 
are less evident in the early year of life (DSM-IV 1994). In addition, 
because children with AS have no general delay in language, they usually 
have a significantly higher verbal mental age than autistic patients do. 
Children with AS show no clinically significant delays in cognitive 
development and tend to show deficit in the development of age 
appropriate self-help ski Ils. 
The prevalence of AS is uncertain, mainly because it is often confused 
with forms of autism where mental retardation is absent. The real 
prevalence is therefore uncertain. Nevertheless, the best estimate, 
obtained from a review of available epidemiological surveys on AS 
revealed a prevalence of 2.5/10 000 (Fombonne et al. 2003; Tidmarsh et 
24 
al. 2003). The AS male/female ratio is 4-10:1 a ratio higher to what is 
observed in autism (Baron-Cohen 2002). 
Childhood Oisintegrative Oisorder 
Unlike AS and autism, children with Childhood Oisintegrative Oisorder 
(COD) appear to develop normally in ail areas of functioning for at least 
their first two years of life; the age of onset is at some point between 2 and 
10 years (OSM-IV 1994; Tanguay 2000). At that time, what is seen is a 
marked regression in acquired social skills and speech. Moreover, 
children with COD also present a variety of different regression, such as 
loss of bowel or bladder control, play, and previously acquired motor skills, 
characteristic that are not observed in POO or at least not to the same 
degree. COD also differs from autism in the nature and pattern of its 
onset and course, and in certain clinical features. For example, children 
with COD have a greater likelihood of mental retardation. A long-term 
follow-up study reported a higher incidence of seizure in COD patients 
than in autistic children (77% versus 25-35%) (Tanguay 2000). In rare 
cases, metachromatic leukodystrophy and Schilder's disease are 
observed along with COD in affected children. COD is an extremely rare 
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condition with a prevalence of 1 in 100 000. Furthermore, COD appears to 
be more common in males (Cohen 1997). 
Rett Syndrome 
Rett syndrome (RS) is a developmental disorder affecting mostly girls and 
is one of the most common causes of mental retardation in females 
(Hagberg 1985). This syndrome is characterized by a period of regression 
following an apparently normal period of development in ail areas of 
functioning (social interaction, communication and behaviour). The onset 
of this disease is between 6 and 18 months and always appears before 
the age of 4 years (OSM-IV 1994). At this point, affected girls show a loss 
of social engagement, severe impairments in expressive and receptive 
language development, and psychomotor retardation. Moreover, RS is 
usually associated with profound mental retardation (OSM-IV 1994; Cohen 
1997), RS differs from autism and other POO in its sex ratio and by its 
particular physical pattern of development: deceleration of head growth, 
loss of previously acquired purposeful hand movements, appearance of 
stereotypie hand-wringing movements, and loss of many gross motor skills 
leading to ataxia and apraxia (Cohen 1997; Tanguay 2000). Furthermore, 
breathing dysfunction, a feature specifie to RS, may be severe. The range 
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of phenotypic variability in RS is very small compared to the high 
variability of symptoms seen in autism. In contrast to autism, self-in jury 
and complex stereotyped activities are rare in RS patients (Leekam et al. 
2002). However, like in autism, seizures are sometimes reported in 
individuals with RS (Tanguay 2000). Other medical conditions such as 
scoliosis and kyphoscoliosis (progressive backward and lateral curvature 
of the spine) tend to develop. The c1assic term RS is use to describe 
individuals presenting ail features Iisted above. Individuals who have a 
less severe phenotype (no deceleration of head growth, no loss of 
walking, etc) are identified with what is called the mild form of RS or 
atypical RS. The prevalence of RS is estimated to be between 1 in 10 000 
to 15 000 females (Miltenberger-Miltenyi et al. 2003). Mutations in 
MECP2 gene, located on X chromosome, are responsible for 80-90% of 
RS cases (Amir et al. 1999; Miltenberger-Miltenyi et al. 2003). 
Pervasive Developmental Disorder Not Otherwise Specified 
Symptoms of Pervasive Developmental Disorder Not Otherwise Specified 
(POONOS) appear during the first year of life and diagnosis of this 
disorder is given only if the patient does not meet the phenotypic criteria 
for another member of the POO. PDDNOS, also referred to as atypical 
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autism, does not have the specifie phenotype observed in RS syndrome, 
nor does it follow any particular pattern su ch as in autism, AS and COD. 
ln fact, this condition does not fit into the diagnostic criteria of any of the 
above diseases. Individuals diagnosed with POONOS exhibit less severe 
symptomatology than is the case with autism; this group of patient is more 
likely to be verbal, to have a higher IQ and thus a better prognosis than 
patients with autism. POONOS has the highest prevalence rate of POO 
and is estimated to affect approximately 15 in 10 000 individuals 
(Tidmarsh et al. 2003). 
The preceding section illustrates that each disorder within the POO class 
presents some differences, measurable according to such variables as 
age of onset, pattern of social interaction, communication ability and 
behavioural development. Moreover, variability in expression exists in 
each disorder (e.g. mild to severe forms of autism) and often this also 
changes over time during child development. However, the eut-off 
phenotypic criteria that are used to distinguish each POO are subtle and 
this tends to cause an overlap with other disorders within as weil as 
outside the POO spectrum (Angelman syndrome, Fragile X syndrome, 
etc.). These factors make obtaining a definitive diagnosis difficult, and 
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whether autism, AS, RS and COD form a single entity or are separate, 
distinct conditions remains unknown. On the other hand, ail disorders in 
the POO group share common features, such as qualitative impairments in 
social interaction and stereotyped patterns of behaviour. These common 
symptoms may be the result of genetically related factors. 
AUTISM OISOROER 
To date there is no curative treatment for autism. However, structured 
education, including behavioural modification focused on the most 
disruptive symptoms, and adapting teaching and living conditions to their 
cognitive limitations, can help autistic children during their development. 
Early interventions seem to be more effective than interventions started at 
a later stage of development (Bristol et al. 1996; Gresham et al. 1998). 
The minimum co st for a special early intervention program for autism is 
$33,000 - $50,000 Iyear/child (Autism Society Canada) but these types of 
treatment are more and more challenged on their efficiency, as weil as 
methodological and ethical grounds (Volkmar et al. 2004). The need for 
lifelong care and pedagogie support, in addition to the high prevalence of 
this disorder makes autism a major challenge for families involved and 
public health in general. Therefore, the identification of a biological marker 
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such as a gene variant that may cause the disease could very weil lead to 
early detection and thus more effective intervention. In turn, more efficient 
interventions will contribute to reduce the burden to families and the long-
term care costs for society. 
History of Autism 
Autism is not restricted to modern society, although it has only become a 
world recognized disorder in the past decade. Autistic-like behaviour has 
almost certainly been present throughout human history. However, it was 
not until 1900th that the medical community began to document cases of 
individuals presenting impairments resembling what we now know to 
characterize autism. The first known documented case of autism, reported 
by the French Ooctor Jean-Marc-Garpard Itard, is the story of "Victor the 
wild boy of Aveyron*". 1 
Interestingly, some of our most famous inventors have been suspected of 
belonging to the POO class. Two well-known examples are Albert 
Einstein (1879-1955), who is credited with developing the theory of 
relativity, and Isaac Newton (1642-1727), who discovered the laws of 
1 • A wild boy who apparently lived his entire childhood alone in the woods and was then 
captured near the village Saint Sernin sur Rance (near Toulouse), France, in 1797. 
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gravity. Recently, a group of researchers studying personality reports of 
the two scholars noticed that both displayed many signs of AS (Baron-
Cohen 2003). 
However, it was Leo Kanner, an American child-psychiatrist, who was the 
first to employ the concept of autism in its modern sense. In his first 
published paper entitled "Autistic Disturbances of Affective Contact" 
(Kanner 1968). Kanner gives an account of 11 children who ail display 
communication and social difficulties, as weil as stereotyped, rigid 
behaviour. He describes these patients as sharing a particular pattern of 
symptoms that form a unique category, which he calls early infantile 
autism (sometimes referred to as Kanner syndrome). Thus, the concept 
of autism was born. Prior to Kanner's description, children presenting 
these types of symptoms would have been incorrectly classified as 
emotionally disturbed or intellectually impaired. A year later, another child-
psychiatrist by the na me of Hans Asperger independently made 
essentially the same discoveries as Kanner. His publication concerned 
investigations of more than 400 children with autistic traits. However, the 
patients he identified ail had speech, and the term Asperger syndrome is 
often used to denote this category of autistic patient. Unfortunately, his 
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work was not recognized until the late 1980s when his book was 
translated into English. As a result, the diagnosis of Asperger syndrome 
was not officially recognized until 1994. 
After Kanner and Asperger's discovery, many different theories regarding 
the cause of autism emerged: Children with autism are unruly kids with 
behavioural difficulties; Parents were observed to treat their autistic child 
without the warmth and affection, that is normally observed between 
parent and child. Freudian psychology presumed that if certain basic 
psychological bonds between parents and children failed to form, the child 
would fail to progress. These old theories of autism remained in vogue in 
the 50's and early 60's. Most importantly, no known factors in the 
psychological environment of a child have been shown to cause autism. 
Fortunately, since the early 80's, we now have compelling evidences on 
the cause of autism which suggests that it is a disorder of abnormal brain 
development, the basis of which is largely genetic (see section 1.5.1 for 
genetic evidence). 
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Associated Disorders 
There are many disorders that are associated with autism. About 75% of 
autistic children have mental retardation. In fact, Intelligence Quotient (IQ) 
score along with the severity of verbal disability are the main criteria used 
to classify autism into two sub-groups: low and high-functioning autism. 
Low functioning autistic individuals have a lower IQ, are more severely 
affected in the areas of social interaction and language development, and 
have a higher incidence of epilepsy, macrocephaly and other comorbidity. 
High-functioning children tend to have a higher IQ (>70) and a better 
prognosis in adult life (Cohen 1997; Szatmari 2000). 
Although less frequent than mental retardation, a range of behavioural and 
medical conditions are reported in a minority of children with autism 
(Tanguay 2000) including hyperactivity, short attention span, and 
impulsivity. The most frequent medical conditions associated with autism 
are listed in table 2. Minor physical anomalies, such as malformation of 
the external ear, dysfunction of eye movement, and lack of facial 
expression are also found in a number of autistic individuals (Rodier 
2000). 
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Table 2. Frequent medical conditions associated with autism 
Diseases 
Seizure disorder 
Fragile-X syndrome 
Tuberous sclerosis 
Neurofibromatosis 1 
Frequency 
Autistic General 
Population Population 
25-35 % 0.7-1% 
2-5% 0.01-0.03% 
0.4-2.8% 0.01-0.06% 
0.3-2.1 % 0.02-0.05% 
References 
20 
10,22 
19 
23,24 
These associated medical conditions can be used to form subgroups 
within the autistic phenotype, thus decreasing in part its variability. 
Moreover, an identified Mendelian condition associated with autism can be 
useful in the search of candidate genes. Nonetheless, these diagnosable 
conditions found with autism account only for a small portion of cases, 
less than 10% (Foistein et al. 2001). The rest of autism cases are 
idiopathie e.g. of unknown causation. 
Neurobiology of Autism 
Although the neurobiological basis of autism has not yet been clearly 
established, sorne observations of abnormalities in brain development, 
brain anatomy and function are consistent across different research 
studies. 
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Neuroanatomical Studies 
The most robust neuroanatomical finding is the larger head circumference 
in many autistic individuals, a trait first recognized by Kanner (review 
(Palmen et al. 2004). Indeed, macrocephaly (head circumference > 97th 
percentile for sa me age individuals) is estimated to be present in 20% of 
autistic children (Fombonne et al. 1999; Palmen et al. 2004). In fact, 
according to Courchesne et al., 90% of autistic children between the ages 
of 2 and 3 have a brain volume larger than the norm (Courchesne et al. 
2001; Courchesne 2004; Courchesne et al. 2004). This observation was 
replicated in an independent study by Sparks et al. (Sparks et al. 2002). 
Interestingly recent quantitative in vivo magnetic resonance imaging (MRI) 
findings revealed normal brain size at birth followed by an overgrowth 
occurring at 2-4 years of age. This brain evolution is preceded byan 
unusually slow or arrested period of development (Courchesne et al. 
2003; Courchesne 2004; Courchesne et al. 2004). What is not clear from 
these studies is whether the whole brain is enlarged or only sorne specifie 
structures. 
Among the brain structures implicated in autism are the cerebellum, 
brainstem nuclei, and several components of the limbic system. Sorne 
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studies have also noted an enlarged amygdala (Lotspeich et al. 1993) 
(Schumann et al. 2004) and hippocampus (Raymond 1996; Schumann et 
al. 2004) in individuals with autism. This makes sense because these two 
structures are involved in cognition, behaviour, and emotional responses 
and learning, which constitute the core disabilities in autism. An 
interesting finding from post-mortem studies of the autistic brain reported 
subtle abnormal neuronal morphologies, with a decreased complexity of 
dendritic branching and underdeveloped neuronal arbors (Raymond 
1996). Additionally, cytoarchitectural features that are frequently abnormal 
in autism cases include reduced numbers of Purkinje neurons in the 
cerebellum and vermis, and small tightly packed neurons in regions of the 
limbic system, especially in the entorhinal cortex and in the medially 
placed nuclei of the amygdala. 
Neurochemical Studies 
Brain neurochemistry has been extensively studied in autism, including 
serotonin (5-HT) (Whitaker-Azmitia 2001), the catecholamine class 
(dopamine, norepinephrine and epinephrine) (Croonenberghs et al. 2000), 
gamma-aminobutyric acid (GABA) (Dhossche et al. 2002) and glutamate 
(Purcell et al. 2001; Jamain et al. 2002). Serotonin metabolism in autistic 
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individuals has been recent focus of interest. The findings related to this 
system constitute the most consistent neurochemical observations -Le. 
increased serotonin blood platelet levels in a large portion of autistic 
patients (Whitaker-Azmitia 2001) and their biological relatives (Leboyer et 
al. 1999). 
The role of the glutamatergic system in the etiology of autism is of interest 
for two main reasons 1) brain regions that are repeatedly implicated in 
autism in neuropathological studies ail contain glutamatergic neurons 
(including amygdale, hippocampus and cortical areas) and 2) glutamate 
antagonists induce symptoms similar to those found in sorne autistic 
patient (Carlsson 1998). Furthermore, dysregulation of glutamate plasma 
levels has been observed in autistic patients and their families (Carlsson 
1998; Aldred et al. 2003). Neurotransmitter signalling systems may be 
relevant to the pathogenesis of autism because of their essential role in 
brain development (Herlenius et al. 2001). Unfortunately, no studies have 
resulted in a unifying hypothesis concerning the pathogenesis of autism. 
Though neurobiological and neuroanatomical findings are promising and 
in favour of a neurobiological basis for autism, to date the majority of the 
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studies have investigated only a very limited number of subjects and the 
significance, specificity and relationship of these brain abnormalities to 
clinical manifestations of autism remain unclear. However, taken together, 
neuroanatomical and cytological data on in vivo and post-mortem tissue 
samples indicate that autism may be associated with global disturbances 
in brain structure and/or metabolism. 
Genetic Influences 
An initial common myth about autism is that it occurs in children who were 
exposed to stimulus-restrictive environments during that critical period of 
their young life when language and motor skills were developing. Another 
blatant misconception is that autism is an emotional disorder principally 
caused by poor parenting (especially from the mother) and neglect. 
Thankfully, these old theories about the cause of autism have been 
rejected in recent decades due to well-constructed scientific studies, and 
we now have solid data that suggests that genetic factors play an 
important role in the aetiology of autism. 
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Genetic Evidence in Autism 
Although the cause of autism is still unknown, a number of studies have 
confirmed that genetic factors play an important role in the aetiology of 
autism (Muhle et al. 2004). 
Results from family studies present the first evidence that genetic factors 
are involved in autism. Initial observations of families with more than one 
autistic child suggest that it may be a genetically inherited disorder. In fact, 
studies of siblings of autistic patients have shown that the recurrence risk 
is 3 to 7%, which is 30 to 70 times more than the prevalence of autism in 
the general population. This estimated relative risk in siblings is higher 
than for any other major psychiatrie disease, suggesting an important role 
for genetics for autism. Moreover, this number may be underestimated 
since families with an autistic child may restrain themselves to having only 
one child, partly due to difficulties surrounding the care of a child with a 
serious handicap such as autism (Jones et al. 1988). 
Nevertheless, the fact that autism is shown to segregate in families does 
not necessarily mean that genes are involved, as family members who live 
together also share environmental factors. 
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Studies on monozygotic (Ml) and dizygotic (Dl) twins provide a way to 
control for environmental factors and constitute the most convincing 
evidence of the role of genes in autism. In fact, the concordance rates for 
autism in monozygotic twins is 70-90 %, whereas for dizygotic twins it is 0 
to 10 % (Bailey et al. 1995; Le Couteur et al. 1996; Shao et al. 2003). The 
large difference between Ml and Dl concordance rates and the relatively 
high recurrence risk supports the idea that autism is a strongly heritable 
condition (heritability > 90 %). Furthermore, the recurrence risk of autism 
in second- and third-degree relatives of autistic subjects decreases 
sharply compared to first-degree relatives (0.18% and 0.12% 
respectively). This dramatic fall-off in risk suggests that autism is a 
complex genetic trait involving more than one genetic locus and possibly 
between-Ioci interactions. This conclusion is consistent with family studies 
which show that an oligogenic mode of transmission or polygenic model is 
the most likely scenario in autism (Pickles et al. 1995; Risch et al. 1999). 
ln addition to family and twins studies, adoption studies provide additional 
data supporting the importance genetic and/or environmental influences 
on a disease. No clear adoption studies have been undertaken in autism, 
but one study reported an increase of what the author's identified as a 
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lesser variant (milder form or incomplete manifestations of autism) of POO 
in biological relatives of the POO proband (including probands with 
autism). Specifically, the authors noted that the lesser variant was more 
frequent in biological relatives of the aftected child compared to the non-
biological relatives, indicating that genes confer susceptibility to at least 
the lesser variant of POO (Szatmari et al. 2000). There is also an increase 
prevalence of AS in autistic proband siblings than in the general 
population, suggesting that common genetic factors may predispose to 
these syndromes (Klin 2000). 
Chromosomal Anomalies 
If genetics play a role in the etiology of autism, one way to search for 
genetic factors consists of look at the chromosomes, a cytogenetic 
approach. 
Several chromosomal anomalies have been reported in autistic 
individuals. These include aneuploidies, inversions, translocations, 
deletions and duplications. The most frequently reported chromosome 
abnormalities involve chromosome 15q11-13, which corresponds to the 
Angelman/Prader Willi syndrome interval (Lauritsen et al. 2001) 
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(Castermans et al. 2004; Muhle et al. 2004). In a recent study of 
chromosomal abnormalities in 100 autistic patients from the South 
Carolina Autism Project, abnormalities on chromosome15 emerged as the 
single most common cause of autism (Gillberg 1998; Schroer et al. 1998), 
, which is consistent with the conclusions of several other studies (Gillberg 
1998). Another recurrent chromosomal anomaly is the 7q22-q33 interval, 
which contains several candidate genes for autism such as RELN, 
FOXP2, IMMP2L and RAY1 (Muhle et al. 2004). In addition to the 
numerous chromosomal aberrations noted, this region is of particular 
interest because of the multiple replications observed in linkage studies. 
Additionally, deletions and translocations on chromosome 2q21-q31, 
containing candidate genes for autism, have been reported in more than 
one autistic individual, another region of interest for candidate genes in 
autism (Ghaziuddin et al. 1999; Borg et al. 2002). Subsequently, two 
reviews of cytogenetic studies on autism unearthed sorne interesting 
candidate regions. Gillberg and colleagues reported possible loci on 
chromosomes 5q, 8, 13q, 17 and 18 (Gillberg 1998). The frequency of 
chromosomal anomalies in individuals with idiopathic autism is usuallY 
reported to be less than 5%. This is not negligible but could not explain the 
vast majority of cases. 
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Although the cytogenetic approach may give some hints with regard to the 
location of genes implicated in autism, the problem with these techniques 
is that they cannot identify specifie genes in affected individuals with a 
normal karyotype. 
Linkage Studies 
Whereas cytogenetic studies aim at searching for inherited or de novo 
genetic abnormalities, linkage studies look for common genetic markers in 
families where autism is present. 
Because families with more than one child affected with autism are 
relatively rare, large international consortiums were formed to overcome 
this difficulty. These consortiums have reported a number of whole 
genome scans using families (with 2 and more affected children). Analysis 
of the genome scan reveals genetic signais of various significant levels on 
almost every arms of every human chromosome (see figure 1) 
(International Molecular Genetic Study of Autism Consortium 1998; Barrett 
et a/. 1999; Philippe et a/. 1999; Risch et a/. 1999; Bradford et a/. 2001; 
Buxbaum et a/. 2001; International Molecular Genetic Study of Autism 
Consortium 2001; Liu et a/. 2001; Alarcon et a/. 2002; Auranen et a/. 2002; 
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Shao et al. 2002; Shao et al. 2002; Auranen et al. 2003; Shao et al. 2003; 
Yonan et al. 2003; Stone et al. 2004)). 
The differences in sample size, the number of markers, map density and 
method of diagnosis are ail elements that may contribute, in part, to the 
various signais obtained from these genome-wide scans. However, there 
are instances where studies have repeated the sa me areas of linkage. 
The most significant and overlapping regions found by linkage are 1 p, 
2q32, 3p25-p26, 5q, 6q21, 7q22, 7q31-33, 13q, 16p13, 17q, 19p and X. 
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Figure 1. Linkage signais from genome-wide scans performed for the 
search for candidate regions predisposing to autism. 
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The square in orange, aligned on the side of almost ail chromosomes, 
illustrates linkage results signais from ail genome-wide scan performed to 
date. These signais included highest linkage scores and weakest scores 
as weil. 
Recently, few research groups have started to do linkage analysis 
according to stratification by phenotype, quantitative linkage. Shao et al., 
2002 took into account the age at acquisition of phrase speech and 
reported that the loci on chromosome 2 showed a stronger signal of 
linkage (Shao et al. 2002), thus providing further support for the 
observation of Buxbaum et al. (Buxbaum et al. 2001). Interestingly, 
Alarcon et al. (Alarcon et al. 2002) reported data supporting the possible 
involvement of two quantitative trait loci (OTLs) on the putative autism-
susceptibility chromosomal region 7q: one OTL for the language and 
repetitive behaviour and one OTL for stereotyped behaviour. This, and 
other data suggests that taking into account some phenotypic traits while 
conducting genetic analyses of autism may help to identify genetic 
determinants of autism (Folstein et al. 2001). 
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Association Studies 
Since linkage studies are probably not the best method to search for 
genes in a non-mendelian disease, association studies have been used to 
test specifie etiological hypotheses in autism. 8ased on their potential 
function in the pathogenesis of autism, the list of candidate genes for 
autism is boundless. Even so, a considerable number of candidate genes 
for autism have been studied thus far. Examples are the homeobox gene 
EN2, considered a good candidate for autism because of its involvement 
in brain development (Zec et al. 1997) and its genomic localization. 
Consequently, significant differences in allele frequencies between autistic 
patients and healthy controls for one marker in this gene were observed 
(Petit 1995). Six other genes, tryptophane hydroxylase, tyrosine 
hydroxylase , insulin, insulin-like growth factor 2, c-Harvey-ras and 
secretin (a peptide that has been investigated as a therapeutic agent in 
autistic children) have been investigated, but only HRAS showed sorne 
association with autistic subjects (Herault J 1994; Yamagata et al. 2002). 
Furthermore, analysis of 9 other candidate genes in the 15q11-13 locus 
have led to the identification of linkage disequilibrium between autism and 
a polymorphism (1155CA-2) located in the gene coding region for the 
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subunit B3 of the gamma-aminobutyric acid receptor (GABRB3) (Cook et 
al. 1998). Independent evidence supporting the involvement of this 
polymorphism (Buxbaum et al. 2001) or other polymorphisms in the 
cluster of GABA related genes located in this region have also been 
reported. Another gene that maps to this chromosomal region is the 
ubiquitin-protein Iigase gene, which has been shown to cause Angelman 
syndrome and was hypothesised to play a role in autism. However, 
screening and association studies of polymorphisms in the coding and 
regulatory regions of this gene did not reveal any association with autism. 
Other studies found an association between the serotonin transporter 
gene located on chromosome 17q11 and autism (Cook et al. 1997) 
(Klauck et al. 1997; Tordjman et al. 2001; Yirmiya et al. 2001). Another 
gene that has aUracted some interest is the gene encoding for a protein 
involved in the development of the cortex, RELN, and reported to be 
dysregulated in the brains of autistic patients (Fatemi et al. 2001) RELN is 
located in a region of interest (7q) and harbours a polymorphie GGC 
repeat in its 5' untranslated region that has been linked to autism (Persico 
et a/. 2001). 
47 
Although these results are promising in the search for a gene involved in 
autism, most of the replication studies have failed to reproduce the original 
positive association. Further studies with very large number of patients 
and controls are needed to confirm these results. 
Candidates Genes Screening 
The list of candidate genes that have been investigated in autism at the 
sequences level is considerable. Expression pattern (specifically in the 
brain), function and genomic localization of a gene are sorne of the many 
criteria used to select candidate genes for autism. 
Whereas no major gene has yet been linked to autism, we now have 
evidence that a single gene mutation can lead to the autism phenotype, 
although the number of families for which where this has been reported is 
small. Recently, two X-linked genes, NLGN3 and NLGN4, were found to 
be mutated in two families with aftected brothers (one with autism and the 
other one with AS). The mutations are a frame shifting and a missense 
mutation within the coding regions of NLGN4 and NLGN3 respectively 
(Jamain et al. 2003). Interestingly, it has been established that the 
truncating mutation arose de novo in the mother, with no other family 
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members inheriting the mutation. The missense mutation was also 
inherited from the mother but it has not been established if it is de novo. 
The fact that both mutations were found in asymptomatic mothers could 
be explained by an X inactivation pattern (skewed vs. random). 
Furthermore, Laumonnier et al. have also reported a 2 base pairs deletion 
located within the coding region of NLGN4 gene, in one family which 
included males affected with autism and POO, as weil as males displaying 
non specifie mental retardation (Laumonnier et al. 2004). NLGN3 and 
NLGN4 belong to the neuroligin family of postsynaptic cell adhesion 
molecules that are widely expressed in the brain (Philibert et al. 2000). 
These gene products are involved in the late stages of synaptogenesis, 
mediating the specifie recruitment of pre- and postsynaptic proteins to the 
site of initial synaptic contact. Two independent in vitro studies have 
shown that the frame shifting and missense mutations described in cases 
of autism alter the formation of presynaptic terminais (Chih et al. 2004) 
(Comoletti et al. 2004). Any gene implicated in this pathway is a good 
candidate gene for autism. 
Mutations in the MECP2 gene an X-linked gene, which leads to the RS 
phenotype, were found in 4 females diagnosed with autism (Lam et al. 
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2000; Carney et al. 2003). This finding may reflect a common 
-J 
pathogenesis since phenotypic similarities exist between autism and RS, 
such as the onset early after birth, stereotypie behaviour, difficulties in 
social interaction, and verbal impairment. MECP2 is a transcription 
repression factor expressed by neurons and preferentially abundant in 
mature neurons. Although we don't yet know ail the target genes, MECP2 
may plays role in synaptic pro cesses (Shahbazian et al. 2002; Balmer et 
al. 2003). In fact, the reduced neuronal size and shortened dendritic 
pattern found in post-mortem studies of autistic patients are also 
consistent with synaptic defects. Thus MECP2 mutations in autistic 
patients are not surprising. However, the clinical overlap between these 
disorders may lead to diagnostic errors, which may be responsible in 
some instances to the finding of mutations in MECP2 in autism. 
ln summary, genetic studies have progressed to the point where 
candidate regions are being identified using cytogenetic and linkage 
studies; the next step is to identify the gene(s). The rapid progress in the 
sequencing of the human genome transforms the positional cloning from a 
labour intensively multi-step effort, involving cloning large segments of 
DNA, identifying genes and testing them for involvement in the disorder, to 
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a single step gene sequence analysis procedure. This wealth of 
information offers an opportunity to further accelerate the identification of 
disease predisposing genes in complex traits. 
RETT SYNDROME 
Rett syndrome (RS) is unlike any other paediatric neurological disorders in 
that it cannot be classified simply as a degenerative condition or 
developmental malformation (Dunn et al. 2001). Rather it appears to be a 
form of arrested development due to a sporadic mutation in the MECP2 
gene (Amir et al. 1999). 
Remarkable progress in our understanding of the clinical, neurobiologic, 
and molecular genetic features of RTT have occurred since the first 
established criteria in mid 1980's. To date, the identification of mutations 
in MECP2 as the molecular basis of girls with RS is the most important 
discovery in this disease. This discovery defines a new class of genetic 
disease that might extend far beyond RS and apply to other 
neurodevelopmental disorders. 
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The MECP2 Gene and Product 
The MECP2 gene spanning 75 865 base pair nucleotide sequences, 
according to the University of California Santa Cruz Genome 
Bioinformatics Site (UCSC browser; http://genome.ucsc.edu/),islocated 
on the human X chromosome, band q28, and contains 4 exons. The gene 
encodes for two different isoforms of 498 (MECPE1) and 486 (MECP2E2) 
ami no acids depending on the use of alternative splice variants 
(Kriaucionis et a/. 2004; Mnatzakanian et a/. 2004). Human, mice and 
monkey studies of the MECP2 gene expression profile show that it is 
abundant in neurons of the central nervous system, highest in postmitotic 
neurons (Akbarian (Akbarian et a/. 2001; Jung et a/. 2003). This 
chromosomal protein acts as a transcriptional repression factor and has 
three functional domains: (1) the methyl CpG binding domain (MBD) 
essential to specifically bind to methylated DNA (2) the transcriptional 
repression domain (TRD) required for recruiting a co-repressor complex 
that mediates repression through deacetylation of core histones, with 
consequent compaction of DNA into heterochromatin and (3) the WW 
domain binding region, that binds specifically to Group Il WW domains of 
splicing factors BP11 and HYPC (Buschdorf et a/. 2004). Through these 
three domains, MECP2 silences key genes that are essential in the 
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ontogeny of neuronal cell development (Wade 2001). Until now, the list of 
genes targeted by MECP2 remained to be established. However, 
preliminary studies identified one possible MECP2 target, the BDNF gene. 
This brain derived neurotrophic factor gene play an important role in 
development, neuronal survival, neural plasticity, learning and memory 
(Chen et al. 2003). 
Mutation Spectrum and Phenotype-Genotype Correlation 
Mutation in the MECP2 gene, the great majority of which are sporadic, is 
found in about 80 % of RS patients when using the current PCR 
(polymerase chain reaction) based method to screening exon 2,3 and 4 
(Van den Veyver et al. 2001; Miltenberger-Miltenyi et al. 2003). Among 
these 80 % correspond to single nucleotide changes mostly located at 
CpG dinucleotides, 17 % are small deletion and 3 % insertions (Percy et 
al. 2004). A fraction of cases, 10 to 15%, may harbour a large deletion of 
MECP2 gene which can only be detected using a specific PCR approach 
(semi-quantitative PCR and multiplex quantitative PCR assay) (Erlandson 
et al. 2003; Schollen et al. 2003; Ariani et al. 2004; Laccone et al. 2004). 
Although yet uncommon, a small portion of RS patients may have 
mutation in the new MECP2 isoform. Overall, mutations in MECP2 are 
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found in up to 90-95% of RS cases. The remaining cases might have a 
mutation in MECP2 promoter/regulatory region or may be the result of 
locus heterogeneity (Van den Veyver et al. 2000; Schollen et al. 2003; 
Laccone et al. 2004). In fact RS is not synonymous with MECP2 mutation 
and on the other hand, MECP2 mutations may be found without RS 
phenotype. Mutated MECP2 leads to many phenotypes with heterogeneity 
across males and females (table 3). 
Table 3. Phenotypes observed with MECP2 mutations 
Female 
Rett Syndrome 
Preserved speech variant 
Delayed Onset Variant 
Mild Learning Disability 
Angelman Syndrome 
Autism 
Normal carrier 
Male 
Fatal Encephalopathy 
Mental Retardation/Progressive Spasticity 
RettlKlinefelter Syndrome 
Somatic mosaicism/neurodevelopmental Delay 
Even though mutations are scattered along the entire gene, three principal 
clusters are observed. Missense mutations are usually grouped within the 
MBD whereas nonsense mutations are more clustered in the TRD, but 
also tend to localize between the MBD and the TRD (the interdomain). 
The small deletions are found to gathering at the C-terminal region, a 
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region name «deletion-prone region» because most of the mutation found 
are deletions (Laccone et al. 2001). 
While a single mutated gene is responsible for the majority of RS cases, a 
wide range of phenotypic expression can be observed. This phenotypic 
variability may be explained by different mechanisms and factors. One 
obvious one is the mutation type. The major consistent 
phenotype/genotype correlation finding is that patients harbouring a 
truncating mutation, compared to those with ail other mutation types, have 
a more severe phenotype (example, an earlier onset of hand stereotypies) 
(Colvin et al. 2004). More over, within truncating mutation types, nonsense 
mutations appear to give a more severe phenotype than frameshifting 
mutation. Patients with a nonsense mutation show an earlier onset of 
regression, an earlier onset of loss of social communication and have a 
more severe phenotype (Chae et al. 2004; Colvin et al. 2004). As 
mentioned earlier, MECP2 contains different important domains. 
Therefore, mutation localization clearly contributes to the phenotypic 
expression variability. Monros et a/., Huppke et al., and more recently 
Colvin et al., demonstrated that mutations within the nuclear localization 
signal, which is itself located inside the TRD, lead to a more severe 
55 
phenotype compare to other localization (Monros et al. 2001; Huppke et 
al. 2002; Colvin et al. 2004). Missense mutation appears to give a less 
severe phenotype and mutation at the C-terminus appears to give a less 
severe phenotype. 
A other important factor that explains the phenotypic variability seen in a 
cohort of RS patients is the pattern of X chromosome inactivation of the 
mutant allele versus the wild type (Chae et al. 2004; Young et al. 2004). 
The MECP2 gene has been show to undergo X inactivation in mice and 
humans (Adler et al. 1995). 
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RATIONAL AND OBJECTIVE OF THE RESEARCH 
Because autism is a complex trait, both from a clinical and from a genetic 
perspective, it is necessary to recruit a large sample of well-characterized 
patients. The sam pie must be large enough to allow us to use robust 
genetic tools such as association studies and linkage disequilibrium. We 
had the opportunity to collect patients of French-Canadian ethnic origin. 
Detailed clinical information was obtained for a subset of patients collected 
in the Montreal Metropolitan area. With such a collection, we then 
proceeded to search for genetic factors involved in autism. To do so, we 
performed association studies and used a candidate gene approach in 
patients suffering form autism, Asperger, PDDNOS as weil as both their 
parents. 
Specific Aims of the Present Project 
Two main projects are at the core of the current thesis, one focusing on 
Rett syndrome, the other on Autism Spectrum Disorder. Each project is 
discusses separately 
57 
Objective of the Autism Spectrum Disorder Study 
The core objective of this project was to map and identify the gene (or 
genes) that may predispose individuals to autism using a family-based 
association and a candidate gene approach. 
The specific aims are: 
To recruit 500 autistic patients and both their parents 
To localize susceptibility regions for autism using a family-based 
association study on the X chromosome 
To perform a family-based association study at the NF1 locus a previously 
reported candidate locus in our subjects 
To analyse the role previously reported candidate genes: NLGN3, NLGN4, 
MBD1, MBD2 and FOXP2 
Objective of the Rett Syndrome Project 
The specific aims are: 
To confirm the role of MECP2 gene in our Canadian cohort of RS patients. 
To evaluate the importance of diagnostic procedures on the mutation 
detection rate. 
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Identification and Characterization of Subjects 
The selection of subjects in a genetic research project is one of the most 
important and critical steps, particularly for complex disorders such as 
autism. As described above, autism is a clinically heterogeneous disorder, 
which progresses and changes over time and overlaps with many different 
disorders, making the diagnosis sometimes difficult. Therefore, it is 
important to have a systematic subject recruitment procedure using 
standardized diagnostic tools that have been developed over the years. 
Autism Spectrum Disorders 
ln order to maximize the homogeneity of our participants and at the sa me 
time increase our chance of recruiting a relatively high number of subjects, 
we used current standardized diagnostic tools for autism with two levels of 
diagnostic evaluation: complete and minimal (see table 4 for summary). 
Complete Evaluation: 
At each referring centre, a trained clinician conducted the Autism 
Diagnostic Interview (ADI-R) (Lord et al. 1994) with the parent of each 
affected participant. The ADI-R is used worldwide in research settings for 
standardized investigator-based assessments of DSM-IV/lCD-1 0 
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diagnostic criteria for autism. It entails a lengthy interview with the parents 
and/or caretakers of the child. Diagnosis of autism is obtained when 
subjects are above the cut-off in each of the 4 relevant areas (social, 
communication, repetitive behaviours and age at onset). In addition, 
subjects were assessed through direct observation, using the ADOS-G 
(Lord et al. 2000) (Autism Diagnostic Observed Schedule-Generic) 
modules 1, 2, 3 or 4 according to the language level of the subject. The 
final diagnostic determination was obtained by combining ADI-R, ADOS-G 
and clinical data. 
Minimal Evaluation: 
A trained assistant confirm the presence of DSM-IV criteria on subject's 
file, and conducted the completion of the autism screening questionnaire 
(ASa) by parents, a tool that has been cross-validated against the ADI 
(Berument et al. 1999). Ali the information was reviewed and patients 
were included in the study using to the following inclusion criteria: The 
subject has been diagnosed with PDD by at least two clinicians and the 
ASa score (completed by parents) is 15 or higher. If the child had been 
diagnosed with PDD by at least 1 clinician, a score of at least 15 on the 
ASa (completed by parents) plus 15 positive ASa items on review of the 
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medical file must be found. Subjects with a co-occurring diagnosis of 
semantic-pragmatic disorder (due to its large overlap with POO), attention 
deficit hyperactivity disorder (seen in a large number of patients with 
autism during development), and idiopathie epilepsy (which is related to 
the core syndrome of autism) were eligible for the study. 
Exclusion criteria were: (a) Estimated Mental age < 18 months, which is 
the lowest inferior limit for the validity of autism diagnosis, determined 
using the medical file. (b) A diagnosis of Rett syndrome or Childhood 
Oisintegrative Oisorder. (c) Any comorbid disorder with a possible genetic 
component including: birth anoxia, rubella during pregnancy, fragile-X 
disorder, encephalitis, phenylketonuria, tuberous sclerosis, Tourette and 
West syndromes. 
Table 4. Summary of procedures used for recruitment of patients with 
an autism spectrum disorders 
Step 1 Step 2 Step 3 
AOI-R Result Parents 
Medical File Recruitment 
Interview 
YES Positive ASa Asa Yes 
Negative Excluded 
NO 2 diagnosis ASa ASa> 15 Yes 
1 diagnosis ASa> 15 Asa> 15 Yes 
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Since the beginning of this project, over a thousand subjects have been 
enrolled in this study. Table 5 presents characteristics of these subjects. 
Table 5. Subject characteristics from our cohort of autism spectrum 
disorders. 
Collection 
Ethnie origin 
Other 
Total sample 
Autistic subjects 
Males 
Females 
Age 
Complete trios 
Affected sib pairs 
Non-affected relatives 
At least one FC 
parents 
Others 
Epilepsy 
Hyperactivity 
ADHD 
Mental retardation 
ASa screening 
ADI/ADOS screening 
1073 
360 
314 
46 
11.87 ± 7.8 
332 
26 
51 
60 % 
40 % 
5% 
18 % 
4% 
45% 
100 % 
40 % 
FC: French-Canadian, ADHA: Attention Deficit Hyperactivity Disorder, 
ADI: Autism Diagnostic Interview, ADOS: Autism Diagnostic Observed 
Schedule. 
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ReU Syndrome 
Blood from RS patients were collected across the country with the help 
and collaboration of Dr. Patrick Macleod and his important Canadian 
clinical network. Therefore, patients have been referred from various 
Canadian centres. Diagnostic information's are described in section 4.6 
Patient and Method 
The following sections are separated according to the articles resulting 
from the work mainly done during my PhD thesis. The two first articles 
concern the work accomplished on the autism project and the third results 
from work done on the RS project. 
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FAMILY-BASED ASSOCIATION STUDY 
This chapter describes the methodology and our results obtained using 
the family-based association approach for the search of gene (s) for 
autism. We use our cohort of autistics patients and their parents to test 
loci on two different chromosomes: X and 17 chromosomes. The X 
chromosome study was my main project in the search of a putative gene 
(s) for autism. The chromosome 17 study was realised in collaboration 
with Dr. Christian Andres in France. The results obtained from theses two 
studies are separated into two articles: The first presents the results 
obtained from our whole X chromosome family-based association study 
while the second present the results obtained from the OMGP gene 
association study located on chromosome 17. 
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Abstract 
It is now weil established that genetic factors play an important role in the 
pathogenesis of autism disorder and converging lines of evidence suggest 
the implication of the X chromosome. Using a sam pie of subjects 
diagnosed with autism spectrum disorders, exclusively composed of 
males from French-Canadian origin, we tested markers covering the entire 
X chromosome using a family-based association study. Our initial analysis 
revealed the presence of association at two loci: DXS6789 (p = 0.026) and 
DXS8043 (p = 0.0101). In a second step, we added support to the 
association at DXS8043 using additional markers, additional subjects and 
a haplotype based analysis (best obtained p-value = 0.00001). These 
results provide support for the existence of a locus on the X chromosome 
that predisposes the French-Canadians to autism spectrum disorders. 
Introduction 
Autism disorder (AD, MIM 209850) is a neurodevelopmental 
neuropsychiatrie disorder characterized by behavioural impairments in 3 
areas of child development: (1) social interaction, (2) verbal and non-
verbal communication and imaginative play, (3) restricted interests and 
stereotypie play (DSM-IV 1994; Bristol et al. 1996; Tanguay 2000). This 
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condition affects up to 1/1000 individuals (Fombonne 2002) with a male to 
female sex ratio of 4: 1 (Fombonne 2003). AD is a clinical diagnosis based 
on criteria defined in the Diagnostic and Statistical Manual of Mental 
Disorder, Fourth Edition (DSM IV); together with Asperger Syndrome and 
Pervasive Developmental Disorder Not Otherwise Specified (PDDNOS) it 
forms the category of Autism Spectrum Disorders (ASD). Research clearly 
substantiates the role of genetics in the etiology of ASD (Lauritsen et a/. 
2001; Muhle et a/. 2004). 
To date, several chromosomal loci have been suspected of harboring 
genes for ASD including loci on X chromosome (Cohen 1997; Tanguay 
2000; Vincent et a/. 2005). In a recent study by Jamain et al, mutations in 
two neuroligin X-linked genes were found in 2 families containing sib-pairs 
affected with Autism and Asperger Syndrome (Jamain et a/. 2003). 
Mutation screenings in 96 of our affected individuals with an autism 
disorder did not reveal any causative variants in these genes (Gauthier et 
a/. 2005). In addition, Vincent et a/. did not find any causative variants in 
196 autistic proband indicating that these two genes are responsible for 
onlya small fraction of ASD cases (Vincent et a/. 2004). These data 
suggest that at least one other locus on the X chromosome may play a 
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role in the development of ASD. Since several independent candidate loci 
appear to exist on the X chromosome (Philippe et al. 1999; Liu et al. 2001; 
Auranen et al. 2002; Shao et al. 2002; Yonan et al. 2003; Vincent et al. 
2005), and much evidence suggest a role of X-linked genetic factors, in 
the present study we choose to examine the entire X chromosome for the 
search of a candidate locus in our population. 
As previously mentioned, ASD affects males more than female (with a 
male to female ratio as high as 8:1 in Asperger syndrome); Although the 
reasons for su ch differential distribution between males and females is not 
entirely understood, it is possible that at least part of this may be due to X 
chromosome loci in a subgroup of patients. Schutz et al. reasoned that if 
an X-linked locus exists for AD or ASD, then affected males are more 
likely to represent a homogenous subgroup of individuals (Schutz et al. 
2002). Therefore, in order to reduce the genetic heterogeneity, we only 
included affected males with ASD in the present study. 
ln addition to increasing homogeneity by studying males only, we selected 
our probands from a population with a strong founder effect, which may 
provide advantages in the search for genes predisposing to complex 
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conditions such as ASD. The existence of a founder effect in the French-
Canadian (FC) population has been confirmed by many studies (Davignon 
et al. 1993; Simard et al. 1994; Heyer et al. 1995). The FC population is 
particularly weil suited for genetic studies of heterogeneous diseases for 
several reasons, including: (1) the vast majority of FC are descendants of 
a small number of ancestors who came to Nouvelle-France (Canada) prior 
to 1760; (2) for socio-economic, religious and linguistic reasons, the 
descendants of these founders did not mix with other immigrants over 
three centuries; (3) there was significant sustained demographic growth of 
the population with doubling of the population every 25-30 years; and (4) 
detailed haplotyping of 10 cM segments of FC chromosomes has shown 
that there are few double recombinants, thus facilitating the use of 
haplotypes for fine mapping. Such founder effects help to reduce noise 
when searching for candidate genes in association studies (Davignon et 
al. 1993; Simard et al. 1994; Heyer et al. 1995). Ultimately, the advantage 
of using a more homogenous population in an association study is that it 
reduces the need for a large sam pie size and for multiple densely spaced 
markers. 
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To date, the majority of studies investigating X chromosome in ASD are 
linkage studies using multiplex families or affected sib-pair subjects. For 
this study, we chose a different approach: we used a sam pie of FC males 
trios (affected child and parents) to evaluate association over the entire X 
chromosome. This analysis was conducted in two steps. In Step l, we 
tested 13 microsatellite markers (spaced -10 Mb) selected on the basis of 
their relevant chromosomal location, including 4 markers previously 
reported to be linked with autism (DXS996, DXS7132, DXS6789 and 
DXS1047), in an initial set of 64 unrelated trios. In Step Il, we added 21 
FC males trios and additional markers at the most promising loci. 
Subjects and Methods 
Subjects diagnosed with autism spectrum disorders and both of their 
parents were recruited from clinics specializing in the diagnosis of 
Pervasive Developmental Disorders (POO), readaptation centers, and 
specialized schools in the Montreal and Quebec regions, Canada. 
Subjects with ASD were diagnosed by child psychiatrists and 
psychologists expert in the evaluation of ASD. Evaluation based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria 
included the use of the Autism Diagnostic Interview-Revised (ADI-R) (Lord 
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et al. 1994) and the Autism Diagnostic Observation Schedule (ADOS) 
(Lord et al. 2000). As an additional screening tool for the diagnosis of 
ASD, the Autism Screening Questionnaire, which is derived from the ADI-
R, was completed (Berument et al. 1999). Furthermore, ail probands 
medical charts were reviewed bya child psychiatrist expert in POO to 
confirm their diagnosis and exclude subjects with any co-morbid disorders. 
Exclusion criteria were: (1) an estimated mental age < 18 months, (2) a 
diagnosis of Rett Syndrome or Childhood Disintegrative Disorder and (3) 
evidence of any psychiatrie and neurological conditions including: birth 
anoxia, rubella during pregnancy, fragile-X disorder, encephalitis, 
phenylketonuria, tuberous sclerosis, Tourette and West syndromes. 
Subjects with these conditions were excluded based on parental interview 
and chart review. However, participants with a co-occurring diagnosis of 
semantic-pragmatic disorder (due to its large overlap with POO), attention 
deficit hyperactivity disorder (seen in a large number of patients with AD 
during development), and idiopathie epilepsy (which is related to the core 
syndrome of AD) were eligible for the study. Because males don't inherit 
their paternal X chromosomes, patients for this study were classified as 
being FC when the maternai grand parents were of FC origin. 
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DNA Screening 
Blood samples were collected from each member of the nuclear families 
(subject, mother, and father) followed by DNA (deoxy-ribonucleic acid) 
extraction from lymphocytes using the Puregene reagents (Gentra 
System, USA). Microsatellite markers were obtained from the Marshfield 
genetic map (Center for Medical Genetics, Marshfield Medical Research 
Foundation) and primer sequences were obtained from the Genome 
Database http://www.gdb.org/ and the UCSC Genome Bioinformatics site 
(http://genome.ucsc.edu/). The marker map positions were based on sex-
averaged maps from the Marshfield Medical Research Foundation. 
Variable number tandem repeats (VNTR) were selected from the UCSC 
Genome Bioinformatics site and primers were designed as described 
above. PCR amplification for microsatellites and VNTR were performed in 
the presence of S35-dATP and amplicons were analyzed on 6% 
denaturing polyacrylamide gel, followed by autoradiography. Allele sizes 
were determined by comparison to an M13mp18 sequence lad der and 
numbered according to the Foundation Jean Dausset CEPH database. 
Single nucleotide polymorphisms (SNP) were chosen from public 
database and genotyping was performed at the McGili University and 
Genome Québec Innovation Centre 
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(http://www.genomequebec.mcgill.ca/) on the Ultra-High Throughput 
Orchid platform. SNP-flanking sequences were tested for the presence of 
repeats or duplicated regions using the BLAT program 
(http://www.genome.ucsc.edu). PCR primers were designed using the 
Autoprimer program (http://www.autoprimer.com). Sequencing for 
mutation detection were done as published elsewhere (Gauthier et a/. 
2003). 
Statistical analysis 
Transmission Oisequilibrium Test (TOT) and haplotype association tests 
were computed using TDTPHASE from UNPHASEO software, a program 
written by Frank Oudbridge (UNPHASED, version 2.403; http://www.mrc-
bsu.cam.ac.uk 
/personal/frank/software/unphased/) (Dudbridge, Koeleman et a/. 2000; 
Koeleman, Herr et a/. 2000; Dudbridge 2003). UNPHASEO is a suite of 
programs for association analysis of multilocus haplotypes from phased 
and unphased genotype data. The programs extend previous methods to 
include haplotypes and missing genotypes and allow X chromosome data. 
ln the case of X chromosome data from males, paternal genotype is 
ignored and only maternai genotypes are considered. Ail of the results 
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presented in this study were done without using the unphased haplotypes 
option in order to have the real representation of the sam pie haplotypes 
and statistics. The significance of each potential association is measured 
bya likelihood ratio statistic (LRS). Odds ratios (ORs) were calculated 
using the pragram 2BY2 version 1.50 from Jurg Ott (Utility pragrams for 
analysis of genetic linkage, 1988-2001). P-values are derived fram the 
Fisher's exact test and the TWO-SIOEO P-value was considered. An odds 
ratio of 1 implies that the allele is transmitted 50% of times, in average. An 
odds ratio greater or lesser than 1 implies that the allele is significantly 
over- or under-transmitted to the affected subject respectively. Linkage 
disequilibrium between markers (D') was calculated using the program 
LOMAX for the input file followed by the use of the GOLO program 
(www.well.ox.ac.uklasthma/GOLO). For ail the analyses do ne in the 
present study, corrections for multiple testing were not carried out. For 
graphie representation, LRS and P-value were converted to the -LOG 10 
P-value. 
Results 
A total of 255 individuals were included in the present study. This 
represents 85 nuclear families of Fe origin. Ali probands were males and 
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they ail received a diagnosis of autism spectrum disorder (Autism, 
Asperger and Pervasive developmental disorder not otherwise specified). 
Average age of the affected subjects was 13.1 years, with a range of 3.3 
to 33.4 years. 
Step 1: X chromosome-wide individual marker association 
TDT was performed using 13 markers (Table 6) in 64 unrelated ASD 
affected FC trios. The average heterozygosity of these 13 markers is 0.73 
and the average genetic distance between contiguous markers is 7 cM. 
Evidence for association at marker DXS6789 (LRS = 18.940, df = 9, P = 
0.0257) and marker DXS8043 (LRS = 20.06, df = 8, P = 0.0101) were 
found with the 64 FC trios (Table 7). For marker DXS6789, linked to ASD 
in previous studies (Auranen et al. 2002; Shao et al. 2002) a departure 
from random transmission is observed with two alleles (Table 7). Allele 3 
(141 bp) is significantly over-transmitted to the affected proband, 
suggesting that it may be a risk allele. In contrast, allele 4 (137 bp) is 
under-transmitted suggesting a protective effect. For marker DXS8043, we 
also observed a pattern of over-transmission of allele 3 (167 bp) 
suggesting that this allele confers risk. Since DXS6789 (LOCUS Xq21.33) 
and DXS8043 (LOCUS Xq27.3) are 32 cM apart, we considered them as 
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two independent loci. None of the other 11 markers was associated with 
ASO in this study sam pie. 
Stage Il: Fine mapping 
To further analyze the associations at LOCUS Xq21.33 and LOCUS 
Xq27.3, we analyzed additional markers and added 21 newly recruited 
males. Markers were chosen according to their physical location. 
LOCUS Xq21.33 
ln this second Step, we added 3 markers; OXS6908, OXS8077 and 
OXS6799 at position 61.88 cM, 62.52 cM and 64.41 cM respectively. TOT 
analysis revealed suggestive association with marker OXS6799 (LRS = 
12.85, df = 5, P = 0.0248). This marker is 1.88 cM centromeric to 
OXS6789. Although the number of informative transmission is very 
modest, the only observed departure from random transmission is 
observed with allele 5 (Transmitted = 1, non transmitted = 7, OR 0.13; CI: 
0.02-1.07, p = 0.00591). 
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LOCUS Xq27.3 
ln addition to microsatellite markers, LOCUS Xq27.3 was also further 
investigated with single nucleotide polymorphism (SNP) because of the 
limited availability of microsatellites within the region. Since SNP are much 
less informative than repeats, we used several SNP to coyer this 
candidate region (see Table 6 for markers used). Analysis of these 
additional markers revealed association with three SNP (rs232684, 
rs232686 and rs232707), which are telomeric to DXS8043 (Table 8). The 
most significant association is found with SNP rs232684 (LRS = 6.641, df 
= 1, P = 0.00996). Ail of theses three SNP represent a C to T transition. 
For ail of them, allele C revealed an OR > 5, suggesting that this allele 
from these three SNP may be associated with increased susceptibility to 
ASD. 
Haplotype analysis 
ln order to determine if we can detect a common susceptibility haplotype 
in the present sample of FC ASD males at LOCUS Xq21.33 and Xq27.3, 
we first determined Linkage Disequilibrium (D') between contiguous pairs 
of markers tested at both loci. Markers in LOCUS Xq21.33 do not show 
any evidence of LD (data not show). However, at LOCUS Xq27.3, values 
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of D' > 0.8 are observed for several pairs of markers (see Figure 2). 
Consequently, for LOCUS Xq27.3 markers in LD, we tested different 
combinations of marker haplotypes using the sliding window approach. 
Looking at the haplotype combination and considering only heterozygous 
mothers for the haplotypes, a chromosomal region composed of seven 
markers (rs 1415636-rs 1339486-rs232684-rs232686-DXS8045-rs232695-
rs232707), and highly in LD, showed a significant departure from random 
transmission. Within this region, several haplotypes windows gave a 
positive value, with the most significant associations being represented in 
Table 9. Among these, three haplotypes showed a p-value equal to 
0.00001. Transmission of these haplotypes represents almost half of 
subjects harbouring these haplotypes. 
Within the associated LOCUS Xq27.3, only two annotated genes lie in that 
region, SL TRK2 and CXORF1. In addition to their physicallocation, these 
genes are of interest as they are mainly brain expressed in region 
reported to be affected in ASD. While the function of CXORF1 is not yet 
known, SL TRK2 is involved in the syntaptogenesis. We therefore 
sequenced in both directions the genomic sequence of these two genes, 
in 8 affected patients and two healthy controls. Patients included in this 
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screening had the largest most common over-transmitted haplotype 
(Table 9: haplotype #7). No mutations were found in any of these subjects. 
Discussion 
To our knowledge, this is the first family-based association study looking 
at the entire X chromosome. In the present study we have identified 2 
potential associations between FC autistic families and markers on the X 
chromosome. Marker DXS6789 is already known to be associated with 
autism (Auranen et al. 2002; Shao et al. 2002) and our results add further 
support for its implication in ASD. Whereas we found a modest 
association with one individual marker, the limited number of markers 
used and the physical position of these markers did not allow us to 
conduct a haplotype analysis (LD (D') < 0.04, data not showed). 
Genotyping more markers within this locus is needed to further analyze it 
possible role in ASD. 
LOCUS Xq27.3 represents the most significant association in the present 
study. Interestingly, two independent studies reported positive linkage at 
this region. Yonan et al. found a proximal linkage (X-MLS = 1.78) with 345 
analyzed multiplex families (Yonan et al. 2003). More recently, Vincent et 
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al. using 22 families found a modest linkage with two markers (MLOD = 
1.3, P = 0.01, and MLOD = 1.7, P =0.005), which are centromeric and 
telomeric to our associated region (Vincent et al. 2005). While for both 
group their linked region is quite large our genomic segment found to be 
most significantly associated with ASD in the present study is quite small, 
representing 274 kb (according to the UCSC Genome database). 
Interestingly the most associated single marker allele, rs232684, is in the 
core of the haplotypes shown in Table 9. This polymorphism is not part of 
any predicted mRNAs and ESTs and the C is not conserved across 
species, which suggest that rs232684 is not a functional polymorphism. 
According to public databases, the associated genomic segment is a gene 
poor region. In fact, the region contains no annotated genes. However, 
several human ESTs and two human mRNAs are present in the interval. 
Among these, only one mRNAs, BC040297, overlaps with a predicted 
transcript, named «flerju». In addition, the region contains many non-
human mRNAs and several conserved regions between human and other 
species. However, these are not overlapping with human ESTs or human 
mRNAs suggesting that they might not be real genes. 
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As we expected to find a large common region in the founder population, 
the identification of a relatively small associated region (274 kb) suggests 
that the susceptibly haplotype may be older than the founding of FC 
population. Consequently many recombination events would have 
occurred before the establishment of the population in Quebec. The 
detection of association at two loci in the sa me cohort of subjects raises 
the possibility of different hypotheses: Two ancestral mutations have been 
introduced in the FC population or one of the associations may be a false 
positive at one locus. In order to confirm that this haplotype is a common 
susceptibility haplotype for ASD, it will need to be replicated in other 
population. 
We have looked at the sequence of two annotated genes, SLlTRK2 and 
CXORF1, which are centromeric to the associated haplotype. While the 
function of CXORF1 is not clear (Redolfi et a/. 1998), the gene product is 
found mainly in the hippocampus, particularly in the granular-cell layer of 
the dentate gyrus, a brain region reported to be involved in autism 
(Raymond 1996; Schumann et a/. 2004). SLlTRK2 is a neuronal 
transmembrane protein which controls neurite outgrowth (Aruga et a/. 
2003; Aruga et a/. 2003). These genes are candidates for ASD; however 
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no mutation was found. Our negative mutational analysis results are 
consistent with the fact that they are located outside of the associated 
genomic segment. 
The present study presents different limitations and the results should be 
interpreted with caution. No correction for multiple testing has been done. 
Moreover association studies are known, especially when using multiple 
marker tests, to produce false positive results. These results need to be 
replicated in an independent FC autistic cohort as weil as non FC cases. 
We are currently collecting additional samples to replicate our results. 
ln conclusion, our data supports the existence of two candidate loci on the 
X chromosome. 
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Table 6. Markers used in our X-chromosome association study 
Marker Initial Additional 
Marker type cM Band 
number markers markers 
1 DXS996 CA (n) 15.66 Xp22.32 
2 DXS8036 CA (n) 22.72 Xp22.2 
3 DXS9896 GATA (n) 30.84 Xp21.3 
4 DXS6810 GATA (n) 42.75 Xp11.3 
5 DXS7132 GATA (n) 52.50 Xq12 
6 DXS990 CA (n) 60.62 Xq21.32 
7 DXS6809 GATA (n) 61.88 Xq21.33 
8 DXS8077 CA (n) 62.52 Xq21.33 
9 DXS6789 GATA (n) 62.52 Xq21.33 
10 DXS6799 GATA (n) 64.41 Xq21.33 
11 DXS8055 CA (n) 70.91 Xq23 
12 DXS1047 CA (n) 82.07 Xq25 
13 DXS8094 CA (n) 82.84 Xq26.3 
14 DXS8106 CA (n) 91.64 Xq27.3 
15 DXS8073 CA (n) 94.22 Xq27.3 
16 DXS8043 CA (n) 94.22 Xq27.3 
17 VNTR6 VNTR 94.22 Xq27.3 
18 DXS8028 CA (n) 95.13 Xq27.3 
19 VNTR35 VNTR 95.13 Xq27.3 
20 VNTR36 VNTR 95.13 Xq27.3 
21 rs871156 CIT 95.13 Xq27.3 
22 rs1416770 CfT 95.13 Xq27.3 
23 rs1415636 CIT 95.13 Xq27.3 
24 rs1339486 CfT 95.13 Xq27.3 
25 rs232684 CIT 95.13 Xq27.3 
26 rs232686 CIT 95.13 Xq27.3 
27 DXS8045 CA(n) 96.94 Xq27.3 
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28 rs232695 CIT 96.94 Xq27.3 
See next page 
29 rs232707 CfT 96.94 Xq27.3 
30 Rs1072196 CIT 96.94 Xq27.3 
31 DXS1200 CA(n) 96.94 Xq27.3 
32 DXS998 CA(n) 96.94 Xq27.3 
33 DXS1215 CA(n) 97.89 Xq28 
34 DXS8087 CA(n) 102.35 Xq28 
Marker genetic localization is from Marshfield genetic map; Band position 
according to NCBI Build 34 fram UCSC July 2003 assembly; DXS markers 
represent micrasatellites markers, rs markers are the single nucleotide 
polymorphisms and VNTR are variable number of tandem repeats. 
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Table 7. TOT analysis results trom OXS6789 and OXS8043 markers in 
64 autistic Fe males trios. 
Allele Size T Freq-T NT Freq-NT OR (CI) P-value 
OXS6789 
1 149 6 0.125 6 0.125 1 (0.30-3.35) 1.00000 
2 145 8 0.167 8 0.167 1 (0.34-2.93) 0.78499 
3 141 20 0.417 6 0.125 5 (1.78-14.01) 0.00043 
4 137 9 0.188 19 0.396 0.35 (0.14-0.89) 0.04226 
5 133 1 0.021 2 0.041 0.49 (0.04-5.58) 1.00000 
6 121 0 0.000 5 0.104 0.08 (0-1.52) 0.00000 
7 117 2 0.042 1 0.021 2.04 (0.18-23.32) 1.00000 
9 153 0 0.000 1 0.021 0.33 (0.01-8.21) 0 
10 157 1 0.021 0 0 3.05 (0.12-76.30) 0 
11 125 1 0.021 0 0 3.05 (0.12-76.30) 0 
LRS = 18.940, OF = 9, P-value = 0.0257 
OXS8043 
1 179 7 0.137 12 0.235 0.52 (0.19-1.44) 0.1256 
2 181 3 0.059 11 0.216 0.23 (0.06-0.87) 0.00767 
3 167 20 0.392 9 0.177 3.01 (1.21-7.51) 0.00782 
4 183 8 0.157 7 0.137 1.17 (0.39-3.51) 0.57731 
6 185 2 0.039 5 0.098 0.38 (0.07-2.03) 0.43638 
7 175 4 0.078 7 0.137 0.53 (0.15-1.95) 0.20027 
8 177 5 0.098 0 0 12.18(0.66-226) 0 
9 171 1 0.020 0 0 3.05 (0.12-76.30) 0 
10 187 1 0.020 0 0 3.05 (0.12-76.30) 0 
LRS = 20.06, OF 8, P-value = 0.0101 
Column T and NT represent transmitted and non transmitted alleles; Freq-
T and Freq-NT are the frequencies of T and NT alleles; OR = Odds Ratio; 
CI = Confidence Interval (CI); LRS = Likelihood Ratio Statistic; OF = 
Degree of freedom, size (bp) 
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Table 8. TOT analysis results from LOCUS Xq27.3 with additional 
markers additional trios 
Allele T Freq-T NT Freq-NT OR (CI) P-value 
OXS8043 
1 7 0.109 14 0.219 0.44 (0.16-1.17) 0.05437 
2 5 0.078 13 0.203 0.33 (0.11-1) 0.07293 
3 23 0.359 11 0.172 2.70 (1.18-6.17) 0.02687 
4 11 0.172 9 0.141 1.27 (0.49-3.31) 0.80825 
6 4 0.063 8 0.125 0.47 (0.13-1.64) 0.36382 
7 6 0.094 8 0.125 0.72 (0.24-2.22) 0.20759 
8 5 0.078 1 0.016 5.34 (0.61-47.05) 0.00000 
9 1 0.016 0 0.000 3.05 (0.12-76.30) 0.00000 
10 1 0.016 0 0.000 3.05 (0.12-76.30) 0.00000 
13 1 0.016 0 0.000 3.05 (0.12-76.30) 0.00000 
LRS = 17.985, OF = 9, P-value = 0.03534 
rs232684 
1 25 0.714 10 0.286 6.25 (2.22-17.63) 0.00010 
2 10 0.286 25 0.714 0.16 (0.06-0.45) 0.00010 
LRS = 6.641, OF = 1, P-value = 0.00996 
rs232686 
1 19 0.704 8 0.296 5.64 (1.75-18.15) 0.00597 
2 8 0.296 19 0.704 0.18 (0.06-0.57) 0.00597 
rs232707 
1 18 0.692 8 0.308 5.06 (1.56-16.44) 0.01182 
2 8 0.308 18 0.692 0.20 (0.06-0.64) 0.01182 
LRS = 3.947, OF = 1, P-value = 0.04695 
Column T and NT represent transmitted and non transmitted alleles; Freq-
T and Freq-NT are the frequencies of T and NT alleles; OR = Odds Ratio; 
CI = Confidence Interval (CI); LRS = Likelihood Ratio Statistic; OF = 
Degree of freedom. 
87 
Table 9. Marker haplotype window for the most significant association at LOCUS Xq27.3. 
1 nformative 
Marker number Haplotype T NT OR (CI) P-value -LOG10 (p) 
mothers 
28-29 C-C 52 28 12 3.96 (1.69-9.26) 0.00049 3.310 
29-30 C-C 49 30 10 6.16 (2.50-15.17) 0.00001 5.000 
28-29-30 C-C-C 49 30 10 6.16 (2.50-15.17) 0.00001 4.959 
29-30-31 C-C-1 63 29 9 5.12 (2.16-12.12) 0.00003 4.495 
28-29-30-31 C-C-C-1 63 29 9 5.12 (2.16-12.12) 0.00003 4.495 
28-29-30-31-32-33 C-C-C-1-C-C 62 29 8 5.93 (2.42-14.51) 0.00001 5.000 
27 -28-29-30-31-32-33 T -C-C-C-1-C-C 57 26 7 5.99 (2.32-15.45) 0.00002 4.638 
28-29-30-31-32-33-34 C-C-C-1-C-C-T 59 18 5 4.74 (1.63-13.83) 0.00453 2.343 
27 -28-29-30-31-32-33-34 T -C-C-1-C-C-C-T 55 16 4 5.23 (1.62-16.89) 0.00553 2.257 
Markers number refers to markers listed in Table 6; T :::: Transmitted; NT:::: Non Transmitted; OR:::: Odds Ratio; CI :::: 
Confidence Interval; the C and 1 in the haplotype column are the single nucleotide and the allele transmitted respectively. 
Figure 2. LD relatianship between LOCUS Xq27.3 markers. Numbers tram 20 ta 34 in bath axes 
represent markers listed in Table 6. 
> 0.06 
0.04-0.06 
< 0.04 
The previous article presented our most promising findings on Xq27.3 for 
autism. While the X chromosome was our main interest, we were 
interested to investigate any other interesting locus. Indeed, we have 
established a friendly collaboration with Dr. Christian Andres and his 
research team at Tours in France. 
IN 2003, Andres and colleagues reported an association between a 
putative functional polymorphism within the OMGP gene, which is located 
on chromosome 17q, and autistic patients. Association was found using a 
group of 65 autistic subjects and 101 controls, both of French origin. In 
order to replicate their own finding and increase their sample number, they 
established collaboration with us and a group from Italy. In total, 3 cohorts 
of trios from three different populations were put together for a family-
based association analysis. The following article describes the samples 
used, the methodology, and the results obtained at the OMGP locus. 
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Abstract 
Background: Autistic disorder is a neurodevelopmental disease where 
genetic factors play an important role. We previously described an 
association between a subgroup of French autistic patients and an allele 
of a single nucleotide polymorphism (SNP: OMGP62) in the gene coding 
for the oligodendrocyte and myelin glycoprotein (OMgp), located at 7 Mb 
from the marker 017S250, linked to autism in two independent genome 
scan studies. 
Methods: We report a study on 455 families from different origins: Italy 
(n=127), United States (65) and French Canada (263), and on 157 Italian 
controls. In a first step, we analyzed the distribution of the two OMGP62 
alleles in the Italian patients and controls. In a second step, we analyzed 
the transmission of the OMGP62 alleles from parents to their affected 
children. 
Results: We observed no significant association in the case-control study 
in the Italian groups (p = 0.28). There was a preferential transmission of G 
allele from parents to affected children (p <0.01) considering ail families. 
The clearest disequilibrium came from the Canadian families although we 
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did not dispose of enough power to conclude definitely (heterogeneity c2 
test = 2.315; P = 0.314). Paternal transmission of the G allele was not 
significantly more frequent than maternai transmission. We found no 
significant difference in the transmission of one of the two aile les taking 
into account the gender of the affected child. 
Conclusion: These results suggest that, at least in some populations, the 
OMGP locus is associated with autistic susceptibility. 
Introduction 
Autistic disorder (AD) (MIM 209850) is a pervasive developmental 
disorder (POO) characterized by impairment in verbal and non-verbal 
communication, deficits in social interaction, and restricted and 
stereotyped behaviours. It appears in early childhood, before the age of 
three years old. Recent studies gave a prevalence for autism, meeting the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, of 
10/10.000 (Fombonne 2003; Volkmar et al. 2004). Considering autism 
spectrum disorder, this prevalence reached the value of 34/10.000 
(Yeargin-Allsopp et al. 2003). 
93 
The importance of genetic factors in the aetiology of autism has been 
demonstrated by family and twin studies (for review, see (Szatmari et al. 
1998; Foistein et al. 2001). 
The prevalence of type 1 Neurofibromatosis (MIM 162200) (NF1) in the 
autistic population is increased 48 fold compared to the general population 
(mean percentage: 1.2%, 95% CI: 0.3% - 2.1 %, calculated after (Gillberg 
et al. 1984; Gaffney et al. 1987; Mbarek et al. 1999). Moreover 30% of 
NF1 patients present cognitive deficits (Stine et al. 1989). Mutations of the 
NF1 gene cause Type 1 Neurofibromatosis. This gene is located on 
chromosome 17 at position q11.2, a chromosomal region linked to autism 
(International Molecular Genetic Study of Autism Consortium 2001; Yonan 
et al. 2003). 
We previously observed in 4 autistic patients a new allele of a 
microsatellite marker (GxAlu), located in the intron 27b of the NF1 gene 
characterized by 6 AAA T repeats (allele 5). This GxAlu allele 5 was 
absent in more than 200 French controls (Mbarek et al. 1999) and in a US 
autistic group (Plank et al. 2001). The nearest (3.6 kb) gene to the GxAlu 
marker is the oligodendrocyte myelin glycoprotein gene (OMGP). This 
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gene, located in intron 27b of the NF1 gene, is composed of two exons 
and one intron, the second exon coding for the entire oligodendrocyte 
myelin glycoprotein (OMgp). OMgp is expressed by neurons and 
oligodendrocytes during the myelination of the central nervous system 
(CNS) and in adult CNS. Mikol et al (1990) described a single nucleotide 
polymorphism (SNP) in the sequence coding for the signal peptide of 
OMgp in the normal population (Mikol et al. 1990). This SNP consisted in 
a G to A transition at position 62 from the start codon, changing a glycine 
in an aspartic acid. We previously reported an association between allele 
A of this OMGP62 marker and a subgroup of French autistic patients with 
a developmental quotient (OQ) higher than 30 (p = 0.015) (Vourc'h et al. 
2003). 
These preliminary results prompted us to perform an association study on 
larger groups of autistic patients from different ethnie origins using both a 
case-control and a family-based approach, i.e. a transmission 
disequilibrium test (TOT) (Spielman et al. 1993). 
Materials and Methods 
Clinical population 
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We recruited 455 families in Canada (263 families), Italy (127 families) 
and the United States (65 families) with an autistic proband, as weil as a 
sam pie of Italian (N = 157) controls. Ali patients had to meet DSM-IV 
criteria for Autistic Disorder and ail the families were from Caucasian 
ancestry. For the TDT, we only considered the families where at least one 
parent was heterozygous for the A associated allele (Canada = 92 
families; Italy = 27 families; USA = 23 families). The study was approved 
by the local ethics committees. Whenever possible, the participants gave 
their informed consent; if not, the parents did. 
Ali 263 Canadian patients (mean age:12 ± 7.8) and their parents were 
recruited from clinics specializing in the diagnosis of PDD located in the 
province of Quebec, Canada. Diagnosis was made according to DSM-IV 
criteria, by at least one psychiatrist, followed by completion of the ADI-R 
(Lord et al. 1994), and/or the ADOS-G (Lord et al. 2000). As an additional 
screening tool for the diagnosis of AD, an autism screening questionnaire 
derived from ADI-R was completed (Berument et al. 1999). Exclusion 
criteria were: (1) an estimated mental age < 18 months, (2) a diagnosis of 
Rett syndrome or childhood disintegrative disorder and (3) evidence in the 
chart file of the patient of any psychiatric and neurological conditions 
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including: birth anoxia, rubella during pregnancy, fragile-X syndrome, 
encephalitis, phenylketonuria, tuberous sclerosis, Tourette and West 
syndromes. However, participants with a co-occurring diagnosis of 
semantic-pragmatic disorder (due to its large overlap with POO), attention 
deficit hyperactivity disorder (seen in a large number of patients with AD 
during development), and idiopathie epilepsy (which is related to the core 
syndrome of AD) were eligible for the study. 
The other families collected in Italy and the United States, as weil as 
Italian controls, have been described in previous studies (Persico et al. 
2001; Conciatori et al. 2004). Briefly, patients were screened for known 
causes of autism or other disorders using MRI, EEG, audiometry, urinary 
ami no acids, organic acids and cytogenic testing. Ali patients received 
fragile-X testing. Patients with dysmorphic features were excluded. 
Sporadic seizures were not an exclusion criterion; patients with frequent 
seizures or focal neurological deficits were excluded. Autistic behaviours 
were characterized both in Italy and USA using the following scales: 
Childhood Autism Rating Scale (Schopler et al. 1980) and Vineland 
adaptive behaviour scales (Sparrow et al. 1985). Some patients were 
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assessed by the Autism Diagnostic Interview (Lord et al. 1994) and Autism 
Diagnostic Observation Schedule - Generic (Lord et al. 2000). 
Genotyping 
We genotyped 1585 samples from different origin: 804 Canadian samples, 
468 Italian samples and 313 United States samples. Genomic DNA was 
isolated from leucocytes in EDTA anti-coagulated blood (see (Sam brook 
1989), for the detailed protocol). OMGP62 polymorphism genotyping was 
performed by PCR-Restriction Fragment Length Polymorphism (PCR-
RFLP) technique (Vourc'h et al. 2003). PCR was performed in a total 
volume of 251..lL, containing 10X PCR Buffer, 1.5mM MgCI2, 100ng 
genomic DNA, 1251..lM dNTP, 200nM of primers (1 F: 5' -
CCCATGCAGATGCCTAAACT - 3'; 1R: 5'-
TTCCACAGAGACCGAGGT AA - 3') and 5 units of Taq DNA Polymerase 
(Takara®). Cycling conditions consisted of initial denaturation at 94°C, 5 
min, followed by 35 cycles at 94 oC 1 min, 53°C 1 min, 72°C 1 min, and a 
final extension at 72°C for 5 min. The PCR products contained two BstNI 
restriction sites. One of the BstNI restriction sites is present in OMGP62 G 
allele (5' - CCTGG - 3') and absent in A allele (5' - CCTGA - 3'). The 
totality of PCR product was digested in a volume of 30l..lL containing 
98 
Restriction Buffer and 5 units of BstNI restriction enzyme (New England 
Biolabs) overnight at 60 c e, to produce a 316-bp fragment for the A allele 
and 188-, 128-bp fragments for the G allele. Restriction fragments were 
separated by electrophoresis on a 2% agarose gel containing O.5IJg/mL 
ethidium bromide. 
Statistical analysis 
We first estimated the OMGP62 allele frequencies by counting the number 
of alleles in the patients and the control groups and the chi square test 
was applied in order to test if the studied groups followed the Hardy-
Weinberg equilibrium and then to test for an association between one of 
the two alleles of OMGP62 and autistic disorder. The X2 TOT was used to 
test if there was an abnormal transmission of one of the OMGP62 alleles 
from parents to their autistic child. 
Results 
Association study 
Genotype frequencies conformed to expectations based on Hardy-
Weinberg Equilibrium (HWE) in ail families and control groups (not 
shown). The frequencies of the OMGP62 alleles assessed in the 
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populations of autistic patients from different origins and in the control 
population are reported in Table 10. We found no significant difference in 
the distribution of the two OMGP62 alleles between Italian patients and 
controls (X2 = 1.175; P = 0.278). We could not compare the other groups of 
patients (Le. United States and Canada) to appropriate geographically-
matched controls. The frequencies of the two alleles of OMGP62 in the 
three groups of autistic patients were significantly different (X2 = 11.61; P = 
0.003), with American and Canadian patients having respectively a 3.0 
and 2.2 time higher frequency of allele A than Italian patients. 
Transmission Disequilibrium Test 
Considering ail families, we observed a significant overtransmission of 
allele G from the parents to affected offspring in the entire sample (p = 
0.003 - Table 11). We tested for heterogeneity between the three 
geographic groups and found no significant difference (p = 0.314 - Table 
11). The highest difference of transmission was seen in the Canadian 
families. Analyzing the transmission in function of the gender of the 
parent, we could not demonstrate a significant difference between fathers 
and mothers (Table 12). There was no significant difference in the 
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transmission of OMGP62 alleles taking into account the gender of the 
autistic proband (Table 13). 
Discussion 
ln this study, we report an overtransmission of allele G of OMGP62 in a 
sample of 455 families of Italian, Canadian and US origin. We observed 
no association between the A allele of OMGP62 and the Italian autistic 
group, in contrast to what we previously described in a French population 
(Vourc'h et al. 2003). Two points need to be underlined. 1) We did not use 
here the stratification of developmental quotients we used in the French 
study. 2) The distribution of the OMGP62 alleles are very different in the 
French and Italian control populations ( X2 = 6.305; d.f. = 1; P = 0.012 for 
repartition of the alleles in French control population given in (Vourc'h et 
al. 2003), making very probable that different linkage disequilibrium exist 
in this region in the two populations. Considering the differences of allelic 
distribution between the three groups of patients, it would be of 
importance to assess these frequencies in control populations, to 
distinguish the effect of ethnie influence from real association in these 
patients. 
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The TOT method avoids the population stratification bias which could exist 
in a case-control study. Intrafamilial association approaches are likely to 
provide the most reliable evidence, and indeed indicate the existence of 
an association which interestingly follows the expected rates of linkage 
disequilibrium based on the known history of admixture of these 
populations (Le., French Canadian > Italian > Caucasian-Americans). In 
fact, using a TOT, we found a significant overtransmission of the allele G 
from parents to their affected offspring and this association was 
particularly visible, although not statistically proved in the French 
Canadian group. The Quebec population of 7.5 million people contains 
about 6 million French-Canadians who are descendants of around 8 000 
French settlers who colonized "Nouvelle-France" between 1608 and 1765 
(Charbonneau 1993). The relative contribution of each founder to the 
Quebec population is highly variable depending, among other factors, on 
their period of arrivai in North America (Heyer et al. 1995) thus, the 3380 
founders who settled before 1680 contribute approximately 70% of the 
present gene pool (Charbonneau 1993). Furthermore, many of these 
founders were related to each other and from the same villages in France 
(Guillemette 1989). As a result, the allele G may have been mainly 
introduced early in the Canadian population leading to subsequent 
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preferential amplification of the allele G. Two explanations can follow from 
the previous observation in the French population (Vourc'h et a/. 2003): (1) 
the mutation is older than the OMGP SNP event. The mutation will then be 
found on both alleles. From the above, we can conclude that the Quebec 
population shares a relatively homogeneous genetic background, thereby 
would make the susceptibility allele more detectable in a family-based 
association study reducing the possible number of susceptibility alleles. 
(2) Mutation arose after the SNP and recombination event happened 
between the SNP and the mutation. Consequently the recombined allele 
G was introduced into the Canadian population. 
We did not prove a difference in transmission of OMGP62 alleles 
depending on the gender of the parent (heterogeneity test p = 0.611), 
although there was a trend in an overtransmission of the G allele from the 
fathers (table 12). This question needs to be readdressed on larger 
samples. 
Stone et al observed a male-specifie region of linkage in this chromosome 
17 locus (Stone et al. 2004). We disposed of too few girls to conclude on a 
difference of transmission of one of the two OMGP62 alleles regarding the 
gender of the affected child (table 13). 
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These results are against the hypothesis of a direct effect of one of the 
two alleles of the OMGP62 polymorphism in the aetiology of autism. 
Recently, a study performed on a group of Japanese autistic patients 
revealed significant differences in allelic distributions of the GXAlu marker 
between patients and controls (Marui et al. 2004). These results and the 
present work speak in favour of the existence of a susceptibility gene for 
autism in the NF1 gene region. More work will be necessary to analyse 
the distribution of intron 278 alleles in different ethnie groups and to 
identify other polymorphisms in this region which may be in linkage 
disequilibrium with OMGP62 alleles. 
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Table 10. Number of chromosomes and frequencies of the OMGP62 
alleles for the three groups of autistic patients (chi-square test, c2 = 
11.6; df: 3; p = 0.003) and the Italian controls. 
Italian Controls Italian Patients American Canadian 
Patients Patients 
Alleles Freq Numbers Freq Numbers Freq Numbers Freq Numbers 
(%) (%) (%) (%) 
G 93.9 295 95.9 280 87.5 168 90.9 491 
A 6.1 19 4.1 12 12.5 24 9.1 49 
Sum 100 314 100 292 100 192 100 540 
Table 11. Transmission Oisequilibrium Test (TOT) for the OMGP62 
alleles in the three groups of families. TR: transmitted, NT: non-
transmitted. 
TR NT Sum TDT Heterogeneity Test 
Italy 20 9 29 c2 = 4.172; P = 0.041 
USA 14 14 28 c2 = 4.337.10-14; P = 1.00 
Canada 64 38 102 c2 = 6.627 ; P = 0.01 c2 = 2.315; P = 0.314 
Total 98 61 159 
Ho 79.5 79.5 c2 = 8.610; P = 0.0033 
Ho Null hypothesis 
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Table 12. Transmission Disequilibrium Test (TOT) for the OMGP62 
alleles in ail families considering the gender of the parents. TR: 
transmitted, NT: non-transmitted 
TR NT Sum TDT Heterogeneity Test 
Paternal 46 27 73 c2 = 4.945; P = 0.026 
Maternai 46 27 78 c2 = 2.513; P = 0.113 c2 = 0.258; P = 0.611 
Total 92 59 151 
Ho 75.5 75.5 c2 = 7.212; P = 0.007 
Table 13. Transmission disequilibrium test (TOT) for the OMGP62 
alleles in ail families considering the gender of the affected child. 
TR NT Sum TDT Heterogeneity Test 
Male 87 55 142 c2 = 7.211; P = 0.007 
Female 10 5 15 c2 = 1.667; P = 0.197 c2 = 0.167; P = 0.682 
Total 97 60 157 
Ho 78.5 78.5 c2 = 8.720; P = 0.003 
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CANDIDATE GENES SCREENING FOR AUTISM 
Two approaches were originally selected for our autism gene identification 
project. Although the association study was our main approach, we also 
wanted to evaluate a candidate gene approach. This approach consist of 
analysing the genomic sequence of a gene which have been selected 
based on literature information such as known function, genomic location, 
and expression pattern. The current chapter presents the candidate genes 
that we have screened for mutation in Autism Spectrum Disorder patients. 
The first candidate gene to be analysed was the FOXP2 gene. At that 
time, the FOXP2 gene have just been reported to be mutated in a family 
with a severe form of language disorder. The gene was selected because 
1) the phenotypic overlap between language disorder and autism 
(language problem is one of the core feature of autism) 2) because it lies 
on the chromosome 7q21-31 a genomic region often linked with autism. 
We screened the coding region of this gene in our cohort of patients. The 
following article described the results on the screen of this gene. 
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Abstract 
Although it is weil established that genetic factors play an important role in 
the etiology of autistic disorder (AD), no specifie genes have as yet been 
implicated. Genetic epidemiological data, particularly the sharp fall in 
concordance rates from monozygotic to dizygotic twins, indicate that the 
mode of transmission of this disorder is complex and may involve several 
genes. The 7q31 locus has been repeatedly linked to AD, suggesting that 
this chromosomal region is likely to harbour a susceptibility gene for AD. 
Recently, variations in the FOXP2 gene were reported to be responsible 
for a severe speech and language disorder. Because of the chromosomal 
location of FOXP2 (7q31) and the putative implication of the 7q31 region 
both in autistic and in language disorders (a feature of AD), it has been 
hypothesized that FOXP2 may be implicated in the pathophysiology of 
AD. To test this hypothesis, we screened the FOXP2 gene coding 
sequence for mutations in subjects diagnosed with AD and in normal 
controls. We identified four silent polymorphisms that were equally 
distributed between patients and controls. Using an intra-family 
association design, we identified no transmission disequilibrium in any of 
the four identified alleles, suggesting that the FOXP2 gene does not play a 
significant role in AD. 
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Introduction 
Autism disorder (AD) is a severe neurodevelopmental condition 
characterized by disturbances in social interaction and communication, by 
repetitive body movements and restricted interests, and by atypical 
language development (DSM-IV 1994; Bristol et al. 1996; Tanguay 2000). 
Severe language delay as weil as language disturbance in the form of 
echolalia, pronoun reversai and stereotyped language, are one of the 
major clinical characteristic of AD (DSM-IV 1994). Although the exact 
pathogenesis of AD is not known, it is now unequivocally established that 
genetic factors play an important role in its pathogenesis. Although 
several chromosomal loci have been suspected on the basis of linkage 
analysis to harbour gene(s) for AD (Foistein et al. 2001), no specifie genes 
have yet been identified. The sharp fall in concordance rates from 
monozygotic to dizygotic twins may indicate that AD is genetically due to 
the concerted action of a number of different mutations, suggesting the co-
existence of numerous mutations in a single individual affected with AD. In 
line with this hypothesis, a recent study reported that two of the clinical 
dimensions of AD (language deficits and repetitive behaviour) may be 
caused, at least in part, by quantitative trait loci on chromosome 7q 
(Alarcon et al. 2002), a region that has been previously implicated in AD 
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by several independent studies (International Molecular Genetic Study of 
Autism Consortium 1998; Philippe et al. 1999; Risch et al. 1999; 
Collaborative Linkage Study of Autism 2001). Another study has also 
supported the hypothesis that linkage to chromosome 7q is strengthened 
when the analysis was restricted to families with autistic children 
displaying severe language disorders (Foistein et al. 2000). Interestingly, 
mutations in the forkhead-domain gene FOXP2, located in chromosome 
7q31, were described by Lai et al. in one family and in an unrelated patient 
with severe speech and language disorder (Speech-Language Disorder 1, 
OMIM #602081) (Lai et al. 2001). The function of FOXP2 is not yet 
identified, but genes containing forkhead domain are known to be 
important regulators of embryogenesis and to have an important role in 
neural functioning (Lai et al. 2001). Human and mouse studies have 
shown that FOXP2 is expressed ubiquitously during adulthood and in 
specifie regions of the brain during embryogenesis, suggesting that this 
gene may have specifie prenatal developmental effects on the brain (Lai et 
al. 2001). 
Because of the chromosomallocation of FOXP2 (7q) and the putative 
implication of this chromosomal region in AD, particularly in language 
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disorders associated with AD, it has been hypothesized that FOXP2 may 
be implicated in the pathogenesis of AD. To test this hypothesis, we 
screened the FOXP2 coding region for mutation in 56 unrelated subjects 
diagnosed with AD and 98 independent controls. Furthermore, we 
genotyped a total of 72 triads for the polymorphisms detected in FOXP2 
and carried out a family-based association study using the extended 
transmission disequilibrium test (ETDT) (Sham et al. 1995). 
Subjects and Methods 
Seventy-nine autistic patients and their parents (seventy-two unrelated 
and seven sib pairs) were referred from clinics specialized in the diagnosis 
of Pervasive Developmental Disorders (PDD) located on the island of 
Montreal. For the case-control study, only unrelated patients plus the 
proband of the sib pairs were used (n = 72). The mean age of the aftected 
group is 15.3 years with a sex ratio of 6M:1 F. 
Inclusion Criteria: participants with autism were included in the study if 
they satisfied either one or the other of the following diagnostic criteria. a) 
For 24 participants, the individual had been previously diagnosed by a 
trained clinician, using the algorithm of the Autism Diagnostic Interview-
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Revised (ADI-R; (Lord et al. 1994), and/or the Autism Diagnostic 
Observation Schedule-Generic (ADOS-G; (Lord et al. 2000). The ADI-R is 
a lengthy semi-structured interview of the child's parents or caretakers. 
The ADOS-G is a semi-structured schedule of interactions between 
clinician and patient that assesses communication, social interaction and 
imaginative use of materials. It includes several modules, which are 
administered depending on the language ability of the individual being 
assessed. High inter-rater and test-retest reliability, as weil as internai 
validity, have been established for both tests. Both of these standardized 
diagnostic instruments are internationally used for research purposes in 
assessing the presence of DSM-IV/ICD-10 criteria for Autism. b) For 48 
participants who had not undergone the full ADI /ADOS interview, a 
French translation of a simplified version of the ADI, the Autism Screening 
Questionnaire (ASQ) was administered by a trained Research Assistant to 
the patient's primary caretakers in order to validate their diagnosis. To 
qualify for participation, where candidates had been previously diagnosed 
as autistic by one clinician, a score of 15 or higher on the ASQ was 
required; where a diagnosis had previously been given by two 
independent clinicians, the score needed to be 10 and above. In fact, ail 
candidates scored higher than 15 on the ASQ. Exclusion criteria: (1) an 
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estimated mental age < 18 months, the estimated inferior Iimit for the 
validity of a diagnosis of autism; (2) file diagnosis of Rett syndrome or 
childhood disintegrative disorder. (3) file evidence of psychiatrie and 
neurological conditions, including: anoxia during birth, rubella during 
pregnancy, fragile-X syndrome, encephalitis, phenylketonuria, tuberous 
sclerosis, Tourette syndrome and West syndrome. However, participants 
with a file diagnosis of semantic-pragmatic disorder (due to its large 
overlap with PDD), Attention Deficit Hyperactivity Disorder (seen in a large 
number of patients with Autism during development), and epilepsy without 
characterized neurological etiology (which is related to the core syndrome 
of autism) were included in the study. Independent controls used for the 
association study were c1inically ascertained randomly as spouses of 
patients with no psychiatrie history. The mean age of the control group is 
68 years and the male:female ration is 2,2M:1 F. 
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Mutation Screening 
Primers design: The entire coding region of FOXP2 and the intronic 
flanking sequences in the introns were amplified by PCR with primer pairs 
designed using genomic sequence information from the human genome 
project working draft site (UCSC, www.genome.ucsc.edu) and the 
Lasergene PrimerSelect program. Before PCR, fragment with the new 
designed primers, were first analyzed using Wave-maker TM software. A 
melting temperature profile is than given from the software and if this 
melting profile was not uniform along the fragment we modified the 
primers by adding GC clamps (4 to 16 bp) to standardize the melting 
profile. This standardization of the fragment increases the chances of 
detecting variations. Mutation detection: PCR products were loaded on 2% 
agarose gel to confirm amplification before analysis for base changes by 
dHPLC (WAVE Nucleic Acid Fragment Analysis System from 
Transgenomic, San Jose, CA). Solvent A consisted of 0.1 mol/L 
triethylammonim acetate (TEM) and 25% acetonitrile and solvent B 
contained 1 M TEM, 25% acenonitril. Either for point mutation detection or 
expansion analysis. ail PCR products from patients were first combined 
with equal amounts of products amplified from a negative control DNA 
(first sequenced before pooling) and then denatured at 95 oC for 5 min 
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followed by a graduai reannealing to 50 oC over a 1-hour period in order to 
enhance heteroduplex formation. PCR products showing a 
chromatographie variation on dHPLC were sequenced directly on an 
automatic sequencer (Gene Reader 4200). Sequencing data were 
analyzed using DNA Star software SeqMan (Lasergene). 
Results 
An original screen of 56 patients leads to the identification of four single 
nucleotide polymorphisms in the FOXP2 sequence (Table 14). One 
polymorphism, Q190Q, is a silent mutation that changes a CM ta a CAG 
(both encoding for glutamine). Three other polymorphisms are located in 
the 3' exon-intron junction of exon 5 and exon 13. None of them affect the 
consensus sequence for pre-messenger splicing. In order to perform 
family-based and case-control association studies, we screen a total of 72 
unrelated patients (the original 56 patients plus 16 new cases) and their 
two parents plus 98 controls for the observed polymorphisms. No 
significant association between AD and any of these alleles were 
observed compared to controls (Table 14), and the transmission 
disequilibrium analysis did not show any significant disequilibrium of 
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transmission of any of these alleles from parents to aftected children 
(Table 15). 
ln addition to the polymorphisms detected by mutation screening, the 
FOXP2 gene is known to contain two tracts of CAG repeats located in 
exons 5 and 6 respectively, which encode for two polyglutamine stretches 
separated from each other by 8 amino acids (Lai et al. 2001). The first 
stretch consists of (CAG)4 (CM) (CAG)4 (CM)2 (CAG)2 (CM)2 (CAG)3 
(CM)5 (CAG) 2 (CM)2 (CAG)5 (CM) (CAG) 5 (CM) (CAG) and 
encodes for 40 consecutive glutamine residues, and the second stretch 
consists of (CAG) 7 (CM) (CAG) (CM) and encodes for 10 glutamine 
residues (Foistein et al. 2000). Although genes encoding for enlarged 
polyglutamine tracts have been implicated mainly in neurodegenerative 
diseases, there is sorne indication that they may also play sorne role in 
neurodevelopmental disorders such as schizophrenia (Joober et al. 1999). 
We therefore tested for an expansion of these two CAG repeats in AD 
patients. None of the autistic patients were carriers of expanded CAG 
repeats on either tract, thus excluding any role they may have had in 
modulating the risk for AD and the language disturbances seen in this 
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disorder. In addition, the two repeats were monomorphic, further excluding 
any role of these repeats in modulating susceptibility to AD. 
Discussion 
These results support the data of Newbury et a/. (Newbury et a/. 2002) 
obtained from the analysis of FOXP2 in a population of autistic individuals. 
Nevertheless, several limitations need to be kept in mind while interpreting 
these results. First, the 5' regulatory region and other regulatory elements 
of FOXP2 were not analysed, because we since mutation in FOXP2 gene 
causing the severe speech and language disorder were found in the 
coding region, (Lai et a/. 2001), th us precluding definitive exclusion of this 
gene as a risk factor for AD. However, the hypothesized involvement of 
other polymorphisms or mutation in this gene in increasing the risk for AD 
seems unlikely given the total absence of linkage disequilibrium between 
AD and any of the four alleles that we identified. Second, it is possible 
that this gene has a small effect in increasing the risk for AD that could not 
be detected in our study given the small patient sample size. However, if 
the observed differences in allelic frequencies in this sample represent 
true population allelic frequencies, the effect size would be extremely 
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small and would require a prohibitively high number of cases and controls 
(> 150 000) to be detected. 
ln conclusion, these results indicate that the phenotypic similarities in 
language impairment between AD and Speech-Language Disorder 1 are 
unlikely to be caused by the same gene. Nonetheless, careful attention 
has to be paid to genes located in the 7q31 region since multiple studies 
replicated positive linkage between AD and this locus. 
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Table 14. Characteristics of the 4 polymorphisms found in FOXP2coding 
sequence and allelic distribution in AD subjects and controls. 
Location Position 7q31 Patients Controls 
X2, df= l, P Variations 
in FOXP2 (UCSC site) (n = 72) (n = 98) 
01900 Exon5 123545599 2 4 0.20,0.65 
T-7G Exon5/ intron 123545643 10 13 0.02,0.88 
C-7G Exon13/ intron 123575324 3 2 0.65,0.42 
A-7G Exon13/ intron 123575341 1 1 0.05,0.82 
Table 15. Extended Transmission Disequilibrium Test (ETDT) of the four 
polymorphisms in FOXP2 and AD. 
Polymorphism Alleles TransmiUed Not transmiUed x2 ETDT*, p 
A 4 3 
Q190Q 0.143, P = 0.705 
G 3 4 
T 7 12 
T7G 1.331, P = 0.249 
G 12 7 
C 4 4 
C7G 0.000, P = 1.000 
G 4 4 
A 6 3 
A7G 1.019, P = 0.313 
G 3 6 
• chI-square for auele-wlse 101 
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Before 2004, no gene was identified as a cause for the Autism Spectrum 
disorders phenotype. However, in 2004 Jamain et al. reported in Nature 
Genetics, the identification of mutations in two X-linked genes, NLGN3 
and NLGN4, in patients diagnosed with autism spectrum disorders. They 
screened a total of 36 pairs of affected siblings and 122 trios with autism 
or Asperger syndrome (140 males and 18 females). Two different 
mutations were detected in two of the screened families. In one instance, 
the mutation occur de novo in the mother. 
ln order to replicate their finding and to better elucidate if these genes play 
a major role in autism spectrum disorder, we analysed the genomic 
sequence of both genes in our sam pie of patients. The following article 
presents our results. 
121 
NLGN3/NLGN4 Gene Mutations are not Responsible for Autism in the 
Quebec Population. 
Julie Gauthier1, Anna Bonnell, Judith St-Ongel, Liliane Karemera1, 
Sandra Laurentl, Laurent Mottron3, Éric Fombonne4, Ridha Joober2 and 
Guy A Rouleau1. 
1 Research Institute of the McGi11 University Health Center, 1650 Cedar 
Ave, Montreal, H3G1A4, Canada; 2 Douglas Hospital Research Center, 
McGill University, 6875 Bd. Lasalle, Verdun, H4H1 R3 Canada; 3 Clinique 
spécialisée des Troubles Envahissants du Développement, Hôpital 
Rivière-des-Prairies, Montréal, Canada; 4 McGill University, Department of 
Psychiatry, the Montreal Children's Hospital, 4018 St. Catherine St. W., 
Montreal, QC H3Z 1 P2, Canada. 
American Journal of Medical Genetics Part B: Neuropsychiatrie Genetics. 
2005 Jan 5;132(1):74-5. © 2005 Wiley-Liss, Inc 
122 
Abstract 
Jamain et al. recently reported mutations in two neuroligin genes in sib-
pairs affected with autism. In order to confirm these causative mutations 
in our autistic population and to determine their frequency we screened 96 
individuals affected with autism. We found no mutations in these X-linked 
genes. These results indicate that mutations in NLGN3 and NLGN4 genes 
are responsible for at most a small fraction of autism cases and additional 
screenings in other autistic populations are needed to better determine the 
frequency with which mutations in NLGN3 and NLGN4 occur in autism 
Article 
It is now weil established that genetic factors play an important role in the 
pathogenesis of Autism (Szatmari et al. 1998). Recently, an X-linked origin 
of autism in 2 families with affected sib-pairs was proven by the 
identification of mutations in NLGN3 and NLGN4, two genes located on 
chromosome X encoding a neuronal cell surface protein (Jamain et al. 
2003). Seeking replication in other samples of autistic patients is important 
to confirm the causative nature of these mutations and to determine their 
frequency. We screened 96 individuals (including 12 cases with familial 
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history of autism) diagnosed with autism spectrum disorder for mutations 
in NLGN3 and NLGN4 genes. 
Genomie DNA was extracted from lymphocytes of patients ascertained 
from clinics specializing in the diagnosis of Pervasive Developmental 
Disorders (POO) and located in the Province of Quebec, Canada. Two 
thirds of our autistic group was of French-Canadian Origin. Ali subjects 
(mean age: 14 ± 7.6; sex ratio: 6.4M: 1 F) were diagnosed according to 
DSM- IV criteria by at least one psychiatrist, followed by administration of 
the ADI-R (n = 43); (Lord et al. 1994), and/or ADOS-G (n = 41) (Lord et al. 
2000). Furthermore, the autism sereening questionnaire (ASQ), a 
questionnaire derived from ADI-R, was administrated to ail patients as an 
additional screening tool. Independent controls with no psychiatrie history 
and matched for ethnicity were ascertained randomly in the same 
population (mean age 66 ± 7.5; sex ratio 8.6M: 1 F). Primers were 
designed according to the human genome project working draft site and 
the Lasergene PrimerSelect program and were carefully chosen taking 
into account the high sequence homologies between neuroligin members. 
The entire coding region and flanking splice junctions of the NLGN3 and 
NLGN4 genes were screened in the 96 autistic subjects. 
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We found no mutation in these X-linked genes in our 96 subjects. 
However, we detected 2 known linked polymorphisms rs374 7333 (C-> T) 
and rs3747334 (C->G) in exon 6 of NLGN4 that form an haplotype (CTC-
> TTG; frequencies: CTC = 0.64, TTG = 0.36). Both SNPs, described in 
the NCBI database, are located in the sa me codon (Leucine), and the T 
allele and G allele are on the same haplotype, giving rise to a silent 
substitution of leucine/leucine. These polymorphisms where also present 
in a control group (n = 56). 
These results indicate that mutations in NLGN3 and NLGN4 genes are 
responsible for at most a small fraction of autism cases. Additional 
screenings in other autistic population are needed to better determine the 
frequency with which mutations in NLGN3 and NLGN4 occur in autism. 
However, given the importance of neuroligin in synaptogenesis (EI-
Husseini et al. 2000; el-Husseini Ael et al. 2002; EI-Husseini Ael et al. 
2002), other members of this gene family or genes coding for proteins 
interacting with neuroligin remain excellent candidates for further genetic 
investigations. 
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Although researchers around the world have been looking for genes that 
could explain one or more symptoms of autism or the POO, only one gene 
was clearly identified as playing a major role: the MECP2 gene which 
leads to the RS phenotype. RS shares symptoms with autism and 
neurobiological data clearly showed that RS and autism are cause by 
factors affecting the early development of the nervous system. One 
possible explanation for these phenotypic similarities is that RS and some 
symptoms of autism result from the malfunctioning of common gene (s). 
Since a gene has been identified for RS, we proposed to use this disease 
as a model for the identification of candidate gene (s ) for autism or at 
least some of its symptoms. 
MECP2 belongs to a family of genes among which we found MB01 and 
MB02. The similarities between MBO genes and MECP2 lead to the 
hypothesis that these genes can be good candidates for the pathogenesis 
of autism. In addition to these similarities, MB01 and MB02 are located 
on chromosome 18q a region showing linkage in autistic families. The 
following manuscript summarise our methodology and results. 
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1 ntrod uction 
Although, the exact pathogenesis of autism is not known, it is now 
unequivocally established that genetic factors play an important role in its 
pathogenesis (Szatmari et al. 1998). Therefore, if the fundamental 
causes of autism are to be understood, any significant finding in the 
genetic aetiology of the POO diseases will be meaningful. To date, the 
identification of MECP2 gene as the cause of Rett syndrome (RS, is the 
most important finding relevant to the comprehension of autism. Even 
tough RS is a distinctive syndrome, the similarities between autism and 
RS such as the onset early after birth, stereotype behaviour, difficulties in 
social interaction, and verbal impairment are common to both diseases 
and possibly reflect the action of similar gene involved in the 
pathogenesis. Moreover, separate groups have investigated 
neuropathology of both disorders and their findings are comparable. 
ln both cases, pyramidal neurons showed an unusual anatomie aspect. In 
autism the neuronal size and the dendritic branching is reduced while 
there is an increase cell density without evidence of degeneration. Similar 
observations occur on RS along with reduction in basilar dendritic 
branching (Raymond 1996; Cohen 1997; Lord et al. 2000; Tanguay 
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2000). Observations confirm that the sa me brain regions are affected in 
both diseases. Genes having similar functions, although not expressed at 
the same time of development, can be involved in the both pathogenesis. 
Moreover, data clearly showed that both disorders are 
neuradevelopmental instead of neuradegenerative and therefore are 
cause by factors affecting early development (Cohen 1997). One 
possible explanation for these phenotypic similarities is that RS and some 
symptoms of AD result from the malfunctioning of common gene or genes 
involved in the same pathway. Since a gene has been found for RS, we 
are using this disease as a model for the identification of candidate genes 
for AD or at least some of its symptoms. So, based on the raie of MECP2, 
different genes appear to be interesting to test as candidate in AD. 
MECP2 belongs to a family of transcription factors containing others 
members such as MBD1 and MBD2. These proteins contain an amino 
acid motif called the methyl-CpG binding domain (MBD) and are capable 
of specifically bind methylated DNA (Hendrich et al. 1998) (Amir et al. 
1999; Hendrich et al. 1999). Ali members of these MBD family are 
ubiquitously expressed in somatic tissues both in human and mice 
(Hendrich et al. 1998). So far, only MBD2 and MECP2 gene have been 
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reported with a deletion (in MBD2 mice model) and mutation (in MECP2 in 
human). MBD2 null mice are viable with normal appearance but present 
an abnormal maternai nurturing, suggesting that MBD2 may play a role in 
fundamental behaviour (Hendrich et a/. 2001). In both cases, mutation in 
MBD2 and MECP2 results in neurological phenotype. Unlike MECP2, 
MBD1 and MBD2 are localized on autosomes and are about 5 Mb apart 
on chromosome 18q21, a region already shown by linkage in autistic 
families (Philippe et a/. 1999). The similarities between these two MBD 
genes and MECP2 and the positive linkage in the region for AD make 
MBD1 and MBD2 as good candidates for the pathogenesis of AD. 
To test this hypothesis we screened the entire coding region of MBD1 and 
MBD2. 
Subjects and Methods 
Ali autistic patients and their parents were referred from clinics specialized 
in the diagnosis of Pervasive Developmental Disorders (POO) located on 
the island of Montreal. Inclusion Criteria: participants with autism were 
included in the study if they satisfied either one or the other of the 
following diagnostic criteria. a) For 24 participants, the individual had been 
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previously diagnosed by a trained clinician, using the algorithm of the 
Autism Diagnostic Interview-Revised (ADI-R; (Lord et al. 1994) and/or the 
Autism Diagnostic Observation Schedule-Generic (ADOS-G;(Lord et al. 
2000). The ADI-R is a lengthy semi-structured interview of the child's 
parents or caretakers. The ADOS-G is a semi-structured schedule of 
interactions between clinician and patient that assesses communication, 
social interaction and imaginative use of materials. It includes several 
modules, which are administered depending on the language ability of the 
individual being assessed. High inter-rater and test-retest reliability, as 
weil as internai validity, have been established for both tests. Both of 
these standardized diagnostic instruments are internationally used for 
research purposes in assessing the presence of DSM-IV/ICD-10 criteria 
for Autism. b) For 48 participants who had not undergone the full ADI 
/ADOS interview, a French translation of a simplified version of the ADI, 
the Autism Screening Questionnaire (ASQ) was administered by a trained 
Research Assistant to the patient's primary caretakers in order to validate 
their diagnosis. To qualify for participation, where candidates had been 
previously diagnosed as autistic by one clinician, a score of 15 or higher 
on the ASQ was required; where a diagnosis had previously been given 
by two independent clinicians, the score needed to be 10 and above. In 
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fact, ail candidates scored higher than 15 on the ASa. Exclusion criteria: 
(1) an estimated mental age < 18 months, the estimated inferior limit for 
the validity of a diagnosis of autism; (2) file diagnosis of Rett Syndrome or 
childhood disintegrative disorder. (3) file evidence of psychiatric and 
neurological conditions, including: anoxia during birth, rubella during 
pregnancy, fragile-X syndrome, encephalitis, phenylketonuria, tuberous 
sclerosis, Tourette syndrome and West syndrome. However, participants 
with a file diagnosis of semantic-pragmatic disorder (due to its large 
overlap with PDD), Attention Deficit Hyperactivity Disorder (seen in a large 
number of patients with Autism during development), and epilepsy without 
characterized neurological aetiology (which is related to the core 
syndrome of autism) were included in the study. 
Primers design: The entire coding region, the untranslated region (UTR) 
and the intronic flanking sequences in the intron of MBD1 and MBD2 were 
amplified by PCR with primer pairs designed using genomic sequence 
information from the human genome project working draft site (UCSC, 
http://www.genome.ucsc.edu/) and the Lasergene PrimerSelect program. 
Designed fragments were first analyzed with the Wave-maker TM 
software from. A melting temperature profile is than given from the 
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software and if this melting profile was not uniform along the fragment we 
modified the primers by adding GC clamps (4 to 16 bp) to standardize the 
melting profile. This standardization of the fragment increases the 
chances of detecting variations. Because of technical methods available 
at that time, MBD1 were screened by single strand conformation 
polymorphism (SSCP) whereas MBD2 was screened by a newly methods 
used in our lab the denaturing High Performance Chromatography 
(dHPLC). In the cases of SSCP detection's, fragments were amplified by 
PCR incorporating a radiolabel nucleotide (S35-dATP) and analysed on 
two non-denaturing gels conditions (MDE and glycerol) followed by 
autoradiography. Detection on the dHPLC was done by cold PCR loaded 
on 2% agarose gel to confirm amplification before analysis for base 
changes (WAVE Nucleic Acid Fragment Analysis System from 
Transgenomic, San Jose, CA). Solvent A consisted of 0.1 mol/L 
triethylammonim acetate (TEM) and 25% acetonitrile and solvent B 
contained 1 M TEM, 25% acenonitril. PCR products from patients were 
first combined with equal amounts of products amplified from a negative 
control DNA (first sequenced before pooling) to avoid missing 
homozygous mutation and th en denatured at 95 oC for 5 min followed by a 
graduai reannealing to 50 oC over a 1-hour period in order to enhance 
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heteroduplex formation. PCR products showing a chromatographie 
variation on dHPLC were sequenced directly on an automatic sequencer 
(Gene Reader 4200). Sequencing data were analyzed using DNA Star 
software SeqMan (Lasergene). 
Results and Discussion 
A total of 50 autistic subjects were used in the present study for detection 
mutation in MBD1 and MBD2. No clear causative mutation or definite 
splicing mutation was detected in MBD1 and MBD2 genes within our 
autistic population. However, nucleotide transitions were seen in the intron 
and exon sequence of both genes (Table 16). Single nucleotide changes 
were detected in exon 8 and 17 of MBD1 gene. 
ln total, four SNP were detected in the MBD2 gene including two newly 
reported located on exon 1 and exon 7. The other one can be found on 
the list of MBD2 SNP at the NCBI site (http://www.ncbLnlm.nih.gov/SNP). 
Their ID SNP's number is rs7614 and rs1259938. In exon 1 of MBD2 we 
found an undescribed C to T transition at position 22 right after the first 
nucleotide. Two AG transitions were detected in exon 7 sequences, which 
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correspond to position 438, 875 and 925 nucleotides after the first base 
pair. 
The absence of any candidate mutations in 50 patients indicates that the 
MBD1 and MBD2 gene are not associated with autism, at least in the 
populations examined. However, as only coding regions were screened 
for mutations in this study it is possible that variations in non-coding 
regulatory regions of the genes, such as in the promoter region and the 
polyadenylation signal, could have been missed using our screening 
strategy. Such variations may have a more subtle effect than missense or 
nonsense mutations, such as by altering the level of transcription or the 
stability of the mRNA. We suggest that it may be worthwhile screening 
other members of the MDB gene family, as weil as genes that encode 
proteins that are involved in the repressor complex, or with similar function 
to MECP2. It is also possible that the pathogenesis of autism, while 
sharing many clinical features with RS, do not originate from the same 
biological gene defect pathways. ' 
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Table 16. Detected polymorphisms in MBD1 and MBD2 genes in our 
cohort of autistic subjects and primers used. 
Gene Nucleotide Exon Primer sequences 
change 
MBD1 8 C~T 5'GCTTCATGCCTCTGCTCCCACCTG 3' 
17 G~T 5' GGCAGCGACGATTTT AACAGCAGA 3' 
5' TGTCTCTTGTGGCCCATCTTACTG 3' 
5' AAA TAGCCAGGACCAGCAAGTTTT 3' 
MBD2 1 C~T 5' GGTGGCTAGCCCGACCAACCTTC 3' 
5' CCGCCGCACTCTCCCCCTCCTC 3' 
2 A~G 5'TGTGGAGAA TATTGTTGCCTTTTG 3' 
5'TTTTGAAGAGCTTTCGAAGTAGCA3' 
7 A~G 5' TGATGCCAGGTGCAA TCTACT 3' 
5' TATATGCGCTATCTTCCTCCAC 3' 
7 G~A 5' TGATCCCTGGGCCTT AGGT 3' 
5' AGGCCAGGTACAGGT AA TGGTT 3' 
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Restriction 
Enzyme 
Acil 
CviTI 
Ecil 
Afl III 
Tsp451 
Xbal 
RETT SYNDROME PROJECT RESUL TS 
During the first year of my PhD thesis, the MECP2 gene was identified as 
a cause for RS. Because we already had DNA samples from RS patients 
in the lab, we decided to investigate whether MECP2 mutations were 
responsible to the RS phenotype in our cohort. In the meantime, of 
analysing these available samples, our collaborator, Dr. Patrick Macleod, 
and others child neurologists help us recruit an additional and relatively 
large number of patients and their parents. The present chapter described 
our work on the MECP2 gene in RS patients. 
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Abstract 
Background: Rett syndrome (RTT) is a severe neurodevelopmental 
disorder of girls, caused by mutations in the X-linked MECP2 gene. 
Worldwide recognition of the RTT clinical phenotype in the early 1980'5 
allowed many cases to be diagnosed, and established RTT as one of the 
most common mental retardation syndromes in females. The years since 
then led to a refinement of the phenotype and the recent elaboration of 
Revised Diagnostic Criteria (ROC). Here, we study the impact of the 
presence versus the absence of the use of diagnostic criteria from the 
ROC to make a diagnosis of RTT on MECP2 mutation detection in 
Canadian patients diagnosed and suspected of having RTT. 
Methods: Using dHPLC followed by sequencing in ail exons of the 
MECP2 gene, we compared mutation detection in a historie cohort of 35 
patients diagnosed with RTT without the use of specifie diagnostic criteria 
to a separate more recent group of 101 patients included on the basis of 
strict fulfillment of the ROC. 
Results: The MECP2 mutation detection rate was much higher in subjects 
diagnosed using a strict adherence to the ROC (20 % vs. 72 %). 
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Conclusions: These results suggest that clinical diagnostic procedures 
significantly influence the rate of mutation detection in RTT, and more 
generally emphasize the importance of diagnostic tools in the assessment 
of neurobehavioral syndromes. 
Introduction 
Rett Syndrome (RTT, OMIM 312750) is characterized by onset in the first 
18 months of life of slowing and arrest of neurodevelopment paralleled 
with a loss of communication and motor ski Ils acquired to that point. 
Purposeful hand movements are replaced by a semi-continuous hand-
washing stereotypy. Social interaction with the family disintegrates, 
resembling autistic withdrawal, and with the passage of time a picture of 
profound mental retardation emerges (Hagberg 2002). However, 
depending on mutation location and extent of X-inactivation skewing, 
individuals with RTT may also exhibit milder phenotypes with preserved 
speech and ambulation, mi Id learning disability, or a clinical picture more 
similar to autism than to classical RTT (Naidu et al. 2003; Weaving et al. 
2003; Schanen et al. 2004). 8ecause of X-linkage, mutations causing 
classical RTT in girls are generally embryonic-Iethal in boys, although 
some rare mild mutations allow survival and a variety of 
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neurodevelopmental phenotypes in males (Meloni et a/. 2000; Orrico et a/. 
2000; Dotti et a/. 2002). 
Following mapping of the RTT candidate locus to Xq27 -28, the use of a 
candidate gene approach allowed identification of the first RTT-causing 
mutations in the four-exon MECP2 gene (Amir et a/. 1999). Since then, 
analysis of exons 2 to 4 of the gene in 32 reports (Miltenberger-Miltenyi et 
a/. 2003; Scholl en et a/. 2003; Ariani et a/. 2004; Karteszi et a/. 2004; 
Laccone et a/. 2004), revealed 221 different mutations in the large exons 
3 and 4, nine of account for 65 % of ail mutations in classical RTT 
patients. No mutations were found in exon 2, and until recently, exon 1 
was not included in mutation analyses, because it was considered to be 
non-coding and representing merely an extension of the 5' untranslated 
region (UTR) (Figure 3). A recent re-evaluation of MECP2 splice variants 
showed that the major brain transcript of the gene utilizes only exons 1, 3 
and 4, in which case the first exon becomes coding (Kriaucionis et a/. 
2004; Mnatzakanian et a/. 2004). As a result, three additional mutations, 
affecting exon 1, were recognized (Mnatzakanian et a/. 2004). We now 
cali the new MECP2 isoform MECP2E1 (E1 for translation initiation site in 
exon 1; nomenclature agreed upon at the international Rett Syndrome 
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Research Foundation meeting, June 2004), and the originally identified 
isoform MECP2E2. The mutations described below are numbered 
according to the MECP2E1 open reading frame (Figure 3). Equivalent 
annotation from MECP2E2 is included in Table 17. 
Initially described in 1966 (Rett 1966), RTT was rediscovered in the early 
1980's and prominently brought to international paediatric attention 
(Hagberg et al. 1983). This allowed many cases to be diagnosed, and 
established RTT as one of the most common mental retardation 
conditions in females (Hagberg 1985). It also led to a refinement of the 
RTT clinical phenotype in the early 1990s. The discovery of MECP2 
mutations in RTT subjects added further knowledge in this disorder, and in 
2001, an international effort was made to establish specific clinical 
guidelines to facilitate clinical diagnosis and recognition of the disorder 
(Hagberg et al. 2002). An updated list of criteria emerged and was called 
the «Revised Diagnostic Criteria (ROC)>> (Table 17; 
http://www.rettsyndrome.org/main/diagnostic_criteria.htm) (Hagberg et al. 
2002). Here, we study the impact of the presence versus the absence of 
the use of diagnostic criteria from the ROC to make a diagnosis of RTT on 
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MECP2 mutation detection in Canadian patients diagnosed and suspected 
of having RTT. 
Patients and methods 
Ali but one patient had been referred from various Canadian centres. This 
patient was referred from the Children's Mercy Hospitals and Clinics, 
Kansas City, Missouri, USA. In order to evaluate the impact of the use of 
specific criteria for RTT diagnosis on MECP2 mutation detection rate we 
subdivided the patients into two groups: we had one historic group (Group 
1, Table 18) of patients without any final diagnosis merely a suspicion of 
RTT in whom specific diagnostic criteria for RTT were not used, and a 
more recent collection (Group 2) where patients were only accepted if they 
strictly met diagnostic criteria for RTT (Table 17). The referring physicians 
in both cases were not distinguishable in background. They were 
Canadian paediatricians, geneticists and paediatric neurologists. 
The entire coding regions of exons 1,2,3 and 4 and their intronic flanking 
sequences were analyzed. Exons 2 to 4 were amplified by PCR with 
primer pairs designed with the use of genomic sequence information from 
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the Human Genome Project working draft site (UCSC, 
www.genome.ucsc.edu) and the Lasergene Primer select program. The 
PCR products were loaded on 2% agarose gel to confirm amplification 
before analysis for base changes by dHPLC (WAVE Nucleic Acid 
Fragment Analysis System from Transgenomic, San Jose, CA). Solvent A 
consisted of 0.1 mol/L triethylammonim acetate (TEM) and 25% 
acetonitrile and solvent B contained 1 M TEM, 25% acenonitril. PCR 
products showing a chromatographic variation on dHPLC were sequenced 
directly on an automatic sequencer (Gene Reader 4200). The sequencing 
data was analyzed using DNA Star software SeqMan (Lasergene). Exon 1 
was PCR amplified and sequenced in ail patients as recently described 
(Mnatzakanian et al. 2004). 
Results 
The MECP2 gene was retrospectively analyzed for mutations in banked 
DNA from a total of 136 patients with a presumptive diagnosis of RTT. 
Average age of the affected subjects was 13 years, with a range of 5 to 46 
years. We identified a total of 33 different MECP2 mutations, presented in 
Table 19. Group 1 was a historic cohort of 35 patients suspected of 
having RTT. Organized diagnostic criteria were not utilized in these 
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patients. Their clinical features are summarized in Table 18. Results 
from mutational analysis in this group revealed mutations in 7 individuals 
(20 %) (Table 19). Five of the nine common point mutations, T170M, 
R180X, R267X, R306X, and R318C were found in this group. Ali 
mutations in Group 1 have been seen previously in classical RTT patients. 
ln Group 2, which included subjects diagnosed with a strict adherence to 
the RTT criteria, mutations were detected in 73 out of 101 individuals (72 
%). Ali previous common RTT point mutations, namely R118W, R145C, 
T170M, R180X, R267X, R282X, R306X, and R318C were detected in this 
group, except one, A152V (A140V). These 8 recurrent mutations account 
for 68.5 % of our Group 2 mutations, with T170M being the most frequent 
(16 times). Three patients had previously undescribed mutations, two in 
exon 3 (762 dei C, and P284S) and one in exon 1 (Table 19). The exon 1 
mutation, a 1A T substitution (ATG->TTG), changes the first Methionine 
codon into a Leucine. The prediction is that MECP2E1 translation would 
be greatly or totally hindered due to absence of a start codon. MECP2E2 
would be normally made (and appears unable to rescue the disease 
phenotype). 
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None of the mutations in Group 1 or 2 were observed in any of the parents 
of our patients, confirming that the great majority of mutations in RTT are 
de novo. Polymorphisms were found in both groups during our mutation 
analysis. They are: S206S, G264G, T311T, S422S and K357K. G264G 
and S422S have not previously been reported. Finally, a hitherto 
unreported variation, P431S, located at the C-terminus of the MECP2 
gene, was found to be transmitted from a normal mother to an RTT-
affected girl. We label this sequence alteration "unclassified variant", as 
recently proposed (Miltenberger-Miltenyi et al. 2003). 
Discussion 
ln this study we have analyzed the entire coding sequence of the MECP2 
gene in two cohorts of subjects, grouped according to the use of 
diagnostic procedure to make a diagnosis. We wanted to evaluate the 
impact of the use of stringent clinical criteria on MECP2 mutation detection 
rate. Our MECP2 screen revealed the presence of multiple mutations in 
both groups of patients; however, the detection rate in Group 1 was much 
lower (20 %) than in Group 2 (72 %). These observations indicate that 
diagnostic procedures strongly influence mutation detection rates. While 
the clinical overlap seen in Group 1 compared to Group 2 is substantial, 
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subjects in the former group may have a more genetically heterogeneous 
etiology than those with a more stringent RTT diagnosis. From the clinical 
point of view, this observation is important, because the majority of 
subjects diagnosed without the use of RTT criteria may represent other 
diseases. In fact, many in Group 1 were given a differential diagnosis of 
Angelman syndrome (Table 18). RTT and Angelman syndrome are both 
neurodevelopmental disorders characterized by severe intellectual 
disability, microcephaly, speech problems, movement disorders with gait 
and/or truncal ataxia, and occasionally a similar facial appearance. As 
mentioned by Ellaway and colleagues, RTT is probably the most common 
mimicker during the infant and toddler ages and AS might represent a 
phenocopy for RTT (Ellaway et al. 1998). The clear distinction between 
the two syndromes will continue evolving over time. On the other hand, in 
the present study, in those who were found negative for MECP2 coding 
sequence mutations, it is still possible they have other mutations such as 
regulatory mutations or large insertions or deletions that would not be 
detected by the methods utilized in this study. However, it is unlikely that 
such a mutation subgroup would be differentially represented Group 1. 
Additional genetic alterations have been associated with the RTT 
phenotype, even in patients with a typical MeCP2 mutation. Longo et al. 
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recently reported three patients with Rett syndrome and rearrangements 
of chromosome 15q11-13, a region known to be implicated in autistic 
phenotypes. This suggests the possibility of the role of additional genes 
with the RTT phenotype, although further studies are necessary to confirm 
this association (Longo et al. 2004). Indeed, in a recent review of 
Weaving et al., at least seven published atypical RTT cases have been 
found to have mutation in the X-linked CDKL5/STK9 gene. This 
serine/threonine-protein kinase of unknown function may represent a 
potential candidate gene for RTT cases without any MECP2 mutation 
(Weaving et al. 2005). 
While most of the observed mutations in this study have been reported 
previously, three are new including one in the newly characterized coding 
tirst exon. One mutation, P284S, would seriously alter the MeCP2 protein 
secondary structure by removing the proline bend at position 284. 
Another, 762 (dei C), shifts the reading frame and results in premature 
truncation. The exon 1 mutation (1A->T) removes the exon 1 initiation 
codon, which would prevent any MeCP2E1 protein from being made. In 
the MECP2E2 transcript it will represent nothing more than a single 
nucleotide change in the 5'UTR. Might this have an effect on MeCP2E2 
150 
protein production? Kriaucionis and Bird recently showed, in tissue 
culture experiments, that the four-exon MECP2E2 transcript makes a 
short peptide initiated at the ATG in exon 1 and terminated in the stop 
codons preceding the MECP2E2 start site in exon 2. They demonstrated 
that if the exon 1 start is removed and the short peptide abolished the 
translation of MECP2E2 increases dramatically. Here, we have a patient 
replicating the Kriaucionis and Bird experiment. If subsequent 
experiments indeed show that in this patient MECP2E2 translation is 
enhanced by the exon 1 ATG A->T mutation, then this would provide 
crucial new insight into RTT. It would imply that MECP2E2 cannot 
compensate for absence of MECP2E1, and that MECP2E1 is necessary 
and sufficient for RTT. These experiments are underway. 
As mentioned by Hagberg and colleagues (Hagberg et al. 2002) even 
though we now know the major genetic cause of RTT, this disease 
remains so far a clinical diagnosis. From a scientific and socio-ecomomic 
point of view, the use of efficient and weil defined clinical criteria is very 
important for many reasons: (1) ln order to replicate research findings, 
such as mutation gene screening, it is essential to use the same 
phenotypic selection method. (2) ln heterogeneous genetic disorders, 
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where more than one gene locus might be involved, it is important to be 
able to discriminate those who harbour a mutation in order to only focus 
on those who do not have mutations to better homogenize the search of 
the unknown locus. (3) The more the diagnostic procedure is precise; the 
more appropriate treatments can be applied to the affected child. (4) The 
diagnosis of RTT remains clinical and this is a critical step that leads (or 
not) to MECP2 mutation gene screening, especially since the cost of 
MECP2 testing is high (currently varies from 500$ to 950$ US). 
Our results show that implementation of beUer clinical diagnostic 
procedures improves the rate of MECP2 mutation detection. Mutations in 
the MECP2 exon 1 occur in 2/136 or 1.5 % of RTT patients, and therefore 
this exon should be included in diagnostic mutation searches in this 
devastating disease. 
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Table 1. Clinical features present in subjects from Group 1. 
Cases Mutation Clinical Features from Medical File Differentiai Diagnosis 
1 NO GDD, seizures, regression, hypotonia, hand-wringing, short stature, obesity PWS, SD 
10 NO GDD, seizures, microcephaly, spactic diplegia, dysmorphic features AS 
11 119deiA GDD, hypotonia, hand-wringing, non-verbal, failing locomotion AS, PDD 
14 NO History of seizures, microcephaly, non-verbal, spastic diparesis, scoliosis, facial dysmorphisms Dev. Delay, MR, PWS 
19 NO Regression, seizures, microcephaly, autistic features, hand-wringing, scoliosis AS 
27 R168X Regression, seizures, hand-ringing, bruxism, abnormal breathing PWS, SMS 
29 NO GDD, not ambulatory, cerebeliar hypoplasia AS, Joubert Syndrome 
29 NO GDD, MR, seizures, not ambulatory Joubert Syndrome 
34 T158M Not available 
35 NO GDD, seizures, hypotonia, inappropriate laughter AS 
38 NO Seizures, difficulty walking, brachycephaly, brain anomalies RTT 
39 NO Seizures, spastic diplegia, al, hyperventilation, hand-flapping, hypotonia, facial dysmorphisms 
40 R255X Not available 
41 NO Seizures, stereotypie hand behaviors, bruxism, occasional abnormal breathing patterns 
42 NO Not available 
45 NO Speech delay, MR, behavioral problems, hand-wringing, hyperventilation, inappropriate laughter AS 
46 1182del2 Not available 
48 NO GDD, intractable epilepsy, ataxia, obesity, hypertriglyceridemia 
5 NO Stereotypie hand movements, fine motor deficits, non-verbal, abnormal EEG AS 
See next page 
64 NO 
65 NO 
77 NO 
77 NO 
78 R306C 
8 NO 
81 NO 
82 NO 
83 NO 
84 NO 
86 NO 
89 NO 
90 R255X 
92 NO 
95 R294X 
Difficulty walking, delayed speech, white matter changes on MRI 
GDD, microcephaly, hypotonia 
Not available 
Not available 
Not available 
Hyperventilation, manneristic hand movements, scoliosis, microcephaly 
GDD, microcephaly, seizures, hand-wringing, bruxism, dysmorphic features, non -verbal 
GDD, microcephaly, poor speech, unsteady gait, ataxia 
GDD, microcephaly, seizures, syndactyly 
GDD, regression, microcephaly, seizures, hand-wringing, cerebral atrophy, bruxism 
Not available 
GDD, hypotonia, dysmorphic features, plagiocephanly, scoliosis, osteoporosis, ab normal EEG 
GDD, no eye contact, recurrent blinking, repetitive behaviours 
GDD, microcephaly, strabismus 
Not available 
AS 
Oculodentodigital 
Dysplasia 
AS, William's 
syndrome 
AS, SMS, RTT 
RTT 
RTT 
PWS 
PDD autism 
GDD: Global Developmental Delay; Dev.: Developmental; pbs: problems; PWS: Prader-Willi Syndrome; SD: Seizures 
Disorder; AS: Angelman Syndrome 
Table 18. Revised Diagnostic Criteria for Rett Syndrome. 
Criteria 
Necessary 1. Apparently normal prenatal and perinatal history 
2. Psychomotor development largely normal through the first 6 
months or may be delayed from birth 
3. Normal head circumference at birth 
4. Postnatal deceleration of head growth in the majority 
5. Loss of achieved purposeful hand skill between ages ~ - 2~ 
years 
6. Stereotypie hand movements such as hand 
wringing/squeezing, clapping/tapping, mouthing and 
washing/rubbing automatisms 
7. Emerging social withdrawal, communication dysfunction, loss of 
learned words, and cognitive impairment 
8. Impaired (dyspraxie) or failing locomotion 
Supportive 1. Awake disturbances of breathing (hyperventilation, breath-
Exclusion 
holding, forced expulsion of air or saliva, air swallowing 
2. Bruxism 
3. Impaired sleep pattern from early infancy 
4. Abnormal muscle tone successively associated with muscle 
wasting and dystonia 
5. Peripheral vasomotor disturbances 
6. Growth retardation 
7. Hypotrophie small and cold feet; small, thin hands 
1. Organomegaly or other signs of storage disease 
2. Retinopathy, optic atrophy, or cataract 
3. Evidence of perinatal or postnatal brain damage 
4. Existence of identifiable metabolic or other progressive 
neurological disorder 
5. Acquired neurological disorder resulting from severe infections 
or head trauma 
155 
Table 19. MECP2 mutation screening trom our two cohorts of subjects. 
MECPE1* MECPE2* 
Nt Position AminoAcid Nt Position Amino Acid Exon Recurrence Reported 
Group 1 
155deiA Fs at 52, stop at 408 119 dei A Fs at 40-stop at 372 3 1 YES 
1218del2 Fs at 430, stop at 439 1182del2 Fs at 394, stop at 403 4 1 YES 
509 C->T T170M 473C->T T158M 4 1 YES 
538 C->T R180X 502C->T R168X 4 1 YES 
799 C->T R267X 763C->T R255X 4 2 YES 
916 C->T R306X 880C->T R294X 4 1 YES 
952 C->T R318C 916C->T R306C 4 1 YES 
Group2 
1A->T M1L 1A->T M1L 1 1 NO 
GTdel Splice variant GTdel Splice variant 1 1 YES 
338 C->G P113R 302C-G P101R 3 1 YES 
352 C->T R118W 316C->T R106W 3 1 YES 
416 C->T P139L 380C->U P127L 4 1 NO 
433 C->T R145C 397C->T R133C 4 2 YES 
434 C->A R145H 398 C->A R133H 4 1 YES 
See next page 
437 C->G S146C 401C->G S134C 4 1 YES 
458insA Y153X 422insA Y141X 4 1 YES 
491 C->G P164R 455C->G P152R 4 1 YES 
505 T->C F169L 469T->C F157L 4 1 YES 
508 A->G T170A 472A->G T158A 4 1 YES 
509 C->T T170M 473C->T T158M 4 16 YES 
538 C->T R180X 502C->T R168X 4 6 YES 
622 del4 Fs at 232, stop at 220 586del4 Fs at 196, stop at 208 4 1 YES 
732deiC Fs at 268, stop at 259 696deiC Fs at 232, stop at 247 4 1 YES 
786deiC Fs at 286, stop at 300 750deiC Fs 250, stop at 288 4 1 NO 
799 C->T R267X 763C->T R255X 4 5 YES 
842deiG Fs at 305, stop at 300 806deiG Fs at 269, stop at 288 4 1 YES 
844 C->T R282X 808C->T R270X 4 9 YES 
850 C->T P284S 814C->T P272S 4 1 NO 
916 C->T R306X 880C->T R294X 4 5 YES 
941 C->A P314H 905C->A P302H 4 1 YES 
941 C->T P314R 905C->T P302R 4 1 YES 
952 C->T R318C 916C->T R306C 4 6 YES 
See next page 
953 G->A R318H 917G->A R306H 4 1 YES 
964C->A 
1000 C->A P334T P322T 4 1 YES 
1000 C->G P334A 964C->G P322A 4 1 YES 
1157del44 
1193del44 Fs at 422, stop at 401 Fs 386, stop at 389 4 1 YES 
1196del33 Fs at 423, stop at 488 1160del33 Fs 387, stop at 476 4 1 YES 
1291 C->T P431S 1255C->T P419S 4 1 NO 
-Base pair position and ami no acids numbered according to the MECP2E1 and the MECPE2 transcript initiator 
codon (NeBI # AY541280). bMECP2 variant present in the mother. Fs: Frameshitf, dei: deletion, nt: nucleotide 
position on the transcript. 
Exon 1 Exon2 Exon3 Exon4 
r---,{L-j TGA 
• 
! Original MECP2 A -, I-+-! H 
5.3 kb 60 kb 736 bp (MECP2E2) 
1~_r J.77 378 1461 MECP2E2 B I----l ! (original numbering) 
TGA TGA b TGîl ~ 1 NewMECP2 C I---l i-----l (MECP2El) 
8 2 63 4~4 1497 MECP2El D ! ! (new numbering) 
Figure 3. Schematic representation of the two MECP2 transcripts. 
(a): Original genomic organization of the MECP2 gene (MECPE2). (b) Original 
nucleotide numbering. (c) Genomic structure of the new MECP2 transcript 
(MECP2E1). (d) Novel nucleotide numbering according the MECPE1.Black 
boxes; untranslated regions; arrow; start site, TGA; stop codon, numbers 
represent nucleotides position. 
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GENERAL DISCUSSION AND SUMMARY 
At the beginning of this thesis project, the RTT gene had not been discovered 
and only four genome-wide linkage studies were completed on autism. Six years 
later, the major cause of RTT is known, and we continue the search for genes 
involved in autism. Autism and RTT belong to the same group of diseases, the 
POO and for this reason they share many features. These disorders are not 
simple traits. Autism is a complex polygenic disorder and RTT a monogenic 
disorder (with complex features). However this does not exclude the possibility 
that they may share a common genetic origin. 
AUTISM 
The scientific community has, until recently, been discouraged with the results of 
genetic investigations of diseases like autism. Considering the numerous 
publications describing negative or equivocal findings, it is not clear how we 
should assess the current state of common-trait genetics. The identification of 
susceptibility genes for autism would represent a potentially powerful avenue to 
begin to understand the pathogenesis of this mysterious and distressing 
syndrome. Studies attempting to map and identify genes predisposing to autism 
have been hampered by: (i) the rareness of multiplex families, (ii) the use of 
subjects with different ethnicity, and (iii) the lack of statistical power and/or 
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robustness of classicallinkage approaches when applied to complex diseases. 
These disadvantages prompted us to use an alternative approach to search for 
candidate genes for autism. We used a family-based association study designed 
to overcome the ethnie background problems and employed a candidate gene 
approach to directly investigate interesting genes. Additionally we took 
advantage of the genetic characteristics of the Quebec population (founder 
effect) to map and identify genes that predispose to autism. 
ln order to achieve this aim we established a collaborative network with Montreal-
based clinical diagnostic experts, allowing us to assemble a unique collection of 
clinical information and DNA samples from individuals affected with an autism 
spectrum disorder. Since autism has an early age of onset, both parents from 
these children were available to participate in the study. This DNA collection is 
unique because it is derived principally from nuclear families (a proband and both 
parents) with a majority French-Canadian background. A large sample size of 
nuclear families is ideal when using a family-based association study because it 
minimizes genetic noise from population stratification. 
We explored the X chromosome as a candidate site harbouring a gene for 
autism. The X chromosome is disproportionately populated with genes 
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associated with higher cognitive function and so far 16 genes, (perhaps 
ultimately more than 100), have been associated with non-syndromic mental 
retardation (Ross et a/. 2005; Skuse 2005). The recent identification of two X-
linked mutated genes associated with autism and Asperger (Jamain et a/. 2003) 
(Laumonnier et a/. 2004; Yan et a/. 2004), argues in favour of one of our 
hypotheses, that the high male: female ratio is partially explained by mutations in 
X chromosome candidate genes. To our knowledge, our study is the first family-
based association study looking at the entire X chromosome. Using this 
approach we were able to define a relatively small chromosomal region which 
may contain a putative gene predisposing to autism spectrum disorders. As we 
expected to find a large common region in the founder population, the 
identification of a relatively small associated region (274 kb) suggests that the 
susceptibly haplotype may be older than the founding of FC population. 
Consequently many recombination events would have occurred before the 
establishment of the population in Quebec. 
Of significant interest to us, two independent groups reported positive linkage 
overlapping our region, thereby supporting our results (Yonan et a/. 2003; 
Vincent et a/. 2005). The positive result from our association on the X 
chromosome may be due to a high number of Asperger and high functioning 
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autistics in our cohort. Autism is part of a spectrum since a wide range of related 
phenotypes can be found at each extremity of the disorder (mild versus severe). 
One end is represented by atypical autism in the presence of mental retardation, 
the most severe form. At the other end we observe a high functioning autism 
phenotype (autism without mental retardation) followed by the Asperger 
Syndrome. One might speculate that an individual with the less severe 
phenotype has a better chance to reproduce and therefore increase his chance 
to transmit the mutated gene. While the exact number of Asperger and high-
functioning autistics cannot be determined due to diagnostic procedures (a 
patient may have more than one diagnosis within the autism spectrum disorder -
autism without MR and Asperger, through the course of his/her life), our sample 
is composed of a majority of patients who received a diagnosis of Asperger and 
high functioning autism. 
The region that we were able to define is at the Xq27.3 band, a gene poor region 
(figure below). 
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Figure 4. Map of the region, according to the UCSC Genome Browser, on X 
chromosome band q27.3 that showed the most significant associated 
region in our French-Canadian population. The black islands represent 
conserved regions between species Iisted below. 
The only known genes mapping to this region, CXORF1 and SLTRK2, were 
sequenced and no causative mutations were found. However, these genes 
cannot be ruled-out as involved in autism since the number of patients screened 
is low. Mutational analysis in a larger sample size of autistic patients will better 
elucidate whether these genes have a role or not. This work is in process. 
Recently, the annotated gene sequence of the entire X chromosome has been 
completed at 99.3% by a collaboration of people from Germany, the UK and the 
USA. This map predicts new cDNA, novel transcripts and novel putative 
transcripts, which will certainly help to elucidate the role of this candidate region 
in autism. 
Our second family-based association study was done using a putative functional 
polymorphism within the OMGP62 gene on chromosome 17, a chromosomal 
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region linked to autism (International Molecular Genetic Study of Autism 
Consortium 2001; Yonan et al. 2003). This gene is an oligodendrocyte myelin 
glycoprotein expressed by neurons and oligodendrocytes during the myelination 
of the central nervous system (CNS) and in adult CNS. In this study, we report an 
overtransmission of one allele of OMGP62 in a sample of 455 families of Italian, 
Canadian and US origin. The association is particularly visible, although not 
statistically proved in the French Canadian group. The Quebec population of 7.5 
million people contains about 6 million French-Canadians who are descendants 
of around 8 000 French settlers who colonized "Nouvelle-France" between 1608 
and 1765 (Charbonneau H 2000). The relative contribution of each founder to the 
Quebec population is highly variable depending, among other factors, on their 
period of arrivai in North America (Heyer et al. 1995) thus, the 3380 founders 
who settled before 1680 contribute approximately 70% of the present gens pool 
(Charbonneau 1993). Furthermore, many of these founders were related to each 
other and from the same villages in France (Guillemette 1989). The Quebec 
population shares a relatively homogeneous genetic background, thereby would 
make the susceptibility allele more detectable in a family-based association study 
reducing the possible number of susceptibility alleles. Considering the 
differences of allelic distribution between the three groups of patients, it would be 
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of importance to assess these frequencies in control populations, to distinguish 
the effect of ethnie influence from real association in these patients. 
This family-based association study does not support the direct effect of one of 
the two alleles of the OMGP62 polymorphism in the aetiology of autism. 
However, the recent study performed on a group of Japanese autistic patients 
revealed significant differences in allelic distributions of one marker at OMGP 
locus between patients and controls (Marui et al. 2004). These results and our 
study speak in favour of the existence of a susceptibility gene for autism in the 
OMGP gene region. More work will be necessary to analyse the distribution of 
alleles in different ethnie groups and to identify other polymorphisms in this 
region which may be in linkage disequilibrium with OMGP62 alleles. 
Our family-based association studies yielded interesting results, though it 
assumed that ail or most of the affected cases share a common causative allele. 
If this were the case, the many genetic studies performed over the years would 
have already been successful. While the hypothesis that there is a common 
mutated gene in our French-Canadian population is plausible, it is not to 
excluded that a portion of cases may result from different mutations in different 
genes or different alleles. Moreover, both transmiUed and de novo mutations 
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could also be involved. A significant rate of de novo mutations can, in part, 
explain why genetic studies have 50 far failed to identify many autism genes. 
Mutations in genes leading to severe diseases where there is a strong negative 
selection against the phenotype, such as lethality in embryonic stages or reduced 
reproductive fitness, will not be transmitted to multiple family members, and 
therefore will not be detected by linkage gene mapping. However, the widely 
distributed linkage and associated positive signais scattered over the genome 
argues against the existence of one or a few major predisposing common 
variants in these diseases. Furthermore, the relatively small numbers of genes 
that have been found to predispose to autism explain only a small fraction of 
cases. This is not to say that sorne common variants will not be found for sorne 
predisposing genes, but this mechanism is unlikely to explain ail the genetics of 
these diseases. Moreover, the hypothesis that both inherited and de novo 
mutation can lead to autism, may explain the phenomenon of the uniform word-
wild incidence of autism. Clinicians and geneticists argue that autism is a highly 
heterogeneous disease, and cannot be explained by a single or even a few 
common variants. It has recently been recognized that complex diseases likely 
result from a mix of common and rare variants. With the exception of variants 
dating back to speciation, one would expect that common variants would result in 
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uneven disease incidence across different populations due to migration, different 
population growth and isolation. This is not the case for autism. 
The far most important key finding into the pathogenesis of autism is the report of 
mutations in NLGN3 and NLGN4 genes. However, we were not able to replicate 
this finding in our cohort of autistic subjects. NLGN3 and NLGN4 belong to the 
neuroligin family of postsynaptic cell adhesion molecules that are widely 
expressed in the brain (Philibert et al. 2000). The product of these genes is 
involved in late steps of synaptogenesis, mediating the specifie recruitment of 
pre- and postsynaptic proteins to the site of initial synaptic contact. This newly 
identified genes open new avenues in the search of causative genes for autism 
for many reasons; the neuroligin family included at least 4 known genes which 
potentially may be good candidate for autism; neuroligin interact with a number of 
different brain protein (neurexin, PSD95, PSD93, SAP102 and S-SCAM as 
example) therefore any genes implicating in this pathway are interesting 
candidate for autism; the finding that two modulating synaptic genes are involved 
in the disorder, any other protein gene implicate in the synaptic development, 
function, modulation or plasticity are good candidate genes. 
Though we have some clues on the biology of autism, the candidate gene 
approach that is mainly based on the relevance to the disease is a daunting task, 
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as most of the brain-expressed genes may be good candidates for autism. Our 
candidate gene approach using FOXP2, MBD1 and MBD2 gene as candidate for 
autism did not revealed any significant finding. These specifie brain expressed 
genes appeared to not be involved into the pathogenesis of autism. To date over 
75 different genes, ail know to be expressed in brain, have been tested by the 
candidate approach. The number of patients analysed for these 75 genes vary 
and range from 1 to 202 patients. None have been found to be the major cause 
of autism. This reflects the complexity of the disorder. It is very likely that there 
are multiple genes involved in susceptibility of autism, even in homogenous 
population such as our French-Canadians population. 
ReU Syndrome 
The goal of this part of the thesis project was to validate the involvement of 
MECP2 mutations in our cohort of RTT subjects and assess the importance of 
the use of strict diagnostic criteria in the rate of mutation detection. This could 
only be achieved via an active collaboration with clinicians ail over the country 
(Canada), which allowed us to recruit a collection of DNA samples from affected 
girls with RTT and both their parents allowing us to increase our chances of 
identifying mutations in that gene. As detailed in chapter 2, the MECP2 gene is 
responsible for a large proportion of our RTT cases. Moreover, using our 
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mutation screening we demonstrated that the procedure used for diagnosis 
significantly impacts on the mutations detection rate. From the clinical point of 
view, this observation is important, because the majority of subjects diagnosed 
without the use of RTT criteria may represent other diseases. In fact, many of our 
subjects having no formai diagnosis of RTT were also given a differential 
diagnosis of other overlapping syndrome such as Angelman syndrome. The 
clear distinction between these overlapping syndromes will continue evolving 
over time. While most of the observed mutations in this study have been reported 
previously, three are new including one in the newly characterized coding first 
exon. The exon 1 mutation (1A->T) removes the exon 1 initiation codon, which 
would prevent any MeCP2E1 protein from being made. In the MECP2E2 
transcript it will represent nothing more than a single nucleotide change in the 
5'UTR. Might this have an effect on MeCP2E2 protein production? Kriaucionis 
and 8ird recently showed, in tissue culture experiments, that the four-exon 
MECP2E2 transcript makes a short peptide initiated at the ATG in exon 1 and 
terminated in the stop codons preceding the MECP2E2 start site in exon 2. They 
demonstrated that if the exon 1 start is removed and the short peptide abolished, 
the translation of MECP2E2 increases dramatically (Kriaucionis et al. 2004). 
Here, we have a patient replicating the Kriaucionis and 8ird experiment. If 
subsequent experiments indeed show that in this patient MECP2E2 translation is 
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enhanced by the exon 1 ATG A->T mutation, then this would provide crucial new 
insight into RTT. It would imply that MECP2E2 cannot compensate for absence 
of MECP2E1, and that MECP2E1 is necessary and sufficient for RTT. These 
experiments are underway. 
As mentioned by Hagberg and colleagues (Hagberg et al. 2002) even though we 
now know the major genetic cause of RTT, this disease remains 50 far a c1inical 
diagnosis. From a scientific and socio-ecomomic point of view, the use of 
efficient and weil defined clinical criteria is very important for many reasons: (1) 
ln order to replicate research findings, such as mutation gene screening, it is 
essential to use the same phenotypic selection method. (2) ln heterogeneous 
genetic disorders, where more than one gene locus might be involved, it is 
important to be able to discriminate those who harbour a mutation in order to only 
focus on those who do not have mutations to better homogenize the search of 
the unknown locus. (3) The more the diagnostic procedure is precise; the more 
appropriate treatments can be applied to the affected child. (4) The diagnosis of 
RTT remains clinical and this is a critical step that leads (or not) to MECP2 
mutation gene screening, especially since the co st of MECP2 testing is high 
(currently varies from 500$ to 950$ US). 
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Our results show that implementation of better clinical diagnostic procedures 
improves the rate of MECP2 mutation detection. Mutations in the MECP2 exon 1 
occur in 2/136 or 1.5 % of RTT patients, and therefore this exon should be 
included in diagnostic mutation searches in this devastating disease. 
The association between the MECP2 gene and RTT is one of the most important 
findings to date in the POO. This discovery, while rather recent, started to allow 
the scientific and medical community to confirm previous hypotheses and more 
importantly to increase our knowledge on several still unknown aspect of this 
syndrome, including better diagnosis and future preventive therapy. As 
mentioned previously and as also observed in our study, portions of RTT 
patients, even clinically weil defined, do not have any mutation in MECP2 gene. 
One expia nation is the presence of locus heterogeneity. In fact, three recent 
studies reported mutations in a cyclin-dependent kinase-like, the COKL5 gene, in 
subjects diagnosed with neurodevelopmental disorders reminiscent of the 
atypical RTT phenotype (Weaving et al. 2003; Weaving et al. 2004; Scala et al. 
2005) supporting the putative genetic heterogeneity in RTT. Most of the 
mutations were found to occur60 
de novo and located in the functional domain of the protein, which supports their 
pathogenic role. Ali patients with mutations in that gene have apparently normal 
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pre and perinatal periods, thereafter developing clinical features strongly 
resembling the early-onset RTT variant. Mutations in CDKL5 gene can also lead 
to a different phenotype (Tao et al. 2004), suggesting that a wide range of clinical 
features, which is also the case for MECP2 mutations. In fact, this phenotypic 
heterogeneity may be the result of the X-chromosome inactivation process, since 
CDKL5, such as MECP2, is on this chromosome. The clinical similarities 
between MECP2 and CDKL5 diseases may indicate that these two genes act in 
a common pathogenic pathway. If this is the case, this will be of great 
importance when considering the candidate genes approach for the search of 
gene in a heterogeneous disorder e.g. exploring candidate genes within the 
same pathway. 
ln addition to the hypothesis implicating another gene as responsible for a portion 
of cases in RTT, there may be diagnostic errors. In support of this hypothesis, we 
have found that using more stringent criteria increases the chance of finding a 
mutation in MEPC2. The impact of this result on future clinical evaluation and 
genetic testing may be significant. 
ln conclusion, 1 can say that my two main contributions to the autism project are 
the collection of DNA samples and the association with the X-chromosome. In 
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fact, the POO project was just starting when 1 joined Dr. Rouleau's lab. At that 
time, only ten RS DNA samples were available in the lab and no DNA sample as 
yet been collected for the autism project. 
It was very important for me to be involved in ail aspect off this genetic project: 
family's recruitment, DNA manipulation, analysis, etc, which 1 find highly 
interesting. Our efforts and precious collaborations lead to collections of DNA 
samples; at the end of my PhD thesis, we had a total of 136 RS trios and more 
importantly, our cohort of Autism Spectrum Disorders trios is now composed of 
500 families, 62 families of which with more than one affected children. Figure 5 
show the evolution in time our cohort of trios for both disorders. In addition to the 
DNA samples, we have collected ail relevant medical information on the affected 
subjects. This collection, without any doubt, will be useful to pursue the search of 
candidate genes in the near future. 
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Figure 5. Cohort of RS and ASD. The line with the diamonds and dots represent 
respectively ASD trios and RS trios collected. 
ln addition to our collection of genetic material from families affected with an 
autism spectrum disorder, this thesis includes the first study on the genetics of 
autistic families from the Quebec population. To further our understanding of a 
disorder, particularly one with mulifactorial etiology, it is necessary to extend our 
research to different populations in other to compare, confirm or revoke specifie 
findings. We can now say that our observations confirm the genetic complexity 
of autism in our population. The Quebec population will certainly contribute to the 
search of candidate genes for autism. 
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Genetic 5tudies of Pervasive Oevelopmental Oisorders (POO) 
Medical Research Consent Form 
, 
PARTICIPATION PROCEDURE 
Steps 3 and 4 of your participation will be determined by your status in the study as a: 
o Affected participant (person affected bya POO) 
o Parent Ilegai guardian of an affected participant 
o Control (person unaffected by a POO, other than a parent or legal 
guardian of an affected participant - i.e. other family member, spouse of 
affected participant, etc.) 
The other steps apply to ail participants in the study, regardless of their status. 
1) Your eligibility for this project will be determined by your attending physician. The 
research team may also consult your medical records in order to obtain additional 
information. 
2) The research assistant will ask you a series of questions concerning your medical and 
family history in order to construct a family tree. 
3) As a parent 1 legal guardian of an affected participant, you will be asked to take 
part in a second interview in order to document the psychological and behavioural 
history of the affected individual. This interview will last 60-120 minutes. 
4) As an affected participant, you may be asked to undergo a neuropsychological 
evaluation in order to document your clinical status. This evaluation will take between 
60-90 minutes and is part of standard medical practice in the treatment of individuals 
with a POO. This evaluation may be videotaped to enable reviewing at a later date. 
These recordings will be kept strictly confidential and will be locked in the files of Dr. 
Guy Rouleau at the CHUM Research Centre. 
o 1 accept that my evaluation be videotaped. 
o 1 refuse that my evaluation be videotaped. 
5) You will be asked to provide a venous blood sample (20-30 ml- the equivalent of about 
4 tablespoons) to enable a genetic variation study. 
6) You may be contacted by telephone in the weeks following the initial interview to obtain 
any missing information. 
7) There may be a yearly follow-up phone interview. You may therefore be contacted 
once a year by a member of the research team for an update on your medical 
condition or, on rare occasions, to collect another blood sample. The genetic analysis 
is expected to take place over the next 25 years. 
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GENETIC ANALYSES 
Definitions: 
DNA: a molecule that contains ail the transmissible genetic information that directs the 
activities of the cells in our bodies. DNA provides a series of instructions that determines 
the hereditary characteristics of ân-individual, such as one's eye colour or blood group. 
Cell line: a method of conserving DNA that enables the generation of an inexaustable 
quantity of DNA for subsequent studies. 
The blood sample will be used to extract DNA and to make cell lines. This DNA will be 
used for the study of genetic markers in order to identify the variations that lead to a 
susceptibility to POO. 
RECRUITMENT OF FAMIL Y MEMBERS 
Ouring the study the research team may require your help or the help of a designated 
individual to contact other members of your family and to invite them to participate in our 
study. The research team is not permitted to directly contact family members for this kind 
of recruitment. 
BENEFITS, RISKS ANO OISAOVANTAGES 
You will not directly benefit from your participation in this study. The results of this 
research could, however, in the long-term benefit individuals with POO as weil as their 
families. For example, they could enable a better understanding of the genetic factors 
implicated in these disorders. Eventually this could lead to new modes of treatment and 
prevention. 
Although blood drawing isn't problematic for the majority of individuals, it could cause 
bleeding, bruising, discomfort, infection, pain, or dizziness. 
As with ail medical researeh, one of the risks associated with this research project is 
related to the disclosure of your personal information to outside parties such as employers 
or insuranee companies. Such risks are, however, minimal since this project enta ils 
genetic tests performed within the framework of fundamental researeh and they are 
therefore of limited interest to outside parties. Furthermore, the laws of Quebec pertaining 
to the rights of the individual and the protection of privacy could proteet you should you 
become subject to invasive inquiries. 
COMPENSATION 
There will be no financial compensation for your participation in this project. 
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CONFIDENTIALITY OF INFORMATION COLLECTED 
The medical information obtained by your treating physician that is used to establish 
your eligibility for the study will be part of your hospital file. It will be subject to the 
confidentiality and privacy regulations of the CHUM. 
The information obtained for the purposes of this study will not be a part of your 
medical files. It will be stored in the investigator's research files and in a computerized file 
at the CHUM. During the study, this information could be shâred with other researchers in 
the context of specifie research agreements. Since the information will be coded (see 
below), confidentiality will be maintained. When the results of this study are published (or 
communicated by other means), no names or other identifiers will be used. 
The DNA samples (DNA extraction and cells lines) obtained for this study will be stored in 
Dr. Rouleau's genetics laboratories at the Notre-Dame Pavilion of the CHUM. We will 
ensure confidentiality by removing your name and assigning a specifie code number to 
your DNA sample. The code-key that connects the numbers to the patients' names can 
only be accessed by the researcher or by a designated individual. During this study, the 
samples could be shared with other researchers within and outside of the CHUM. The 
samples being coded, confidentiality will be respected at ail times. You may withdraw your 
sam pie from the project at any time during the study. 
Once the study is complete, the samples will be rendered anonymous and will be used for 
research on other hereditary diseases, provided that these projects have been approved 
by the research ethics committee. This could include your sample being sent to other 
researchers outside of the CHUM. Since the samples will be anonymous at this point, it 
will be impossible to identify them. You will therefore no longer be able to withdraw your 
sample from the DNA bank. Ali of the samples will be destroyed 25 years after the end of 
the project. 
o 1 agree ta my anonymous sample being preserved for other research. 
o 1 refuse my anonymous sam pie being preserved for other research. 
Your personal results will not be accessible to outside parties such as employers, 
government agencies, insurance companies or teaching institutions unless you specifically 
consent to this disclosure or unless we receive an order from a court of law. This same 
rule of confidentiality applies to the disclosure of results to your spouse, to other members 
of your family and to your doctor. However, in order to ensure the ethical management of 
research, it is possible that a member of the research ethics committee from the CHUM or 
a representative of Health Canada will consult your research data and your medical file. 
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COMMUNICATION OF RESUL TS 
You may communicate with the research team in order to obtain information about the 
progress of the study or the general results of the project. However, we will not directly 
communicate any specifie results to you concerning the genetic variations identified in your 
DNA sample., __ _ 
GENETIC COUNSELING SERVICES 
You may consult with a genetic counselor at any time. 
POSSIBILITY OF MARKETING-RENUNCIATION 
The analysis of your DNA sample could contribute to the creation of commercial products 
for which you will receive no financial compensation. 
FREEDOM OF CONSENT, FREEDOM TO WITHDRAW AND PERIOD OF REFLEXION 
Your participation is completely free and voluntary. Your decision will not affect the quality 
of the health services you will receive. You can take the time to reflect and to discuss your 
participation with your peers and/or relatives before giving us an answer. You are also 
free to withdraw from this research project at any time up until the DNA samples are 
rendered anonymous. If you withdraw, your sam pie and research file will be destroyed. 
LEGAL RIGHTS 
If you experience prejudice in relation to your participation in this project, you maintain ail 
legal recourses against the various partners of this research. Furthermore, by signing this 
consent form, you do not give up any of your legal rights, nor do you release the 
researcher or the hospital of their legal and professional responsibilities. 
REQUEST FOR MORE INFORMATION 
You may request more information about this study at any time. Dr Guy Rouleau (514-
890-8000, ext. 24621) is available to answer your questions and concerns. 
If you would like to obtain more information regarding patients' rights or if you would like to 
discuss your participation with someone who is not directly involved in the project, you 
may contact the Service Ouality Commissioner of the Notre-Dame Hospital, Madame 
Louise Brunelle at (514) 890-8000, ext. 26047. 
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CONSENT 
hereby declare that 1 have read and understood this consent form, particularly the 
sections concerning the nature of the participation requested and the risks this entails. A 
member of the research team has explained the project to me, has answered ail of my 
questions and has given me the time tQ_make an informed decision. 
o 1 freely and voluntarily consent to take part in th.is research project. 
OR 
o 1 freely and voluntarily consent to have the person for whom 1 am legally 
responsible take part in this research project. 
1 will receive a signed copy of this consent form. By signing this form, 1 am not giving up 
any of my legal rights, nor am 1 liberating the researcher or the hospital of their civil and 
professional responsibilities. 
Participant: 
Witness: 
Name 
Participant's signature (consent or 
assent) 
Signature of parent or legal guardian 
Surname 
Date 
Date 
Witness' name Witness' signature 
RESEARCHERENGAGEMENT 
Date 
The research project and the methods of participation were described to the participant. A 
member of the research group answered his/her questions and explained that his/her 
participation is free and voluntary. 
Investigator or delegate's name Investigator or delegate's signature Date 
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Autism spectrum disorders associated with 
X chromosome markers in French-Canadian males 
J Gauthier1•2 , R Joobers, M-P Dubé4 , J St-Onge1, A Bonnel1, D Gariépy1, S Laurent1, R Najafee1, 
H Lacasse1 , L St-Charles5 , É Fombonne6 , L Mottron7 and GA Rouleau1.8 
, Centre Hospitalier de l'Université de Montréal, Research Centre, Notre Dame Hospital, Montreal, QC, Canada; 2Department 
of Biology, McGiII University, Montreal, QC, Canada; 3Department of Psychiatry, McGill University and Douglas Hospital 
Research Centre, Montreal, QC, Canada; 4Department of Medicine, Université de Montréal and Institut de cardiologie de 
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It Is now weil establlshed that genetic factors play an important role in the pathogenesls of 
autism dlsorder and converglng lines of evldence suggest the Implication of the X 
chromosome. Uslng a sam pie of subjects diagnosed with autlsm spectrum dlsorders, 
excluslvely composed of males from French-Canadlan (FC) orlgln, we tested markers coverlng 
the entlre X chromosome using a famlly-based association study. Our initiai analysls revealed 
the presence of association at two loci: DXS6789 (P=0.026) and DXS8043 (P=0.0101). In a 
second step, we added support to the association at DXS8043 uslng addltlonal markers, 
addltlonal sUbJects and a haplotype-based analysls (best obtalned P-value = 0.00001). These 
results provlde support for the existence of a locus on the X chromosome that predisposes the 
FC to autlsm spectrum dlsorders. 
Mo/ecular Psychiatry (2006) 11, 200-213. doi: 10.1 0381sj.mpA001756; published online 1 November 2005 
Keywords: autism spectrum disorders; French-Canadian; association study; X chromosome; 
haplotype analysis 
Introduction 
Autism disorder (AD, MIM 209850) is a neurodeve-
lopmental neuropsychiatric disorder characterized 
by behavioral impairments in three areas of child 
development: (1) social interaction, (2) verbal and 
nonverbal communication and imaginative play, 
(3) restricted interests and stereotypic play.1-3 This 
condition affects up to 1/1000 individuals4 with a 
male to female sex ratio of 4:1.5 AD is a clinical 
diagnosis based on criteria defined in the Diagnostic 
and Statistical Manual of Mental Disorder, Fourth 
Edition (DSM IV); together with Asperger Syndrome 
and Pervasive Developmental Disorder Not Otherwise 
Specified (PDDNOS) it forms the category of Autism 
Spectrum Disorders (ASD). Research clearly substan-
tiates the role of genetics in the etiology of ASD. 6 •7 
To date, several chromosomal loci have been 
suspected of harboring genes for ASD including loci 
on X chromosome.2.8 •9 In fact, X chromosome contains 
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genes which have aIready been linked to autism spec-
trum phenotype. the two-neuroligin genes, NLGN3 
and NLGN4. Mutations were originally found in two 
families containing sib pairs affected with autism and 
Asperger. Mutation analysis in our AD cases, as well 
as those of other groupsl0.11 did not reveal any causa-
tive variants in NLGN3 or NGLN4.10 This indicates 
that these two genes are responsible for only a small 
fraction of ASD cases. In addition, these genes may 
not be specific to the autism phenotype since 
mutations were also found in subjects having non-
specific mental retardation.12-14 Other X-linked dis-
ease genes like FMR1, MECP2 and ARX have been 
found to be mutated in autistic cases.H - 17 Again, these 
represent a small fraction of ASD cases. These data 
suggest that other locus on the X chromosome may 
play a role in the development of ASD. Since several 
independent candidate loci appear to exist on the 
X chromosome,9,l8-22 and much evidence suggest a 
role of X-linked genetic factors, in the present study 
we choose to examine the entire X chromosome for 
the search of a candidate locus in our population. 
As previously mentioned, ASD affects males more 
than female (with a male to female ratio as high as 8:1 
in Asperger syndrome); Although the reasons for su ch 
differential distribution between males and females is 
not entirely understood, it is possible that at least part 
of this may be due ta X chromosome loci in a 
subgroup of patients. Schutz et al.23 reasoned that if 
an X-linked locus exists for AD or ASD, then affected 
males are more likely to represent a homogenous 
subgroup of individuals. Therefore, in order to reduce 
the genetic heterogeneity, we only included affected 
males with ASD in the present study. 
ln addition to increasing homogeneity by studying 
males only, we selected our probands from a popula-
tion with a strong founder effect, which may provide 
advantages in the search for genes predisposing to 
complex conditions such as ASD. The existence of 
a founder effect in the French-Canadian (FC) popula-
tion has been confirmed by many studies.24- 26 The 
FC population is particularly well suited for genetic 
studies of heterogeneous diseases for several reasons, 
including: (1) the vast majority of FC are descendants 
of a smaU number of ancestors who came to NouveUe-
France (Canada) prior to 1760; (2) for socio-economic, 
religious and linguistic reasons, the descendants of 
these founders did not mix with other immigrants 
over three centuries; (3) there was significant sus-
tained demographic growth of the population with 
doubling of the population every 25-30 years; and (4) 
detailed haplotyping of 10 cM segments of FC chro-
mosomes has shown that there are few double 
recombinants, thus facilitating the use of haplotypes 
for fine mapping. Such founder effects help ta reduce 
noise when searching for candidate genes in associa-
tion studies.2 4-26 Ultimately, the advantage of using a 
more homogenous population in an association study 
is that it reduces the need for a large sample size and 
for multiple densely spaced markers. 
Ta date, the majority of studies investigating X 
chromosome in ASD are linkage studies using multi-
plex families or affected sib-pair subjects. For this 
study, we chose a different approach: we used a 
sample of FC males trios (affected child and parents) 
ta evaluate association over the entire X chromosome. 
This analysis was conducted in two steps. In Step l, 
we tested 13 micro satellite markers (spaced -10Mb) 
selected on the basis of their relevant chromosomal 
location, including four markers previously reported 
to be linked with autism (DXS996, DXS7132, 
DXS6789 and DXS1047), in an initial set of 64 
unrelated trios. In Step n, we added 21 FC males trios 
and additional markers at the most promising loci. 
Subjects and methods 
Subjects diagnosed with autism spectrum disorders 
and both of their parents were recruited from clinics 
specializing in the diagnosis of Pervasive Develop-
mental Disorders (PDD) , readaptation centers, and 
specialized schools in the Montreal and Quebec 
regions, Canada. Subjects with ASD were diagnosed 
by child psychiatrists and psychologists expert in the 
evaluation of ASD. Evaluation based on the DSM 
criteria included the use of the Autism Diagnostic 
Interview-Revised (ADI_R)27 and the Autism Diagnos-
tic Observation Schedule (ADOS).28 As an additional 
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screening tool for the diagnosis of ASD, the Autism 
Screening Questionnaire, which is derived from the 
ADI-R, was completed.29 Furthermore, aU probands 
medical charts were reviewed by a child psychiatrist 
expert in PDD to confum their diagnosis and exclude 
subjects with any comorbid disorders. Exclusion 
criteria were: (1) an estimated mental age < 18 months, 
(2) a diagnosis of ReU Syndrome or Childhood 
Disintegrative Disorder and (3) evidence of any psy-
chiatric and neurological conditions including: birth 
anoxia, rubella during pregnancy, fragile-X disorder, 
encephalitis, phenylketonuria, tuberous sclerosis, 
Tourette and West syndromes. Subjects with these 
conditions were excluded based on parental interview 
and chart review. However, participants with a co-
occurring diagnosis of semantic-pragmatic disorder 
(due to its large overlap with PDD), attention deficit 
hyperactivity disorder (seen in a large number of 
patients with AD during development) and idiopathic 
epilepsy (which is related to the core syndrome of AD) 
were eligible for the study. As males do not inherit 
their paternal X chromosomes, patients for this study 
were classified as being FC when the maternaI grand 
parents were of FC origin. 
Genotyping 
Blood samples were coUected from each member of 
the nuclear families (subject, mother and father) 
foUowed by DNA extraction from lymphocytes using 
the Puregene reagents (Gentra System, USA). Micro-
satellite markers were obtained from the Marshfield 
genetic map (Center for Medical Genetics, Marshfield 
Medical Research Foundation) and primer sequences 
were obtained from the Genome Database (http:// 
www.gdb.orgl) and the UCSC Genome Bioinformatics 
site (http://genome.ucsc.edul). The marker map posi-
tions were based on sex-averaged maps from the 
Marshfield Medical Research Foundation. Variable 
number tandem repeats (VNTR) were selected from 
the UCSC Genome Bioinformatics site and primers 
were designed as described above. PCR amplification 
for microsatellites and VNTR were performed in the 
presence of S35_dATP and amplicons were analyzed 
on 6% denaturing polyacrylamide gel, foUowed by 
autoradiography. AI1ele sizes were determined by 
comparison to an M13mp18 sequence ladder and 
numbered according to the Foundation Jean Dausset 
CEPH database. Single nucleotide polymorphisms 
(SNP) were chosen from public database and geno-
typing was performed at the McGill University and 
Genome Québec Innovation Centre (http://www. 
genomequebec.mcgill.cal) on the Ultra-High Through-
put Orchid platform. SNP-flanking sequences were 
tested for the presence of repeats or duplicated 
regions using the BLAT program (hUp:/ /www.genome. 
ucsc.edu). PCR primers were designed using the 
Autoprimer program (http://www.autoprimer.com). 
Mutational analysis of SUTRK2 and CXORFl 
We sequenced both strands of the genomic sequence 
coding for aU available exons (one exon for CXORFl 
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and five for SLITRK2), flanking splice junctions and 
untranslated regions (as shawn in the University of 
California, Santa Cruz (UCSC: http://genome.ucsc. 
edul) genome browser) of the CXORFl and SLITRK2 
genes. Primers were designed using genomic 
sequence information from UCSC genome browser 
and the Lasergene PrimerSelect pro gram. The sequen-
cing procedures for mutation detection were per-
formed as published elsewhere. 30 
Statistical analysis 
Transmission disequilibrium test (TDT) and haplo-
type association tests were computed using TDTP 
HASE from UNPHASED software, a program written 
by Frank Dudbridge (UNPHASED, version 2.403; 
http://www.mrc-bsu.cam.ac.uklpersonal/franklsoftware/ 
unphasedl).30-32 UNPHASED is a suite of programs for 
association analysis of multilocus haplotypes from 
phased and unphased genotype data. The programs 
extend previous methods ta include haplotypes and 
missing genotypes and aUow X chromosome data. In 
the case of X chromosome data from males, paternal 
genotype is ignored and only maternal genotypes are 
considered. AH of the results presented in this study 
were performed without using the unphased haplo-
types option in order to have the real representation 
of the sample haplotypes and statistics. The signifi-
canee of each potential association is measured by a 
likelihood ratio statistie (LRS). Odds ratios (OR) were 
calculated using the program 2BY2 version 1.50 from 
Jurg Ott (Utility programs for analysis of genetic 
linkage, 1988-2001). P-values are derived from the 
Fisher's exact test and the TWO-SIDED P-value was 
considered. An OR of 1 implies that the aUele is 
transmitted 50% of times, in average. An OR greater 
or lesser than one implies that the aUele is signifi-
cantly over- or undertransmitted to the affected 
subject, respectively. Linkage disequilibrium bet-
ween markers (D') was calculated using the program 
LDMAX for the input file fo11owed by the use of the 
GOLD program (www.weU.ox.ac.uk/asthma/GOLD). 
For a11 the analyses performed in the present study, 
corrections for multiple testing were not carried out. 
For graphie representation, LRS and P-value were 
converted to the -LOG 10 P-value. 
Results 
A total of 255 individuals were included in the 
present study. This represents 85 nuc1ear families of 
FC origin. AU probands were males and they aU 
received a diagnosis of autism spectrum disorder 
(Autism = 53, Asperger = 21 and Pervasive develop-
mental disorder not otherwise specified = 11). Aver-
age age of the affected subjects was 13.1 years, with a 
range of 3.3-33.4 years. 
Step 1: X chromosome-wide individual marker 
association 
TDT was performed using 13 markers (Table 1) in 64 
unrelated ASD affected FC trios. The average hetero-
Molecular Psychiatry 
zygosity of these 13 markers is 0.73 and the average 
genetic distance between contiguous markers is 7 cM. 
Evidence for association at marker DXS6789 (LRS = 
18.940, df=9, P=0.0257) and marker DXS8043 
(LRS=20.06, df=8, P=0.0101) were found with the 
64 FC trios (Table 2). For marker DXS6789, linked ta 
ASD in previous studies,18.21 a departure from random 
transmission is observed with two aUeles (Table 2). 
AUeie 3 (141 bp) is significantly overtransmitted ta the 
affected proband, suggesting that il may be a risk 
aUele. In contrast, aUele 4 (137bp) is undertransmitted 
suggesting a protective effect. For marker DXS8043, 
we also observed a pattern of overtransmission of 
aUele 3 (167 bp) suggesting that this aUele confers risk. 
Since DXS6789 (LOCUS Xq21.33) and DXS8043 
(LOCUS Xq27.3) are 32cM apart, WB considered them 
as two independent loci. None of the other 11 markers 
was associated with ASD in this study sample. 
Step II: fine mapping 
To further analyze the associations at LOCUS Xq21.33 
and LOCUS Xq27.3, we analyzed additional markers 
and added 21 newly recruited males. Markers were 
chosen according ta their physicallocation. 
LOCUS Xq21.33 
In this second step, we added three markers; 
DXS6908, DXS8077 and DXS6799 at position 61.S8, 
62.52 and 64.41 cM, respectively. TDT analysis reve-
aled suggestive association with marker DXS6799 
(LRS = 12.85, df = 5, P= 0.0248). This marker is 
1.88 cM centromeric ta DXS6789. Although the num-
ber of informative transmission is very modest, the 
only observed departure from random transmission 
is observed with aUele 5 (Transmitted = l, non-
transmitted=7, OR 0.13; CI: 0.02-1.07, P=0.00591). 
LOCUS Xq27.3 
In addition ta mierosatellite markers, LOCUS Xq27.3 
was also further investigated with SNP because of the 
limited availability of microsatellites within the 
region. Since SNP are much less informative than 
repeats, we used several SNP ta coyer this candidate 
region (see Table 1, for markers used). Analysis of 
these additional markers revealed association with 
three SNP (rs232684, rs232686 and rs232707), which 
are telomeric ta DXSS043 (Table 3). The most 
significant association is found with SNP rs232684 
(LRS=6.641, df=l, P=0.00996). AH of these three 
SNP represent a C ta T transition. For aIl of them, 
aUele C revealed an OR > 5, suggesting that this 
allele from these three SNP may be associated with 
increased susceptibility to ASD. 
Haplotype analysis 
In arder to determine if we can detect a common 
susceptibility haplotype in the present sample of 
FC ASD males at LOCUS Xq21.33 and Xq27.3, we 
first determined Linkage Disequilibrium (D') bet-
ween contiguous pairs of markers tested at both 
loci. Markers in LOCUS Xq21.33 do not show any 
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Table 1 Markers used in our association study 
Marker no. Initial markers Additional markers Markers type cM Band 
1 DXS996* CA(n) 15.66 Xp22.32 
2 DXS8036* CA(n) 22.72 Xp22.2 
3 DXS9896* GATA(n) 30.84 Xp21.3 
4 DXS6810* GATA(n) 42.75 Xpll.3 
5 DXS7132* GATA(n) 52.50 Xq12 
6 DXS990* CA(n) 60.62 Xq21.32 
7 DXS6809 GATA(n) 61.88 Xq21.33 
8 DXS8077 CA(n) 62.52 Xq21:33 
9 DXS6789* GATA(n) 62.52 Xq21.33 
10 DXS6799 GATA(n) 64.41 Xq21.33 
11 DXS8055* CA(n) 70.91 Xq23 
13 DXSI047* CA(n) 82.07 Xq25 
17 DXS8094* CA(n) 82.84 Xq26.3 
18 DXS8106* CA(n) 91.64 Xq27.3 
19 DXS8073 CA(n) 94.22 Xq27.3 
20 DXS8043* CA(n) 94.22 Xq27.3 
21 VNTR6 VNTR 94.22 Xq27.3 
22 DXS8028 CA(n) 95.13 Xq27.3 
23 VNTR35 VNTR 95.13 Xq27.3 
24 VNTR36 VNTR 95.13 Xq27.3 
25 rs871156 Cff 95.13 Xq27.3 
26 rs1416770 Cff 95.13 Xq27.3 
27 rs1415636 Cff 95.13 Xq27.3 
28 rs1339486 Cff 95.13 Xq27.3 
29 rs232684 Cff 95.13 Xq27.3 
30 rs232686 Cff 95.13 Xq27.3 
31 DXS8045 CA(n) 96.94 Xq27.3 
32 rs232695 Cff 96.94 Xq27.3 
33 rs232707 Cff 96.94 Xq27.3 
34 rs1072196 Cff 96.94 Xq27.3 
35 DXS1200 CA(n) 96.94 Xq27.3 
36 DXS998 CA(n) 96.94 Xq27.3 
37 DXS1215 CA(n) 97.89 Xq28 
38 DXS8087* CA(n) 102.35 Xq28 
Markers used in Step 1 are indicated by *; Marker genetic localization is from Marshfield genetic map; band position 
according to NCBI build 34 from UCSC July 2003 assembly; DXS markers represent microsatellites markers, rs markers are 
the single nucleotide polymorphisms and VNTR are variable number of tandem repeats. 
evidence of LD (data not shown). However, at LOCUS 
Xq27.3, values of D'>0.8 are observed for severai 
pairs of markers (see Figure 1). Consequently, for the 
LOCUS Xq27.3 markers in LD, we tested different 
combinations of marker haplotypes using the sliding 
window approach. Looking at the haplotype combi-
nation and considering only heterozygous mothers 
for the haplotypes, a chromosomal region composed 
of seven markers (rs1415636-rs1339486-rs232684-
rs232686-DXS8045-rs232695-rs232707), and highly 
in LD, showed a significant departure from random 
transmission. Within this region, several haplotypes 
windows gave positive values, with the most sig-
nificant associations being represented in Table 4. 
Among these, three haplotypes showed a P= 0.00001. 
Transmission of these haplotypes represents almost 
haH of subjects harboring these haplotypes. 
Within the associated LOCUS Xq27.3, only two 
annotated genes lie in that region, SLTRK2 and 
CXORF1. In addition to their physicallocation, these 
genes are of interest as they are mainly brain 
expressed in region reported to be affected in ASD. 
While the function of CXORF1 is not yet known, 
SLTRK2 is involved in the synaptogenesis. We there-
fore sequenced in both directions the genomic 
sequence of these two genes, in eight affected patients 
and two healthy controls. Patients included in this 
screening had the large st most common overtrans-
mitted haplotype (Table 4: haplotype #7). No muta-
tions were found in any of these subjects. 
Discussion 
To our knowledge, this is the first family-based 
association study Iooking at the entire X chromosome. 
In the present study we have identified two potentiai 
associations between FC autistic families and markers 
on the X chromosome. Marker DXS6789 is already 
known to he associated with autism U,21 and our 
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Table 2 TDT analysis results from DXS6789 and DXS8043 markers in 64 autistic FC males trios 
Allele Size (bp) T Freq-T NT Freq-NT OR (CI) P-value 
DXS6789 
1 149 6 0.125 6 0.125 1 (0.30-3.35) 1.00000 
2 145 8 0.167 8 0.167 1 (0.34-2.93) 0.78499 
3 141 20 0.417 6 0.125 5 (1.78-14.01) 0.00043 
4 137 9 0.188 19 0.396 0.35 (0.14-{).89) 0.04226 
5 133 1 0.021 2 0.042 0.49 (0.04-5.58) 1.00000 
6 121 0 0.000 5 0.104 0.08 (0-1.52) 0.00000 
7 117 2 0.042 1 0.021 2.04 (0.18-23.32) . 1.00000 
9 153 0 0.000 1 0.021 0.33 (0.01-8.21) 0 
10 157 1 0.021 0 0 3.05 (0.12-76.30) 0 
11 125 1 0.021 0 0 3.05 (0.12-76.30) 0 
LRS = 18.940. DF = 9. P-value = 0.0257 
DXS8043 
1 179 7 0.137 12 0.235 0.52 (0.19-1.44) 0.1256 
2 181 3 0.059 11 0.216 0.23 (0.06-0.87) 0.00767 
3 167 20 0.392 9 0.177 3.01 (1.21-7.51) 0.00782 
4 183 8 0.157 7 0.137 1.17 (0.39-3.51) 0.57731 
6 185 2 0.039 5 0.098 0.38 (0.07-2.03) 0.43638 
7 175 4 0.078 7 0.137 0.53 (0.15-1.95) 0.20027 
8 177 5 0.098 0 0 12.18 (0.66-226.37) 0 
9 171 1 0.02 0 0 3.05 (0.12-76.30) 0 
10 187 1 0.02 0 0 3.05 (0.12-76.30) 0 
LRS=20.06, DF 8. P-value=0.0101 
Column T and NT represent transmitted and nontransmitted aneles; Freq-T and Freq-NT are the frequencies of T and NT 
aneles; OR = odds ratio; CI = confidence interval (CI); LRS = likelihood ratio statistic; DF = degree of freedom. Data in bold 
indicate positive association. 
Table 3 TDT analysis results from LOCUS Xq27.3 with additional markers additional trios 
Allele T Freq-T NT Freq-NT OR (CI) P-value 
DXS8043 
1 7 0.109 14 0.219 0.44 (0.16-1.17) 0.05437 
2 5 0.078 13 0.203 0.33 (0.11-1) 0.07293 
3 23 0.359 11 0.172 2.70 (1.18-6.17) 0.02687 
4 11 0.172 9 0.141 1.27 (0.49-3.31) 0.80825 
6 4 0.063 8 0.125 0.47 (0.13-1.64) 0.36382 
7 6 0.094 8 0.125 0.72 (0.24-2.22) 0.39645 
8 5 0.078 1 0.016 5.34 (0.61-47.05) 0.20759 
9 1 0.016 0 0.000 3.05 (0.12-76.30) 0.00000 
10 1 0.016 0 0.000 3.05 (0.12-76.30) 0.00000 
13 1 0.016 0 0.000 3.05 (0.12-76.30) 0.00000 
LRS = 17.985, DF = 9, P-value = 0.03534 
rs232684 
1 25 0.714 10 0.286 6.25 (2.22-17.63) 0.00010 
2 10 0.286 25 0.714 0.16 (0.06-0.45) 0.00010 
LRS = 6.641, DF = 1, P-value = 0.00996 
rs232686 
1 19 0.704 8 0.296 5.64 (1.75-18.15) 0.00597 
2 8 0.296 19 0.704 0.18 (0.06-0.57) 0.00597 
LRS=4.615, DF=l, P-value=0.0317 
rs232707 
1 18 0.692 8 0.308 5.06 (1.56-16.44) 0.01182 
2 8 0.308 18 0.692 0.20 (0.06-0.64) 0.01182 
LRS=3.947, DF=l, P-value = 0.04695 
Column T and NT represent transmitted and nontransmitted aneles; Freq-T and Freq-NT are the frequencies of T and NT 
aneles; OR = odds ratio; CI = confidence interval (CI); LRS = likelihood ratio statistic; OF = degree of freedom. 
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Figure 1 LD relationship between LOCUS Xq27.3 markers. Numbers from 20 to 34 in both axes represent markers listed in 
Table 1. 
Table 4 Marker haplotype window for the most significant association at LOCUS Xq27.3 
Markers no. Haplotype Informative T NT OR {Cl} P-value -LOC,o Cp} 
mothers 
28-29 C-C 52 28 12 3.96 (1.69-9.26) 0.00049 3.310 
29-30 C-C 49 30 10 6.16 (2.50-15.17) 0.00001 5.000 
28-29-30 C-C-C 49 30 10 6.16 (2.50-15.17) 0.00001 4.959 
29-30-31 C-C-l 63 29 9 5.12 (2.16-12.12) 0.00003 4.495 
28-29-30-31 C-C-C-l 63 29 9 5.12 (2.16-12.12) 0.00003 4.495 
28-29-30-31-32-33 C-C-C-I-C-C 62 29 8 5.93 (2.42-14.51) 0.00001 5.000 
27-28-29-30-31-32-33 T -C-C-C-I-C-C 57 26 7 5.99 (2.32-15.45) 0.00002 4.638 
28-29-30-31-32-33-34 C-C-C-I-C-C-T 59 18 5 4.74 (1.63-13.83) 0.00453 2.343 
27-28-29-30-31-32-33-34 T -C-C-I-C-C-C-T 55 16 4 5.23 (1.62-16.89) 0.00553 2.257 
Markers number refers to markers listed in Table 1; T = transmitted; NT = nontransmitted; OR = odds ratio; CI = confidence 
interval; the C and 1 in the haplotype column are the single nucleotide and the allele transmitted, respectively. 
results add further support for its implication in ASD. 
Whereas we found a modest association with one 
individual marker, the limited number of markers 
used and the physical position of these markers did 
not allow us to conduct a haplotype analysis (LD (D') 
<0.04, data not showed). Genotyping more markers 
within this locus is needed to further analyze it 
possible role in ASD. 
LOCUS Xq27.3 represents the most significant 
association in the present study. Interestingly, two 
independent studies reported positive linkage at 
this region. Yonan et 01. 22 found a proximal linkage 
(X-MLS = 1.78) with 345 analyzed multiplex families. 
More recently. Vincent et oP using 22 families found 
a modest linkage with two markers (MLOD = 1.3, 
P=0.01, and MLOD=1.7, P=0.005), which are 
centromeric and telomeric to our associated region. 
While for both group their linked region is quite large 
our genomic segment found to be most significantly 
associated with ASD in the present study is quite 
smaH, representing 274 kb (according to the UCSC 
Genome database). Interestingly, the most associated 
single marker allele, rs232684, is in the core of the 
haplotypes shown in Table 4. This polymorphism is 
not part of any predicted mRNAs and ESTs and the C 
is not conserved across species, which suggest that 
rs232684 is not a functional polymorphism. Accord-
ing to public databases, the associated genomic seg-
ment is a gene poor region. In fact, the region contains 
no annotated genes. However, several human ESTs 
and two human mRNAs are present in the interval. 
Among these, only one mRNAs, BC040297, over-
laps with a predicted transcript, named 'flerju'. In 
addition, the region contains many non-human 
mRNAs and several conserved regions between 
human and other species. However, these are not 
overlapping with human ESTs or human mRNAs 
suggesting that they might not be real genes. 
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As we expected to find a large common region 
in the founder population, the identification of a 
relatively small associated region (274kb) suggests 
that the susceptibly haplotype may be oIder than 
the founding of FC population. Consequently, many 
recombination events would have occurred before 
the establishment of the population in Quebec. The 
detection of association at two loci in the same cohort 
of subjects rais es the possibility of multiple hypo-
theses; among these are (1) the possibility that two 
ancestral mutations have been introduced in the FC 
population or (2) that one of the associations may be 
a false positive at one locus. In order to confum that 
this haplotype is a common susceptibility haplotype 
for ASD, it will need to be replicated in other 
population. 
We have looked at the sequence of two annotated 
genes, SLITRK2 and CXORF1, which are centromeric 
to the associated haplotype. While the function of 
CXORFl is not clear,33 the gene product is found 
mainly in the hippocampus, particularly in the 
granular-celllayer of the dentate gyrus, a brain region 
reported to be involved in autism.34.35 SLITRK2 is a 
neuronal transmembrane prote in which controls 
neurite outgrowth. 36•37 These genes are candidates 
for ASD; however, no mutation was found. Our nega-
tive mutational analysis results are consistent with 
the fact that they are located outside of the associated 
genomic segment. However, the small number of 
patients screened and the fact that the regulatory 
regions of these genes were not analyzed do not allow 
us to exclude them as candidate for ASD. 
The present study presents different limitations 
and the results should be interpreted with caution. No 
correction for multiple testing has been performed. 
Moreover, association studies are known, especially 
when using multiple marker tests, to produce false 
positive results. These results need to be replicated in 
an independent FC autistic cohort as well as non-FC 
cases. We are currently collecting additional samples 
to replicate our results. 
In conclusion, our data supports the existence of 
two candidate loci on the X chromosome. 
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Although it is weIl established that genetic 
factor~ p!ay ~ important role in the etiology 
of aubstlc disorder (AD), no specific genes 
have as yet been implicated. Genetic epide-
miological data, particularly the sharp fall in 
concordance rates from monozygotic to 
dizygotic twins, indicate that the mode of 
transmission of tbis disorder is complex and 
may involve several genes. The 7q31 locus 
has been repeatedly linked to AD, suggesting 
that this chromosomal region is likely to 
harbor a susceptibility gene for AD. 
Recently, variations in the FOXP2 gene were 
reported to be responsible for a severe 
speech and language disorder. Because of 
the chromosomallocation of FOXP2 (7q31) 
and the putative implication of the 7q31 
region both in autistic and in language 
disorders (a feature of AD), it has been 
hypothesized that FOXP2 may be implicated 
in the pathophysiology of AD. To test tbis 
hypothesis, we screened the FOXP2 gene 
coding sequence for mutations in subjects 
diagnosed with AD and in normal controls. 
We identified four silent polymorphisms that 
were equally distributed between patients 
and controls. Using an intra-family associa-
tion design, we identified no transmission 
disequilibrium in any of the four identified 
alleles, suggesting that the FOXP2 gene does 
not play a significant role in AD. 
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INTRODUCTION 
Au.t~sm disorder (~) is a severe neurodevelopmental 
conditIon charactenzed by disturbances in social inter-
action and communication, by repetitive body move-
ments and restricted interests, and by atypical langu 
age development [DSM-IV, 1994; Bristol et al., 1996; 
Tanguay, 2000]. Severe language delay as weIl as 
language disturbance in the forro of echolalia, pronoun 
reversal, and stereotyped language, are one of the major 
clinical characteristic of AD [DSM-IV, 1994]. Although 
the exact pathogenesis of AD is not known it is now ~nequivocally established that genetic facto~s play an 
Important role in its pathogenesis. Although several 
chromosomal loci have been suspected on the basis of 
linkage analysis to harbar gene(s) for AD [Folstein and 
~se~-Sheidley, 2001], no specifie genes have yet been 
IdentIfied. The sharp fall in concordance rates from 
monozygotic to dizygotic twins may indicate that AD is 
genetically due ta the concerted action of a number of 
different mutations, suggesting the co-existence of 
numerous mutations in a single individual affected with 
AD. In line with this hypothesis, a recent study reported 
that two of the clinical dimensions of AD Oanguage 
?eficits and repetitive behavior) may be caused, at least 
ln part, by quantitative trait loci on chromosome 7q 
~Alru:con et ~., 2002], a region that has been previously 
Imphcated ID AD by several independent studies 
[International Molecular Genetic Study of Autism 
Consortium, l, 1998; Philippe et al., 1999; Risch et al. 
1999; Collaborative Linkage Study of Autism, 2001]: 
~other study has also supported the hypothesis that 
linkage to chromosome 7q is strengthened when the 
analysis was restricted to families with autistic children 
displaying severe language disorders Wolstein and 
Mankoski, 2000]. Interestingly, mutations in the fork-
head-dom~ gene FOXP2,located in chromosome 7 q31, 
were descnbed by Lai et al. [2001] in one family and in an 
unrelated patient with severe speech and language 
disorder (speech-language disorder 1, OMThf #602081). 
The function of FOXP2 is not yet identified, but genes 
containing forkhead domain are known to be important 
regulators of embryogenesis and to have an important 
role in neural functioning [Lai et al., 2001]. Human and 
mouse studies have shown that FOXP2 is expressed 
ubiquitously during adulthood and in specific regions of 
the brain during embryogenesis, suggesting that this 
gene may have specific prenatal developmental effects 
on the brain [Lai et al., 2001]. 
Because of the chromosomallocation of FOXP2 (7q) 
and the putative implication ofthis chromosomal region 
in AD, particularly in language disorders associated 
with AD, it has been hypothesized that FOXP2 may be 
implicated in the pathogenesis of AD. To test this 
hypothesis, we screened the FOXP2 coding region for 
mutation in 56 unrelated subjects diagnosed with AD 
and 98 independent controls. Furthermore, we geno-
typed a total of 72 triads for the polymorphisms detected 
in FOXP2 and carried out a family-based association 
study using the extended transmission disequilibrium 
test (ETDT) [Sham and Curtis, 1995]. 
SUBJECTS AND METHODS 
Subjects 
Seventy-nine autistic patients and their parents 
(72 unrelated and seven sib pairs) were referred from 
clinics specialized in the diagnosis of pervasive devel-
opmental disorders (PDD) located on the island of 
Montreal. For the case-control study, only unrelated 
patients plus the proband of the sib pairs were used 
(n = 72). The mean age of the affected group is 15.3 years 
with a sex ratio of 6M: IF. 
Inclusion criteria. Participants with autism were 
included in the study if they satisfied either one or the 
other of the following diagnostic criteria. (a) For 
24 participants, the individual had been previously 
diagnosed by a trained clinician, using the algorithm of 
the autism diagnostic interview-revised (ADI-R; [Lord 
et al., 1994]), and/or the autism diagnostic observation 
schedule-generic (ADOS-G; [Lord et al., 2000]). The 
ADI-R is a lengthy semi-structured interview of the 
child's parents or caretakers. The ADOS-G is a se mi-
structured schedule of interactions between clinician 
and patient that assesses communication, social inter-
action, and imaginative use of materials. It includes 
several modules, which are administered depending on 
the language ability of the individual being assessed. 
High inter-rater and test-retest reliability, as weIl as 
internal validity, have been established for both tests. 
Both of the se standardized diagnostic instruments are 
internationally used for research purposes in assessing 
the presence of DSM-IV/ICD-10 criteria for Autism. (b) 
For 48 participants, who had not undergone the fullADI! 
ADOS interview, a French translation of a simplified 
version of the ADI, the autism screening questionnaire 
(ASQ) was administered by a trained Research Assis-
tant to the patient's primary caretakers in order to 
validate their diagnosis. To qualify for participation, 
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where candidates had been previously diagnosed as 
autistic by one clinician, a score of 15 or higher on the 
ASQ was required; where a diagnosis had previously 
been given by two independent clinicians, the score 
needed to be 10 and above. In fact, all candidates scored 
higher than 15 on the ASQ. 
Exclusion criteria. (1) An estimated mental 
age <18 months, the estimated inferior limit for the 
validity of a diagnosis of autism; (2) file diagnosis of Rett 
disorder or childhood disintegrative disorder. (3) Evi-
dence, form file review, and parental interview, of 
psychiatric and neurological conditions, including: 
anoxia during birth, rubella during pregnancy, fragile-
X syndrome, encephalitis, phenylketonuria, tuberous 
sclerosis, Tourette syndrome, and West syndrome. 
However, participants with a file diagnosis of seman-
tic-pragmatic disorder (due to its large overlap with 
PDD), attention deficit hyperactivity disorder (seen in 
a large number of patients with autism during develop-
ment), and epilepsy without characterized neurological 
etiology (which is related to the core syndrome of autism) 
were not excluded from the study. (In the sample 
included in this study, 11 patients had a comorbid 
ADHD, three patients had a semantic-pragmatic dis-
order, and two patients had the diagnosis of idiopathic 
seizures.) Independent controls used tor the association 
study were clinically ascertained randomly as spouses of 
patients with no psychiatric history. The mean age of the 
control group is 68 years and the male:female ratio is 
2.2M:1F. 
Mutation Screening 
Primers design. The entire coding region of 
FOXP2 and the intronic flanking sequences in the 
introns were amplified by PCR with primer pairs 
designed using genomic sequence information from the 
human genome project working draft site (VCSC, 
www.genome.ucsc.edu) and the Lasergene PrimerSe-
lect program. Before PCR, fragment with the new 
designed primers, were first analyzed using Wave-
maker™ software. A melting temperature profile is 
then given from the software and ifthis melting profile 
was not uniform along the fragment we modified the 
primers by adding GC clamps (4-16 bp) to standardize 
the melting profile. This standardization of the frag-
ment increases the chances of detecting variations. 
Mutation detection. PCR products were loaded on 
2% agarose gel to confirm amplification before analysis 
for base changes by dHPLC (WAVE Nucleic Acid 
Fragment Analysis System from Transgenomic, San 
Jose, CA). Solvent A consisted of 0.1 mol/L triethylam-
monim acetate (TEAA) and 25% acetonitrile and solvent 
B contained 1 M TEAA, 25% acenonitril. Either for point 
mutation detection or expansion analysis, all PCR 
products from patients were first combined with equal 
amounts of products amplified from a negative control 
DNA (first sequenced before pooling) and then dena-
tured at 95°C for 5 min followed by a gradual reanneal-
ing to 50°C over a 1-h period in order to enhance 
heteroduplex formation. PCR products showing a 
chromatographic variation on dHPLC were sequenced 
174 Gauthier et al. 
TABLE 1. Characteristics orthe Four Polymorphisms Found in FOXP2 Coding Sequence and 
Allelic Distribution in Autism Disorder (AD) Subjects and ControIs 
Location in Position on 7q31 Patients Controis 
Polymorphism FOXP2 (UCSCsite) (n = 72) (n=98) l,df=l,P 
Q190Q Exon 5 123545599 2 4 0.20,0.65 
T--G Exon 5/intron 123545643 10 13 0.02,0.88 
C-+G Exon 13/intron 123575324 3 2 0.65,0.42 
A-+G Exon 13/intron 123575341 1 1 0.05,0.82 
directly on an automatic sequencer (Crime Reader 4200). 
Sequencing data were analyzed using DNA Star soft-
ware SeqMan (Lasergene). 
RESULTS AND DISCUSSION 
An original screen of 56 patients leads to the 
identification of four single nucleotide polymorphisms 
in the FOXP2 sequence (Table n. One polymorphism, 
Q190Q, is a silent mutation that changes a CAA to a 
CAG (both encoding for glutamine). Three other poly-
morphisms are located in the 3' exon-intronjunction of 
exons 5 and 13. None of them affect the consensus 
sequence for pre-messenger splicing. In order to perform 
family-based and case-control association studies, we 
screen a total of 72 unrelated patients (the original 56 
patients plus 16 new cases) and their two parents plus 98 
controls for the observed polymorphisms. No significant 
association between AD and any of these alleles were 
observed compared to controls (Table n, and the 
transmission disequilibrium analysis did not show any 
significant disequilibrium of transmission of any of 
these alleles from parents to affected children (Table II). 
In addition to the polymorphisms detected by muta-
tion screening, the FOXP2 gene is known to contain two 
tracts of CAG repeats located in exons 5 and 6, 
respectively, which encode for two polyglutamine 
stretches separated from each other by eight amino 
acids [Lai et al., 2001]. The first stretch consists of 
(CAG)4 (CAA) (CAG)4 (CAA)2 (CAG)2 (CAA)2 (CAG)3 
(CAA)5 (CAG) 2 (CAA)2 (CAG)5 (CAA) (CAG) 5 (CAA) 
(CAG) and encodes for 40 consecutive glutamine 
residues, and the second stretch consists of (CAGh 
(CAA) (CAG) (CAA) and encodes for ten glutamine 
residues [Foistein and Mankoski, 2000]. Although genes 
encoding for enlarged polyglutamine tracts have been 
implicated mainly in neurodegenerative diseases, there 
is some indication that they may also play some role in 
neurodevelopmental disorders such as schizophrenia 
[Joober et al.,' 1999]. We, therefore, tested for an 
expansion of these two CAG repeats in AD patients. 
None of the autistic patients were carriers of expanded 
CAG repeats on either tract, thus excluding any role 
they may have had in modulatingthe risk for AD and the 
language disturbances se en in this disorder. In addition, 
the two repeats were monomorphic, further excluding 
any role of these repeats in modulating susceptibility to 
AD. 
These results support the data of Newbury et al. 
[2002] obtained from the analysis of FOXP2 in a 
population of autistic individuals. N evertheless, several 
limitations need to be kept in mind while interpreting 
these results. First, the 5' regulatory region and other 
regulatory elements of FOXP2 were not analyzed, thus 
precluding definitive exclusion of this gene as a risk 
factor for AD. However, the hypothesized involvement of 
other polymorphisms or mutation in this gene in 
increasing the risk for AD seems unlikely given the 
total absence of linkage disequilibriutn between AD and 
any of the four alleles that we identified. Nonetheless, 
given that linkage disequilibrium could be restricted to 
very small regions, further analyses of the non-coding 
regions, particularly the regulatory regions of this gene 
need to be performed. Second, it is possible that this gene 
has a small effect in increasing the risk for AD that could 
not be detected in our study given the small patient 
sample size. However, if the observed differences in 
allelic frequencies in this sample represent true pop-
ulation allelic frequencies, the effect size would be 
extremely small and would require a prohibitively 
TABLE II. Extended Transmission Disequilibrium Test (ETDT) of the Four Polymorphisms in 
FOXP2andAD 
Polymorphism Alleles Transmitted Not transmitted X2ETlYI"',p 
Q190Q A 4 3 0.143,0.705 
G 3 4 
T-+G T 7 12 1.331, 0.249 
G 12 7 
C-+G C 4 4 0.000, 1.000 
G 4 4 
A-+G A 6 3 1.019, 0.313 
G 3 6 
·Chi·square for allcle·wise TDT. 
high number of cases and controls (>150,000) to be 
detected. 
In conclusion, these results indicate that the pheno-
typic similarities in language impairment between AD 
and speech-language disorder 1 are unlikely to be 
caused by the same gene. Nonethel,ess, careful attention 
has to be paid to genes }ocated in the 7q31 region since 
multiple studies replicated positive linkage between AD 
and this locus. 
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NLGN3/NLGN4 Gene Mutations Are not Responsible for 
Autism in the Quebec Population 
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Jamain [2003: Nat Genet 34:27-29] reeently 
reported mutations in two neuroligin genes in 
sib-pairs affeeted with autism. In order to confirm 
these causative mutations in our autistic popu-
lation and to determine their frequency we 
screened 96 individuals affected with autism. We 
found no mutations in these X-linked genes. These 
results indicate that mutations in NLGN3 and 
NLGN4 genes are responsible for at most a smalI 
fraction of autism cases and additional screenings 
in other autistic populations are needed to better 
determine the frequencywith which mutations in 
NLGN3 and NLGN4 occur in autism. 
e 2004 Wiley·Liss. Inc. 
KEY WORDS: neuroligin; autism; X-chromosome 
It is now weil established that genetic factors play an 
important role in the pathogenesis of Autism [Szatmari et aL, 
1998). Recently, an X-linked origin of autism in two families 
with affected sib-pairs was proven by the identification of 
mutations in NLGN3 and NLGN4, two genes located on chro-
mosome X encoding a neuronal cell surface protein [Jamain 
et al., 2003). Seeking replication in other samples of autistic 
patients is important to confirm the causative nature of these 
mutations and to determine their frequeney. We screened 96 
individuals (including 12 cases with familial history of autism) 
diagnosed with autism spectrum disorder for mutations in 
NLGN3 and NLGN4 genes. 
Genomic DNA was extracted from lymphoeytes of patients 
aseertained from clinies specializing in the diagnosis of 
Pervasive Developmental Disorders (PDD) and located in the 
Province of Quebec, Canada. Two-thirds of our autistic group 
were of French·Canadian Origin. AlI subjects (mean age: 
14 ± 7.6; sex ratio: 6.4M:IF) were diagnosed aecordingto DSM-
IV criteria by at least one psyehiatrist, followed by adminis-
tration oftheADI-R (n =43) [Lord et al., 1994), and/or ADOS-G 
(n = 41) [Lord et al., 2000). Furtherrnore, the autism screening 
questionnaire (ASQ), a questionnaire derived fromADI-R, was 
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administrated to ail patients as an additional sereening tool 
[Berument et al., 1999). Independent controls with no 
psychiatrie history and matched for ethnicity were ascertained 
TABLE 1. Primer Sequences Used for NLGN3 and NLGN4 
Mutation Screening. 
NLGN3 gene 
EXIA-F 
EXIA-R 
EXIB-F 
EXIB-R 
EX2-F 
EX2-R 
EX3-F 
EX3-R 
EX4a-F 
EX4b-R 
EX5LI-Fa 
EX5L2-Ra 
EX5A-F 
EX5A-R 
EX5B-F 
EX5B-R 
EX5C-F 
EX5C-R 
EX6A-F 
EX6A-R 
EX6B-F 
EX6B-R 
EX6C-F 
EX6C-R 
NLGN4gene 
EX2-F 
EX2-R 
EX3-F 
EX3-R 
EX4-F 
EX4-R 
EX5L2-F" 
EX5L2-Ra 
EX5A-F 
EX5A-R 
EX5B-F 
EX5B-F 
EX5C-F 
EX5C-R 
EX5D-F 
EX5C-R 
EX6A-F 
EX6A-R 
EX6B-F 
EX6B-R 
EX6C-F 
EX6C-R 
TGGGCTGATGCTGTGACOCTGGAG 
CTGGGGGCACACTGGGGGAAAGT 
AGCTCCCCCGATCGGCGAGAAA 
CGGACAATGCTGGGAGAGGGAAGA 
GGCTTGCTGGGCCACACTGC 
CAGACAGACAGACGGGGCTTCTCC 
GTGGGGGAGCAAGGGCATCC 
CCAGCTAGAGAAGCAAGGCTATCT 
CACTATTCCACCTCCCCTGTTGACC 
GAGCTGGCCGATTCCCTTGGATG 
TCCCCAAGCCCTCAGAATGTG 
CAGGAAGGGGAGATAGGAAGATGA 
CAGCCTCAGTGACAAAGGAATGAA 
GGTAGCGGGCTGGCTGGATGTC 
ATGGTGGACTGTCTTCGGCAAAAG 
TTTACGGCGGGTCTCAGGGTTGTC 
GGTAAGGACACCCTGCGAGAG 
GAAGGGATATGATGGAAGAGGTTTAG 
AATGCTGGGCCTTTTCCTCATCCA 
GGCCGCTTGGTGCTCCAGGTC 
CGCCTCCGGATACCACCCACAG 
GGGGACCGGCCTCACACTCGT 
CTTCGCTGCCCTCTACTACCGTAAGG 
GTGTGCATGTGTTCCTGGAT 
GAGCCACATCACTGGGACAGC 
ATAAAACCCTCCTAGCAAATCTCT 
AGTCAAAATAGGGAAATCAGTGAA 
GAGCCCCGTCAA~CGAGA 
TCTAATTGGTGGGGGTGAGAGT 
TCATTTCTTGGTTCAGGGTATTTG 
GAAGGGGGAATGGAAATGAAAATG 
GCACGTGGCAGTAGAAGCAACA 
CACAGCCTTCATTGCTCAGTAAAA 
TTGGGCGTCACACCGTCCTCGTTA 
CGGACATGGTAGAATGCCTGCG 
CCGCGTCTCCGGGTTTTCCTTATC 
ACGGCTACCCTGAAGGGAAAGACA 
CTCATCACCATGGGCCGAATCTG 
CGGCTCCCCCACCTACTTCTATGC 
GGACACAAACAAGTGGCAAGGATA 
TCACGTCACATGTGGAAGAGTATG 
GATTGCTGGGCGTTTGGTGGTT 
AGACATGACATCATTTCCCTATGG 
GAGCGATATCATTTGTGGTGTTTC 
GCGGCGCTGTACTACAAAAAGGAC 
GAGCGGGTAGGGCAGAGGGATAG 
·Primers used for nested peRo 
NLGN3/NLGN4 Gene Mutations Are not Responsible for Autism in the Quebec Population 75 
randomly in the same population (mean age 66 ± 7.5; sex ratio 
8.6M:IF). Primers were designed according to the human 
genome project working draft site and the Lasergene Primer-
Select program and were carefully chosen taking into account 
the high sequence homologies between neuroligin members 
(Table 1). The entire codingregion and flankingsplicejunctions 
of the NLGN3 and NLGN4 genes were screened in the 96 
autistic subjects. We found no mutation in these X-linkedgenes 
in our 96 subjects. However, we detected two known linked 
polymorphisms rs3747333 (C->T) and rs3747334 (C->G) in 
exon 6 of NLGN4 that forro an haplotype (CTC->TTG; 
frequencies: CTC = 0.64, TTG = 0.36). Both SNPs, described 
in the NCBI database, are located in the same codon (Leucine), 
and the T allele and G allele are on the same haplotype, giving 
rise to a silent substitution of leucine/leucine. These poly-
morphisms where also present in a control group (n = 56). 
These results indicate that mutations in NLGN3 and 
NLGN4 genes are responsible for at most a small fraction of 
autism cases. Additional screenings in other autistic popula-
tion are needed to better determine the frequency with 
which mutations in NLGN3 and NLGN4 occur in autism. 
However, given the importance ofneuroligin in synaptogenesis 
[EI-Husseini et al., 2000, 2002; EI-Husseini and Bredt, 2002], 
other members ofthis gene family or genes coding for proteins 
interacting with neuroligin remain excellent candidates for 
further genetic investigations. 
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ORIGINAL ARTICLE 
Clinical Stringency Greatly Improves 
Mutation Detection in Rett Syndrome 
Julie Gauthier, Giovana de Amorim, Gevork N. Mnatzakanian, Carol Saunders, 
John B. Yincent, Sylvie Toupin, David Kauffman, Judith St-Onge, 
Sandra Laurent, Patrick M. Macleod, Berge A. Minassian, Guy A. Rouleau 
ABSTRACT: Background: Rett syndrome (RTf) is a severe neurodevelopmental disorder of girls, caused by mutations in the X-linked 
MECP2 gene. Worldwide recognition of the RTf clinical phenotype in the early 1980's allowed many cases to be diagnosed, and 
established RTf as one of the most corn mon mental retardation syndromes in females. The years since then led to a refinement of the 
phenotype and the recent elaboration of Revised Diagnostic Criteria (RDC). Here, we study the impact of the presence versus the 
absence of the use of diagnostic criteria from the RDC to make a diagnosis of RTf on MECP2 mutation detection in Canadian patients 
diagnosed and suspected of having RTf. Methods: Using dHPLC followed by sequencing in ail exons of the MECP2 gene, we 
compared mutation detection in a historie cohort of 35 patients diagnosed with RTf without the use of specifie diagnostic criteria to a 
separate more recent group of lOI patients included on the basis of strict fui fi lime nt of the RDC. Results: The MECP2 mutation 
detection rate was much higher in subjects diagnosed using a striet adherence to the RDC (20% vs. 72%). Conclusions: These results 
suggest that clinieal diagnostic procedures significantly influence the rate of mutation detection in RTf, and more generally emphasize 
the importance of diagnostic tools in the assessment of neurobehavioral syndromes. 
RÉSUMÉ: Un examen clinique rigoureux améliore beaucoup la détection de mutations dans le syndrome de Rett./ntroduction: Le syndrome 
de Rett (RTf) est une maladie neurodéveloppementale sévère observée chez les filles et causée par des mutations du gène MECP2 situé sur le 
chromosome X. L'identification à l'échelle mondiale du phénotype clinique du RTf au début des années 1980 a permis de diagnostiquer de nombreux 
cas et a démontré que le RTf est un des syndromes de retard mental les plus fréquents chez les filles. Depuis, la description du phénotype a été raftinée 
et des critères diagnostiques révisés (CDR) ont récemment été formulés. Nous avons étudié l'impact sur la détection de mutations du gène MECP2 dç 
l'utilisation ou de la non-utilisation de ces critères diagnostiques pour poser le diagnostic de RTf chez des patientes diagnostiquées ou soupçonnées 
d'être porteuses du RTf. Méthodes: Au moyen de la chromatographie liquide à haute pression en condition dénaturante suivie du séquençage de tous 
les exons du gène MECP2, nous avons comparé la détection de mutations dans une cohorte historique de 35 patientes porteuses d'un diagnostic de RTf, 
fait sans l'aide de critères diagnostiques spécifiques, à un groupe de 101 patientes dont le diagnostic avait été posé sur la base des CDR. Résultats: Le 
taux de détection de mutations du gène MECP2 était beaucoup plus élevé chez les sujets dont le diagnostic était basé sur une utilisation rigoureuse des 
CDR (20% vs 72%). Conclusions: Ces résultats suggèrent que la démarche utilisée pour poser le diagnostic clinique influence le taux de détection de 
mutations dans le RTT et, de façon plus générale, souligne l'importance des outils diagnostiques dans l'évaluation des syndromes 
neurocomportementaux. 
Rett Syndrome (RTf, OMIM 312750) is characterized by 
onset in the first 18 months of life of slowing and arrest of 
neurodevelopment paralleled with a loss of communication and 
motor skills acquired to that point. Purposeful hand movements 
are replaced by a semi-continuous hand-washing stereotype. 
Social interaction with the family disintegrates, resembling 
autistic withdrawal and, with the passage of time, a pieture of 
profound mental retardation emerges. t However, depending on 
mutation location and extent of X-inactivation skewing, 
individuals with RIT may also exhibit milder phenotypes with 
preserved speech and ambulation, mild learning disability, or a 
clinical picture more similar to autism th an to classieal RTf.2-4 
Because of X-linkage, mutations causing classical RTf in girls 
are generally embryonic-Iethal in boys, although sorne rare mild 
mutations allow survival and a variety of neurodevelopmental 
phenotypes in males.5.1 
Following mapping of the RTf candidate locus to Xq27-28, 
THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 
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the first RTf-causing mutations in the four-exon MECP2 gene.8 
Since then, analysis of exons 2 to 4 of the gene in 32 reports9• t3 
revealed 221 different mutations in the large exons 3 and 4, nine 
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account for 65% of aU mutations in classical RTT patients. No 
mutations were found in exon 2, and until recently, exon 1 was 
not included in mutation analyses, because it was considered to 
be non-coding and representing merely an extension of the 5' 
untranslated region (UTR) (Figure). A recent re-evaluation of 
MECP2 splice variants showed that the major brain transcript of 
the gene utilizes only exons l, 3 and 4, in which case the first 
exon becomes coding. 14.15 As a result, three additional mutations, 
affecting exon l, were recognized. 14 We now caU the new 
MECP2 isoform MECP2El (El for translation initiation site in 
exon 1; nomenclature agreed upon at the international Rett 
Syndrome Research Foundation meeting, June 2004), and the 
originally identified isoform MECP2E2. The mutations 
described below are numbered according to the MECP2E 1 open 
reading frame (Figure). Equivalent annotation from MECP2E2 is 
included in Table 1. 
InitiaUy described in 1966,16 RTT was rediscovered in the 
early 1980's and prominently brought to international paediatric 
Table 1: MECP2 mutation screening from our two cohorts of subjects 
MECPEla MECPE2a 
Nt Position AminoAcid Nt Position AminoAcid Exon Recurrence Reported 
Group 1 
155 dei A Fs al 52, stop at 408 119 dei A Fs at 40, stop at 372 3 1 Yes 
1218 dei 2 Fs at 430, stop at 439 Il 82DEL2 Fs at 394, stop at 403 4 1 Yes 
509C->T Tl70M 473C->T TI58M 4 1 Yes 
538 C->T RI80X 502C->T RI68X 4 1 Yes 
799 C->T R267X 763C->T R255X 4 2 Yes 
916 C->T R306X 88OC->T R294X 4 1 Yes 
952 C->T R318C 916C->T R306C 4 1 Yes 
Grou'p2 
IA->T MIL lA->T MIL 1 No 
GTdel Splice variant GTdel Splice variant 1 Yes 
338 C->G PII3R 302C-G PIOIR 3 Yes 
352 C->T Rl18W 316C->T RI06W 3 Yes 
416 C->T P139L 38OC->U P127L 4 No 
433 C->T R145C 397C->T RI33C 4 2 Yes 
434 C->A RI45H 398 C->A RI33H 4 1 Yes 
437 C->G SI46C 401C->G S134C 4 1 Yes 
458 insA Y153X 422insA Y141X 4 1 Yes 
491 C->G PI64R 455C->G P152R 4 1 Yes 
505 T->C F169L 469T->C F157L 4 1 Yes 
508A->G Tl70A 472A->G Tl58A 4 1 Yes 
509 C->T Tl70M 473C->T Tl58M 4 16 Yes 
538 C->T R180X 502C->T R168X 4 6 Yes 
622 dei 4 Fs al 232, stop al 220 586de14 Fs at 196, stop at 208 4 1 Yes 
732 dei C Fs at 268, atop at 259 696delC Fs at 232, stop at 247 4 1 Yes 
786 dei C Fs al 286. stop at 300 750deiC Fs 250. stop at 288 4 1 No 
799 C->T R267X 763C->T R255X 4 5 Yes 
842 dei G 305300 806deiG Fs at 269, stop at 288 4 1 Yes 
844 C->T R282X 808C->T R270X 4 9 Yes 
850 C->T P284S 814C->T P272S 4 1 No 
916 C->T R306X 88OC->T R294X 4 5 Yes 
941 C->A P314H 905C->A P302H 4 1 Yes 
941 C->T P314R 905C->T P302R 4 1 Yes 
952 C->T R318C 916C->T R306C 4 6 Yes 
953 G->A R318H 917G->A R306H 4 1 Yes 
IOOOC->A P334T 964C->A P322T 4 Yes 
lOOOC->G P334A 964C->G P322A 4 Yes 
1193 deI 44 Fs al 422. stop at 401 Il 57del44 Fs 386. stop at 389 4 Yes 
1196 deI 33 Fs al 423, stop at 488 1160de133 Fs 387, stop al 476 4 Yes 
1291 C->"P' P431S 1 255C->Tb P419S 4 No 
"Base pair position and amino acids numbered according to the MECP2El and the MECPE2 transcript initiator codon (NCBI # 
AY541280). bMECP2 variant present in the mother. Fs: Frameshitf, dei: deletion, nt: nucleotide position on the transcript. 
322 
LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES 
EXODl ExoDl ExoaJ EJ.OD4 
• r-+-4 r
GA 
0rigiaaI MECP2 A - 1-+-1 .. (MECPlEl) 5.3 kit ~Idt 736bp 
~ ~ 1461 MECP1El B 1 (orfgbaal DU.beriue) 
TGA TGA 
b TGÎI~ ! NewMECPl C I--l  (MECPlEl) 
t:r 13 "UJ4 1197 MECPlEl D (aew nambering) 
Figure: Sehematie representation of the IWO MECP2 trallseripts. (A) Original gellomie organizatioll of the MECP2 gene (MECPE2). (B) Origillal 
III1c/eotide nllmbering. (C) Cenomie strueWre of the new MECP2 transcript (MECP2El). (D) Novel lIuc/eotide nWllbering accordillg the 
MECPE1.Black boxes; untrallslated regions; arroI>"; start site. TGA; stop eodo/l. nll/llbers represent III1c/eotides position. 
attentionY This allowed many cases to be diagnosed, and 
established RTf as one of the most common mental retardation 
conditions in females. lg It also led to a refinement of the RTf 
clinical phenotype in the early 1990s. The discovery of MECP2 
mutations in RTf subjects added further knowledge in this 
disorder and, in 2001, an international effort was made to 
establish specifie clinical guidelines to facilitate clinical 
diagnosis and recognition of the disorder. 19 An updated list of 
criteria emerged and was called the «Revised Diagnostic Criteria 
(RDC)>>(Table 2; http://www.rettsyndrome.org/main/diagnostic_ 
criteria.htm).19 Here, we study the impact of the presence versus 
the absence of the use of diagnostic criteria from the RDC to 
make a diagnosis of RTf on MECP2 mutation detection In 
Canadian patients diagnosed and suspected of having RIT. 
PATIENTS AND METHODS 
Al! but one patient had been referred from various Canadian 
centres. This patient was referred from the Children's Mercy 
Hospitals and Clinics, Kansas City, Missouri, USA. In order to 
evaluate the impact of the use of specific criteria for RTf 
diagnosis on MECP2 mutation detection rate we subdivided the 
patients into two groups: we had one historic group (Group l, 
Table 2) of patients without any final diagnosis merely a 
suspicion of RTf in whom specific diagnostic criteria for RTf 
were not used, and a more recent collection (Group 2) where 
patients were only accepted if they strictly met diagnostic criteria 
for RIT (Table 2). The referring physicians in both cases were 
not distinguishable in background. They were Canadian 
paediatricians, geneticists and paediatric neurologists. 
The entire coding regions of exons l, 2, 3 and 4 and their 
intronic flanking sequences were analyzed. Exons 2 to 4 were 
amplified by polymerase chain reaction (PCR) with primer pairs 
designed with the use of genomic sequence information from the 
Human Genome Project working draft site University of 
Califomia Santa Cruz (UCSC, www.genome.ucsc.edu) and the 
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Table 2: Revised Diagnostic Criteria (RDC) for RTT 
Necessary 
CRITERIA 
1. Apparently nonnal prenatal and perinatal history 
2. Psychomotor development largely nonnal through the flISt 
6 months or may be delayed from birth 
3. Nonnal head circumference at birth 
4. Postnatal deceleration of bead growth in the majority 
5. Loss of achieved purposeful band skill between ages 
V, - 2Yz years 
6. Stereotypie band movements such as band 
wringing/squeezing, c\apping/tapping, mouthing and 
washing/rubbing automatisms 
7. Emerging social withdrawal, communication dysfunction. 
loss of learned words, and cognitive impairment 
8. Impaired (dyspraxie) or failing locomotion 
Supportive 1. Awake disturbances of breathing (hyperventilation, breath-
holding, forced expulsion of air or saliva, air swallowing 
2. Bruxism 
3. Impaired sleep pattern from early infancy 
4. Abnormal muscle tone successively associated with muscle 
wasting and dystonia 
5. Peripheral vasomotor disturbances 
6. Growth retardation 
7. Hypotropbie small and cold feet; small, thin bands 
Exclusion 1. Organomegaly or other signs of storage disease 
2. Retinopathy. optic atropby, or cataract 
3. Evidence of perinatal or postnatal brain damage 
4. Existence of identifiable rnetabolic or other 
progressive neurological disorder 
5. Acquired neurological disorder resulting From 
severe infections or head trauma 
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Table 3: Cinical features present in subjects from Group 1 
Case Mutation Clinical Features from Medical File Differentiai Diagnosis 
1 NO 
10 NO 
Il 1l9DELA 
14 NO 
19 NO 
27 RI68X 
29 NO 
29 NO 
34 TI58M 
35 NO 
38 NO 
39 NO 
40 R255X 
41 NO 
42 NO 
45 NO 
46 Il 82del2 
48 NO 
5 NO 
51 NO 
64 NO 
65 NO 
77 NO 
77 NO 
78 R306C 
8 NO 
81 NO 
82 NO 
83 NO 
84 NO 
86 NO 
89 NO 
90 R255X 
92 NO 
95 R294X 
GDD, seizures, regression, hypotonia, hand-wringing, short stature, obesity 
GDD, seizures, microcephaly, spactic diplegia, dysmorphic features 
GDD, hypotonia, hand~.wringing, non-verbal, failing locomotion 
History of seizures, microcephaly, non-verbal, spastic diparesis, scoliosis, facial dysmorphisms 
Regression, seizures, microcephaly, autistic features, hand-wringing, scoliosis 
Regression, seizures, hand-wringing, bru xi sm, abnormal breathing 
GDD, not ambulatory, cerebellar hypoplasia 
GDD, MR, seizures, not ambulatory 
Not available 
GDD, seizures, hypotonia, inappropriate laughter 
Seizures, difficulty walking, brachycephaly, brain anomalies 
PWS,SD 
AS 
AS,PDD 
Dev. Delay, MR, PWS 
AS 
PWS,SMS 
AS, Joubert Syndrome 
Joubert Syndrome 
AS 
RIT 
Seizures, spastic diplegia, non-verbal, hyperventilation, hand-flapping, hypotonia, facial dysmorphisms 
Not available 
Seizures, stereotypie hand behaviors, bruxism, occasional abnormal breathjng patterns 
Not available 
Speech deIay, MR, behavioral problems, hand-wringing, hyperventilation, inappropriate laughter, drooling 
Not available 
AS 
GDD, in tractable epilepsy, ataxia, obesity, hypertriglyceridemia 
Stereotypie hand movements, fine motor deficits, non-verbal, abnormal EEG 
GDD, seizures, abnormal MRI, lert hemiparesis, hand-wringing, non-verbal, history of bruxism 
Difficulty walking, delayed speech, white matter changes on MRI 
GDD, microcephaly, hypotonia 
Not available 
Not available 
Not available 
Hyperventilation, manneristic hand movements, scoliosis, microcephaly 
GDD, microcephaly, seizures, hand-wringing, bruxism, dysmorphic features, non -verbal 
GDD, microcephaly, poor speech, unsteady gait, ataxia 
GDD, microcephaly, seizures, syndactyly 
GD D, regression, microcephaly, seizures, hand-wringing, cerebral atrophy, bruxism 
Not available 
GDD, hypotonia, dysmorphic features, plagiocephanly, scoliosis, osteoporosis, abnormal EEG 
GDD, no eye contact, recurrent blinking, repetiùve behaviours 
GDD, microcephaly, strabismus 
Not available 
AS 
AS 
AS 
Oculodentodigital Dysplasia 
AS, William's syndrome 
AS,SMS, RIT 
RIT 
RIT 
PWS 
PDD autism 
GDD: Global Developmental Delay; Dev.: Developmental; pbs: problems; PWS: Prader-Willi Syndrome; SD: Seizures Disorder; AS: 
Angelman Syndrome; POO: pervasive developmental disorders; MR: mental retardation; SMS: Smith-Magenis Syndrome; EEG: 
electroencephalogram; MRI: magnetic resonance imaging. 
Lasergene Primer select program. The PCR products were 
loaded on 2% agarose gel to confirm amplification before 
analysis for base changes by denaturing high performance Iiquid 
chromatography (OHPLC) (WAVE NucIeic Acid Fragment 
Analysis System from Transgenomic, San Jose, CA). Solvent A 
consisted of 0.1 moIIL triethylammonim acetate (TEAA) and 
25% acetonitrile and solvent B contained lM triethylammonim 
acetate, 25% acenonitril. PCR products showing a chromato-
graphic variation on dHPLC were sequenced directly on an 
automatic sequencer (Gene Reader 4200). The sequencing data 
was analyzed using ONA Star software SeqMan (Lasergene). 
Exon 1 was PCR amplified and sequenced in aIl patients as 
recently described.l~ 
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RESULTS 
The MECP2 gene was retrospectively analyzed for mutations 
in banked DNA from a total of 136 patients with a presumptive 
diagnosis of RIT. Average age of the affected subjects was I3 
years, with a range of five to 46 years. We identified a total of 33 
different MECP2 mutations, presented in Table 1. Group 1 was 
a historic cohort of 35 patients suspected of having RIT. 
Organized diagnostic criteria were not utilized in the se patients. 
Their clinical features are summarÏzed in Table 3. Results from 
mutational analysis in this group revealed mutations in se ven 
individu ais (20%) (Table 1). Five of the nine common point 
mutations, Tl70M, RI80X, R267X, R306X, and R318C were 
found in this group. AIl mutations in Group 1 have been seen 
previously in cIassical RIT patients. 
ln Group 2, which included subjects diagnosed with a strict 
adherence to the RIT criteria, mutations were detected in 73 out 
of 101 individuals (72%). Ail previous common RIT point 
mutations, namely R118W, R145C, Tl70M, R180X, R267X, 
R282X, R306X, and R318C were detected in this group, except 
one, A152V (AI40V). These eight recurrent mutations account 
for 68.5% of our Group 2 mutations, with Tl70M being the 
most frequent (16 times). Three patients had previously 
undescribed mutations, two in exon 3 (762 (dei C), and P284S) 
and one in exon 1 (Table 1). The exon 1 mutation, a IA-T 
substitution (ATG->ITG), changes the first Methionine codon 
into a Leucine. The prediction is that MECP2El translation 
would be greatly or totally hindered due to absence of a start 
codon. MECP2E2 would be normally made (and appears unable 
to rescue the disease phenotype). 
None of the mutations in Group 1 or 2 were observed in any 
of the parents of our patients, confirming that the great majority 
of mutations in RIT are de novo. Polymorphisms were found in 
both groups during our mutation analysis. They are: S206S, 
G264G, T311T, S422S and K357K. G264G and S422S have not 
previously been reported. Finally, a hitherto unreported 
variation, P431S, located at the C-terminus of the MECP2 gene, 
was found to be transmitted from a normal mother to an RIT-
affected girl. We label this sequence alteration "unclassified 
variant", as recently proposed.9 
DISCUSSION 
ln this study we have analyzed the entire coding sequence of 
the MECP2 gene in two cohorts of subjects, grouped according 
to the use of diagnostic procedure to make a diagnosis. We 
wanted to evaluate the impact of the use of stringent clinicat 
criteria on MECP2 mutation detection rate. Our MECP2 screen 
revealed the presence of multiple mutations in both groups of 
patients; however, the detection rate in Group 1 was mu ch lower 
(20%) than in Group 2 (72%). These observations indicate that 
diagnostic procedures strongly influence mutation detection 
rates. While the clinicat overlap seen in Group 1 compared to 
Group 2 is substantial, subjects in the former group may have a 
more genetically heterogeneous etiology than those with a more 
stringent RIT diagnosis. From the clinicat point of view, this 
observation is important, because the majority of subjects 
diagnosed without the use of RIT criteria may represent other 
diseases. In fact, many in Group 1 were given a differential 
diagnosis of Angelman syndrome (Table 3). Rett syndrome and 
Angelman syndrome are both neurodevelopmental disorders 
characterized by severe intellectual disability, microcephaly, 
speech problems, movement disorders with gait and/or truncal 
ataxia, and occasionally a similar facial appearance. As 
mentioned by Ellaway and colleagues20, RIT is probably the 
most common mimicker during the infant and toddler ages and 
Angelman Syndrome might represent a phenocopy for RIT.20 
The clear distinction between the two syndromes will continue 
evolving over time. On the other hand, in the present study, in 
those who were found negative for MECP2 coding sequence 
mutations, it is still possible they have other mutations such as 
regulatory mutations or large insertions or deletions that would 
not be detected by the methods utilized in this study. However, it 
is unlikely that such a mutation subgroup would be differentially 
represented Group l. Additional genetic alterations have been 
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associated with the RIT phenotype, even in patients with a 
typical MeCP2 mutation. Longo et al21 recently reported three 
patients with Rett syndrome and rearrangements of chromosome 
15q 11-13, a region known to be implicated in autistic 
phenotypes.21 This suggests the possibility of the role· of 
additional genes with the RTT phenotype, although further 
studies are necessary to confirm this association. Indeed, in a 
recent review of Weaving et al.22, at least seven published 
atypical RIT cases have been found to have mutation in the X-
linked CDKL5/STK9 gene. This serinelthreonine-protein kinase 
of unknown function may represent a potential candidate gene 
for RIT cases without any MECP2 mutation. 
While most of the observed mutations in this study have been 
reported previously, three are new, including one in the newly 
characterized coding first exon. One mutation, P284S, would 
seriously alter the MeCP2 protein secondary structure by 
removing the proline bend at position 284. Another, 762 (dei C), 
shifts the reading frame and results in premature truncation. The 
exon 1 mutation (IA->T) removes the exon 1 initiation codon, 
which would prevent any MeCP2EI protein from being made. 
ln the MECP2E2 transcript it wi\1 represent nothing more th an a 
single nucleotide change in the 5'UTR. Might this have an effect 
on MECP2E2 protein production? Kriaucionis and Bird l5 
recently showed, in tissue culture experiments, that the four-exon 
MECP2E2 transcript makes a short peptide initiated at the start 
codon (ATG) in ex on 1 and terminated in the stop codons 
preceding the MECP2E2 start site in exon 2. They demonstrated 
that if the exon 1 start is removed and the short peptide 
abolished, the translation of MECP2E2 increases dramatically. 
Here, we have a patient replicating the Kriaucionis and Bird 
experiment. If subsequent experiments indeed show that in this 
patient MECP2E2 translation is enhanced by the exon 1 ATG A-
>T mutation, then this would provide crucial new insight into 
RTT. It would imply that MECP2E2 cannot compensate for 
absence of MECP2EI, and that MECP2El is necessary and 
sufficient for RIT. These experiments are underway. 
As mentioned by Hagberg and colleagues l9 even though we 
now know the major genetic cause of RTT, this disease remains 
so far a clinical diagnosis. From a scientific and socio-economic 
point of view, the use of efficient and wel1 defined clinical 
criteria is very important for man y reasons: (1) ln order to 
replicate research findings, such as mutation gene screening, it is 
essential to use the same phenotypic selection method. (2) ln 
heterogeneous genetic disorders, where more th an one gene 
locus might be involved, it is important to be able to discriminate 
those who harbour a mutation in order to only focus on those 
who do not have mutations to better homogenize the search of 
the unknown locus. (3) The more the diagnostic procedure is 
precise; the more appropriate treatmenCs can be applied to the 
affected child. (4) The diagnosis of RTT remains clinical and this 
is a critical step that leads (or not) to MECP2 mutation gene 
screening, especially since the cost of MECP2 testing is high 
(currently varies From $500 to S950 US). 
Our results show that implementation of better clinical 
diagnostic procedures improves the rate of MECP2 mutation 
detection. Mutations in the MECP2 exon 1 occur in 2/136 or 
1.5% of RIT patients, and therefore this exon should be included 
in diagnostic mutation searches in this devastating disease. 
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